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-Abstract- 
               The molecular composition and localization of Dystrophin-
Associated Protein Complexes (DPCs) and ε-sarcoglycan in mammalian 
brain. 
            Duchenne muscular dystrophies (DMD) arise from mutations in the DMD 
gene. In the brain, the DMD gene product, dystrophin, localizes at the post-synaptic 
density (PSD) of inhibitory GABAergic neurons (Brunig et al, 2002). PSDs are 
specialised cytoskeletal structures that underlie and are attached to the post-synaptic 
membrane. In PSDs of the brain, dystrophin is part of a multi-protein complex, namely 
the dystrophin-associated protein complex (DPC) found exclusively at GABAergic 
synapses. Recent studies have identified a novel alternatively spliced dystrophin product 
in the brain, referred to as delta dystrophin, whose molecular associations and functions 
are unknown. In this thesis I have investigated whether delta dystrophin may form novel 
DPC complexes at GABAergic synapses of the brain. Results suggest that in the brain, 
delta dystrophins exhibit different regional and subcellular distributions when compared 
to classical dystrophins and do not co-localise with any of the PSD markers or DPC 
components tested. Rather, delta dystrophins fully co-localise with β3-tubulin, a 
component of the microtubule (MT) cytoskeleton. These studies suggest, that unlike 
classical dystrophin, delta dystrophin is likely to form novel delta DPC complexes 
outside rather than within the GABAergic synapse, and therefore may have a different 
molecular composition and function compared to classical dystrophin-containing DPC 
complexes. Therefore, delta dystrophin co-localisation with the MT network may provide 
a potential novel route by which cognitive pathology in DMD patients may be initiated.  
                  ε-sarcoglycan, is a well-established DPC component in smooth muscle. 
However, the present studies suggest that it may not be a component of classical and 
delta dystrophin-containing DPC complexes at GABAergic synapses and microtubule 
structures, respectively. Its membrane localization suggests ε-sarcoglycan is likely to be 
part of novel, yet unidentified complexes in the brain. However, attempts to raise high 
affinity antisera that could be used to purify and characterize ε-sarcoglycan complexes 
were unsuccessful. 
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             Glossary of Abbreviations 
 
AA                    amino acid 
α-DG                α-dystroglycan 
Amp                  Ampicillin 
AO                    antisense oligonucleotides 
B                       brain 
β-DG                β-dystroglycan 
BH                    Brain Homogenate 
bla                     ampicillin resistance gene            
BL21(DE3)      an all purpose strain of competent cells for high-level protein expression and easy  
                          induction     
BLAST             Basic Local Alignment Search Tool 
BMD                Becker Muscular Dystrophy 
C                       cerebellum 
Ca+                           calcium 
CA1                  Cornus Ammonis area 1 
cDp                   classical dystrophin 
cDp427             427kDa classical dystrophin 
cDp140             140kDa classical dystrophin 
cDp116             116kDa classical dystrophin  
cDp71               71kDa classical dystrophin 
Cexon 78          classical exon 78 
CH                    calponin homology domain 
CHO                 Chinese Hamster Ovary 
CNS                  Central Nervous System 
Cos                   acronym, derived from the cells being CV-1 (simian) in Origin, and carrying the     
                          SV40 genetic material 
Cos-7                a form of Cos cell line 
Cre-loxP           causes recombination-locus of X-over P1 
Cs                     cell soluble 
CT                    C-terminus 
Cys                   cysteine 
DB                    dystrobrevin 
DBS                  Deep Brain Stimulation 
 dDp                  delta dystrophin 
dDp427             427kDa delta dystrophin    
dDp140             140kDa delta dystrophin 
dDp116             116kDa delta dystrophin 
dDp71               71kDa delta dystrophin           
Dexon 78          delta exon 78 
div                    days in vitro 
DMD                Duchenne Muscular Dystrophy 
DMEM             Dulbeccos modified eagles media 
DMSO              dimethyl sulphoxide 
DYT11-MDS   Myoclonus Dystonia Syndrome due to a mutation of the SGCE gene 
DNA                 Deoxyribonucleic acid 
DPC                  Dystrophin Associated Protein Complex 
E. coli               Escherichia coli 
EF hand            helix-loop-helix structural domain              
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EGFP                enhanced green fluorescent protein 
ER                     endoplasmic reticulum 
ERK                  extracellular-signal-regulated kinase 
ERS                  even-related synchronization 
F                       forebrain 
F1 origin           f1 origin of replication 
F-actin              filamentous polymers of actin 
G                       general 
GABA A R        γ-aminobutyric acid receptor 
GAD65             glutamic acid decarboxylase 65 
Gp                     glycoprotein 
Gpi                   Globus pallidus internus 
Grb2                 growth factor receptor-bound protein 2 
H                       hinge 
H1 and H2        helical leucine-heptad motifs 
HBS                  HEPES buffered saline 
HFS                  high frequency stimulation 
His-tag              Histidine-tag 
HS                     horse serum 
IgG                   Immunoglobulin G 
IP                      Immunoprecipitate 
IPTG                 Isopropyl β-D-1-thiogalactopyranoside 
IQ                     Intelligence quotient 
Kif5A               kinesin heavy chain isoform 5A 
lac 1                  lac repressor 
Leu                   leucine 
LGMD              limb-girdle muscular dystrophy 
LM                    light membrane 
LNS                  laminin, neurexin, sex-hormone-binding protein domain 
LTD                  long-term depression 
LTP                   long-term potentiation 
M                      muscle 
µ                       micro 
mAb                 Monoclonal Antibody 
ng                      nanogram 
nm                    nanometer 
M                      marker 
MAP2               microtubule-associated protein 
MCS                 multiple cloning site 
mdx                  a strain of mouse used as a disease model for human muscular dystrophy 
MEK2               mitogen-activated protein kinase kinase 
Mc                    microsomes 
mRNA              messenger RNA 
Mt                     mitochondria 
MT                   microtubule 
My                    myelin 
N                       n-octyl-pyranoside 
nNOS                neuronal nitric oxide synthase 
NMDA R          N-methyl D-aspartate receptor 
Np65, 55           neuroplastin 65, 55 
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OMIM              Online Mendelian Inheritance in Man 
np                     neuroplastin 
ORF                  Open Reading Frame 
Ori                    Origins of Replication 
P                       Purkinje 
P2                     Pellet 2 
PAGE               Polyacrylamide gel electrophoresis 
PBS                   phosphate buffered saline 
PDZ                  post synaptic density protein, Drosophila disc large tumor suppressor, zonula     
                          occludens-1 protein 
PEG 6000         polyethylene glycol 
pEGFP-N3 vector, expression vector that can be transfected into mammalian cells 
pET32b vector, a bacterial plasmid designed to enable quick production of a desired protein             
PFA                  paraformaldehyde 
PH                     pleckstrin homology domain 
pH                     potential of hydrogen, a measure of the acidity or basicity of an aqueous solution 
Phal                   rhodamine-phalloidin 
PI                      protease inhibitors 
PSD                  Post-Synaptic Density 
R                       retinal 
R(1-23)             rod domain 
rEK                   recombinant enterokinase 
RIPA buffer      radioimmunoprecipitation assay buffer 
RNA                 ribonucleic acid  
RNase               ribonuclease A         
S                       Schwann cells 
SDS                  sodium dodecyl sulphate 
Ser                    serine 
sg                      sarcoglycan 
SGCE               ε-sarcoglycan gene 
SM                    synaptic membrane 
Synapto            synaptophysin 
S-tag                 15 amino acid long peptide (S-peptide) derived from the N-terminus of RNase A 
STD                  short-term depression 
STP                   short-term potentiation 
SU                    syntrophin unique domain 
Syn                   syntrophin 
T                       Triton X-100 
TCA cycle        tricarboxylic acid cycle     
Thr                    threonine 
TM                   transmembrane 
TMS                 transcranial magnetic stimulation 
TrxA                 thioredoxin 1 
Trp                    tryptophan  
Vr3                   variable region 3 
Wt                     Wild type 
WW domain     a protein domain with two highly conserved tryptophans that binds                             
                          proline-rich peptide motifs 
ZZ                     (zinc-binding)-type zinc domain 
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                1.1 The DPC complex in the Brain 
 
                                     1.1.1 Introduction and major aims 
 
                        Duchenne Muscular Dystrophy (DMD) is a recessive, fatal, X-linked 
disorder discovered by French physician Duchenne de Boulogne (Duchenne et al, 
1860), whilst he was examining the motion and verbal skills of a seven year old boy 
(reviewed by Blake et al, 2000). It was only by 1987 that Koenig et al, through a 
technique known as positional cloning approach, isolated and characterized the gene 
responsible for DMD, and named it the DMD gene (Koenig et al, 1987; Koenig et al, 
1988). The protein product of the DMD gene, named dystrophin, was identified by 
Hoffman et al (1987). The name of the DMD gene product, whose mutation gives rise 
to DMD, was chosen to reflect the effects the muscle undergoes in DMD patients. In 
brief, when a DMD muscle carries out a simple movement, the muscle tears and only 
at the early stages of the disease can the muscle repair the damages caused. With 
time, the muscle is no longer able to rescue all the damage being continuously 
created, degenerates and thus the disease starts to take over. It is this muscle wasting 
that suggested the DMD protein product to be named dystrophin, in latin, meaning 
muscle wasting. Muscle dystrophin is a very large protein, precisely 427kDa.  
 
                        DMD involves a complex pathophysiology that is not easily explained 
by the loss of the protein dystrophin, the primary defect in DMD (Wehling-Henricks 
et al, 2009). This is because dystrophin (427kDa) in the muscle is part of a 
multiprotein complex called the Dystrophin Associated Protein Complex (DPC), 
which in turn binds to a series of additional proteins, many of which have already 
been identified, that together lead to DMD. One well established function of the DPC 
complex is to maintain the integrity of the muscle tissue by linking the intracellular 
parts of the cell to the exterior of neighboring cells and the extracellular matrix. In 
other words, when a healthy individual utilizes his/her own muscle, the muscle 
remains intact, thanks to these functional inter-linking mechanisms between 
neighboring cells of the muscle tissue. A mutation of the DMD gene disrupts the 
dystrophin protein, which in turn breaks the linking mechanism normally exhibited by 
the DPC complex, thus generating DMD in the muscle whenever the muscle is being 
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utilised. At birth, these boys appear clinically normal, but the continuing muscle 
tearing as a consequence of a mutated DMD gene generates neuromuscular wasting 
which becomes clinically evident by the age of five. As they grow older, the muscle 
progressively weakens such that by the age of twelve they are confined to a wheel 
chair. It is the weakening and hence failure of diaphragm and cardiac muscles that 
eventually leads to death of most patients by their early twenties (Benson et al, 1996; 
Blake et al, 1999; reviewed in Blake et al, 2002). 
 
                        The muscle is not the only organ to be affected in these individuals, 
the brain, the focus of this thesis, is also affected. Cognitive defects were first 
identified as a feature of the pathology of DMD in 1868 (Duchenne et al, 1868; Allen 
et al, 1960, Marsh et al, 1974). When numerous DMD individuals faced simple 
language skills (IQ) tests, it became evident that DMD boys have IQs that are about 
one standard deviation below normal, and more than 30% of DMD boys score in the 
mentally retarded range (Karagan et al, 1979; Emery et al, 1993; Deng et al, 2009), 
encountering poor language skills as well as other cognitive impairments (Lidov et al, 
1996). There is now a sufficient body of evidence to show that cognitive impairment 
in one third of these patients is a consequence of the mutation of the DMD gene 
(reviewed in Blake et al, 2002). The route by which mental impairments in DMD 
patients originates appears to have high similarity to that in the muscle, as several 
groups (Brunig et al, 2002, Culligan et al, 2002) including our collaborators (Blake et 
al, 1999) have revealed the existence of DPC complexes in the brain, which are of 
similar although not identical composition to the muscle DPC complex. However, the 
neurological aspects of DMD are still not well understood. 
 
                        The DMD gene product in brain, which in this thesis I will refer to as 
classical full-length dystrophin, is a 427kDa protein. Unlike the muscle, the brain 
contains a variety of shorter classical dystrophin isoforms that arise from highly 
regulated promoters located along the DMD gene. These shorter classical dystrophin 
isoforms are also known to form additional DPC complexes in the brain (Blake et al, 
1999), however, to date only DPC complexes containing the classical full-length 
dystrophin have been identified at the synapse of neurons (Blake et al, 1999; Culligan 
et al, 2002; Blake et al 2009). Studies have shown that mice lacking the full-length 
protein only, whilst shorter classical dystrophin isoforms continue to be expressed in 
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the brain, can lead to mental impairments that are very similar to the brain 
dysfunctions observed in DMD patients (Kim et al, 1992). This is a crucial finding as 
it demonstrates that classical full-length dystrophin plays a major role in the brain 
abnormalities observed in DMD patients. On the basis of these studies, in this thesis I 
present a new and potentially very important protein. It is the alternatively spliced 
form of classical full-length dystrophin protein. I named this novel protein delta full-
length dystrophin. Very little is known about this protein, but given its high 
homology to classical full-length dystrophin, and the crucial importance classical full-
length dystrophin is known to have on the brain (see section on the mdx mouse), I 
determined (chapter 3 & 4) whether delta full-length dystrophin can replace classical 
full-length dystrophin to form novel and yet unidentified delta DPC complexes in the 
brain. This would help better understand the molecular dynamics underlying DMD 
brains, and increase our understanding on the molecular complexity and functional 
roles of DPCs in the rat brain.   
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                    1.1.2 Molecular genetics of the DMD gene and encoded 
proteins 
 
                       I begin by describing the molecular genetics of the DMD gene (figure 
1.1.2.1). The DMD gene is the largest gene found in human beings, it comprises of 
nearly 0.1% (2.5 Mb of genomic DNA) of the entire genome (Koenig et al, 1987; 
Anderson et al, 2002) and it is found within chromosome Xp21.2 (Koenig et al, 1987; 
Muntoni et al, 2003). This gene is very complex, and comprises of 85 exons 
including seven unique exons (figure 1.1.2.1) linked to the independent tissue-
specific promoters, generating at least three full-length and four shorter dystrophin 
isoforms (Muntoni et al, 2003; Sadoulet-Puccio et al, 1996).  Three independently 
regulated promoters (namely B, M and P) are found within a 400kb genomic interval 
(Mehler et al, 2000), these encode full-length dystrophin for muscle (Dp427m), brain 
(Dp427b) and Purkinje cells (Dp427p) (reviewed in Blake et al, 2002; Muntoni et al, 
2003).  Each transcribed product consists of a unique first promoter, followed by a 
common set of 78 exons that generate a 427kDa protein product (Torelli et al, 1999; 
Spence et al, 2004).  Four internal promoters independently regulate the expression of 
shorter dystrophin proteins. The four shorter dystrophin isoforms each contain a 
unique 5’-exon, but contain a C-terminal domain that is identical to that of full-length 
dystrophin. Each of these promoters (figure 1.1.2.1) uses a unique first exon that 
splices into exons 30, 45, 56, and 63, respectively, to generate shorter dystrophin 
products whose names are given based on their molecular weight, i.e 260kDa 
(Dp260), 140kDa (Dp140), 116kDa (Dp116) and 71kDa (Dp71), respectively.  
 
                        In addition to these isoforms, the dystrophin gene generates an even 
greater number of isoforms by using an alternative poly(A)-addition site, localized in 
intron 70 of the dystrophin gene, and also by alternative splicing that occurs at the 3’-
end of the dystrophin gene (Feener et al, 1989; Kudoh et al, 2005). This thesis strictly 
focuses on two dystrophin isoforms only, the classical full-length dystrophin and the 
delta full-length dystrophin (figure 1.1.2.2). In other words, the DMD gene is 
transcribed into pre-mRNA, and if the cell machinery decides to keep classical exon 
78, a classical full-length dystrophin protein is obtained (figure 1.1.2.2A). On the 
other hand, if the pre-mRNA of dystrophin undergoes alternative splicing of classical 
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exon 78 (Cexon78) at the C-terminus, and replaces it by a longer and unique 
sequence I name delta exon 78 (Dexon78) (figure 1.1.2.2B), a delta full-length 
dystrophin product is produced. This alternative splicing is known as mutually 
exclusive alternative splicing. That is, the two exons are never present together in the 
dystrophin protein, if classical exon 78 is present, delta exon 78 is not, and vice versa. 
Hence the two proteins can be easily distinguished from one another using an 
antibody that strictly targets one of the two exons only.  
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Figure 1.1.2.1: Domain structure of classical full-length and shorter dystrophin 
isoforms. The figure shows the domain structure of classical dystrophin isoforms. 
There are 7 tissue-specific promoters along the DMD gene. The dystrophin proteins 
are named according to their molecular weight, hence Dp427 (427kDa protein), 
Dp260, Dp140, Dp116, and Dp71. The promoters are referred to as M-promoter 
(Muscle), B-promoter (Brain), P-promoter (Purkinje), R-promoter (Retinal), Brain-3 
promoter (Brain & kidney), S-promoter (Schwann cells) and G-promoter (General). 
CH, calponin homology domain; H1 & H2, hinge regions; WW, tryptophan-
containing domain; EF, EF hand domain; Cys, cysteine-rich region; ZZ, zinc finger 
domain; CT, C-terminal domain. This figure is adapted from Blake et al (2000). 
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Figure 1.1.2.2: Domain structure of classical and delta dystrophin. 
The figure shows the domain structure of classical and delta full-length dystrophin, 
both have a similar molecular weight close to 427kDa. They comprise of an N-
terminal domain, a rod domain, WW domain, cysteine-rich domain (2 EF hands and 1 
ZZ domain) and a C-terminal (CT) domain. An unknown domain region separates the 
coiled-coil domain from the C-terminal site where alternative splicing can occur. 
Cexon 78 and Dexon78, represented by the blue and red box respectively, are the 
exonic sequences that distinguish classical full-length dystrophin from delta full-length 
dystrophin. Delta full-length dystrophin arises via alternative splicing, whereas 
classical full-length dystrophin is taken as a conventional isoform. In brackets is the 
amino acid sequence of Cexon78 (blue) and Dexon78 (red), respectively. Delta 
dystrophin is 20 amino acids longer than classical dystrophin. This figure is adapted 
from Blake et al (2000). 
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                    1.1.3 Localization and developmental expression of 
dystrophins  
                      
                        As highlighted in the preceding section, dystrophin in the brain exists as 
various isoforms of differing molecular weights. Seven separate promoters at the DMD 
gene locus code for alternate transcripts that exhibit nervous system developmental, 
regional and cell type specificity (figure 1.1.2.1). There are three separate full-length 
dystrophin transcripts whose protein products are restricted to distinct sites. Dp427m 
(muscle dystrophin) is expressed predominantly in skeletal, cardiac, and smooth 
muscles, and also at very low concentrations, in brain astrocytes and vascular 
endothelial cells (Mehler et al, 2000). Dp427b (brain dystrophin) is an isoform 
expressed in the forebrain, precisely within hippocampal and cortical neurons (Nudel et 
al, 1989; Mehler et al, 2000). Dp427p (Purkinje dystrophin) is expressed in fetal 
cerebral cortex and in mature cerebellar Purkinje cells and skeletal muscle (Torelli et 
al, 1999; Mehler et al, 2000; Spence et al, 2004). Immunofluorescent studies on adult 
mice have demonstrated that the dystrophin isoforms localize within proximal 
somadendritic regions, notably in cerebral cortex, hippocampus and cerebellum 
(Gorecki et al, 1992; Lidov et al, 1993). According to immunoblotting studies, only the 
full-length dystrophin isoform localizes in neurons (Lidov et al, 1990; Kim et al, 1993; 
Blake et al, 1999), whereas the shorter isoforms localize in glial cells (Blake et al, 
1999).  
 
                        The brain contains additional shorter dystrophin transcripts whose cell, 
tissue and developmental transcription are also highly controlled. Dp260 is present in 
the retina, precisely at the synapse between retinal photoreceptor and on bipolar cells 
(reviewed in Mehler et al, 2000). Dp140 is expressed in the brain and kidney and 
various other parts of the CNS, such as the astroglial processes throughout the neuropil 
during development, on leptomeningeal surfaces and along penetrating blood vessels, 
ensheathing the olfactory nerve and in the neurohypophysis (Lidov et al, 1990; Lidov 
et al, 1995; Lidov et al, 1996). Dp116 is expressed in the late human fetal brain and in 
the postnatal diencephalon (caudate/putamen). Dp116 is also expressed in the 
peripheral nerve. Dp71 is ubiquitously expressed in the brain (Lederfein et al, 1992; 
Austin et al, 1995). Dp71 is found in early embryonic stem cells, in areas of 
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mesenchymal-epithelial interactions, in embryonic midbrain and hindbrain (reviewed 
in Mehler et al, 2000). It is also present in perinatal brain correlated with stages of 
terminal neural differentiation, and preferentially in early embryonic forebrain. Dp71 
expression continues from embryonic stages until adult life, specifically in the cerebral 
cortex, granule neurons of the dentate gyrus of the hippocampus, olfactory bulb, 
pituitary and retina (reviewed in Mehler et al, 2000). Dp71 is also present in 
neocortical regions associated with continuing neurogenesis and synaptic plasticity 
(reviewed in Mehler et al, 2000). At a subcellular level, Dp71 transcripts are present in 
association with synaptic vesicles, microsomes and mitochondria (reviewed in Mehler 
et al, 2000).  
 
                        Dystrophins play important roles in brain neural development. 
Truncated dystrophin isoforms are known to be present in the developing neural tube 
prior to the onset of neurogenesis and the start of regional patterning (reviewed in 
Mehler et al, 2000). They are also located in selected areas of the embryonic and 
postnatal neuraxis, suggesting dystrophin isoforms may be involved in the regulation 
of neurogenesis, neuronal migration and cellular differentiation during development 
(reviewed in Mehler et al, 2000). Separate studies suggest full-length dystrophin is 
only detectable at week 12 of gestation, reaching peak at week 15 and then remaining 
stable, thus full-length dystrophin is most probably involved in stabilization of specific 
neuronal structures, rather than participation in neuronal network formation (Spence et 
al, 2004). Thus existing synaptic connections are maintained and excessive remodeling 
prevented (Brunig et al, 2002; Fritchy et al, 2003). However, there is still no clear 
understanding on the function of dystrophin during development. Furthermore, given 
that the brain contains classical and well as delta dystrophin isoforms, it would be 
interesting to separately investigate their localization and expression time points during 
brain neural development, such that their involvement in brain development can be 
studied and compared in more detail. 
 
                        Once all the neural networks are formed and have reached a state of 
maturity, classical full-length dystrophin, but no shorter isoforms, is enriched in the 
PSD fraction (Blake et al, 1999; Brunig et al, 2002). What is more, Brunig et al (2002) 
show classical dystrophin exclusively localizes at the PSD of inhibitory (GABAergic) 
synapses in mature hippocampal neurons. Together, these studies suggest classical full-
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length dystrophin modulates the functions of the inhibitory synapse apparatus. 
Immunochemical analyses using adult mouse brain confirm the localization of classical 
dystrophins at post-synaptic densities (PSDs) not only in hippocampus, but also in the 
cerebral cortex, cerebellum, and olfactory bulb, with highest regional expression of 
dystrophin being in the cerebellum (Kim et al, 1992; Lidov et al, 1993). The PSD is a 
proteinaceous structure found at the post-synapse of neurons and is important for 
receiving many signals from the presynaptic nerve ending and converting them to the 
appropriate responses in the postsynaptic neuron. Given its localization at the PSD, 
classical full-length dystrophin may be implicated in modulating synaptic terminal 
integrity, plasticity as well as cellular signal integration. PSD localization of classical 
full-length dystrophin at these brain regions also suggests that it is implicated in 
cognitive functions, motor coordination, olfactory information processing, and altered 
synaptic plasticity, respectively (Kim et al, 1992). In fact, mutation of classical full-
length dystrophin in brain, whilst shorter classical dystrophin isoforms continue to be 
expressed, leads to mental impairments that are very similar to the brain dysfunction 
observed in DMD patients (Kim et al, 1992). This clearly suggests that classical full-
length dystrophin exhibits a very important role in the brain. It is therefore one of the 
foci of my thesis to compare the cellular and subcellular distribution of classical full-
length dystrophin with a novel and potentially important delta full-length dystrophin 
(figure 1.1.2.2), to determine whether it too may contribute to the brain dysfunctions in 
DMD patients.  
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                    1.1.4 Structure of classical and delta dystrophin 
 
                        Koenig et al (1988) carried out a number of structural studies and 
sequence analyses that highlight five different structural domains (figure 1.1.2.1 & 
1.1.2.2) present in the DMD gene product. Given that classical and delta exon 78 are 
not included and do not interfere with these structural domains, I confidently suggest 
that these structural domains apply to both classical full-length dystrophin as well as 
delta full-length dystrophin. The proteins contain an N-terminal domain, a rod domain, 
WW domain, ZZ-type domain and a coil-coiled C-terminal domain. At the N-terminus 
of both dystrophin proteins there exist two calponin homology domains (CH1 and 
CH2) altogether encoding three actin-binding sites (ABS1-3), thus allowing dystrophin 
to associate with actin (Winder et al, 1997; Norwood et al, 2000). CH is a superfamily 
of actin-binding domains found in both cytoskeletal and signal transduction proteins, 
which cross-link actin filaments into bundles and networks. Pairs of CH domains are 
also said to confer binding to microtubules and α-helical peptide motifs (Slep et al, 
2007, Sjoblom et al, 2008), however, this binding ability has yet to be investigated in 
dystrophin proteins.  An unknown domain region separates the CH domain from the 
rod domain, made of 23 spectrin-like α-helical repeats. The rod domain (R1-23) 
enables the protein to be flexible, such that homo- and hetero-oligomeric parings can 
take place. The two subdomains R1-3 and R4-19 interacts with lipids and F-actin, 
while the distal sub-domain R20-23 does not exhibit any interaction (Legardinier et al, 
2009). R16 and 17 in classical full-length dystrophin anchor nNOS to the membrane 
(Lai et al, 2009). An unknown domain region separates the rod domain from the WW 
domain, a short 32 amino acid sequence which folds as a stable, triple stranded beta-
sheet. The name of the WW domain derives from the presence of two signature 
tryptophan (Trp,W) residues. The WW domain of dystrophin binds to proteins with 
proline rich domains (for example, the cytoplasmic proline rich C-terminal domain, 
XPPY motif, of β-dystroglycan) (Einbond et al, 1996), and it is frequently associated 
with other domains typical for proteins in signal transduction processes, such as γ1-
syntrophin (Culligan et al, 2002). An unknown domain separates the WW domain from 
the ZZ (zinc-binding)-type zinc domain. The ZZ domain is able to bind two zinc 
atoms, and contains finger-like protrusions that make tandem contacts with their target 
molecule, thought to function in protein-protein interactions. 
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                        The coding significance of classical exon 78 and delta exon 78, for 
classical and delta dystrophin proteins respectively, is not known. Both exons encode 
two completely different sequences to one another (figure 1.1.2.2). In chapter 3 & 4 I 
have investigated the significance of these exons. I have determined whether they are 
homologous to any already established functional domains recently published on the 
database. What is more, I have tested whether this C-terminal difference affected the 
subcellular distribution and function of classical full-length dystrophin when compared 
to delta full-length dystrophin.  
 
                        Shorter classical and delta dystrophin isoforms are identical to the 
classical and delta full-length dystrophin isoforms, but lack parts of the N-terminus 
domain, as shown in figure 1.1.2.1.. 
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                    1.1.5 DMD gene mutations  
 
                        The DMD gene has a high mutation rate, 1 x 10–4 genes per generation 
(Amalfitano et al, 1997), that occurs at a frequency of about 1 in 3,500 new born males 
(Emery et al, 1993). Duchenne Muscular Dystrophy (DMD) and Becker Muscular 
Dystrophy (BMD) are two disease phenotypes that originate by mutation of the DMD 
gene. As a result, the brain and other organs are affected. Approximately one third of 
all new cases result from a spontaneous mutation (Barbujani et al, 1990; Anderson et 
al, 2002; Nowak et al, 2004) of the DMD gene, these are mostly due to very small 
deletions and point mutations that lead to premature stop codons (reviewed in Blake et 
al, 2002). Hundreds of independent mutations can be found (reviewed in Blake et al, 
2002) which include frame-shift (due to insertion), deletion or point mutations 
(www.dmd.com). Spontaneous mutations seem to lead to the expression of very 
unstable protein products, which may explain the very low amounts of the protein that 
can be detected (reviewed in Blake et al, 2002). 
 
                        Depending on the type of DMD gene mutation, a more severe (DMD) 
or less severe (BMD) phenotype is obtained. The most common type of mutation in the 
DMD gene is an intragenic deletion. In fact these account for 65% of dystrophin 
mutations, whose consequences can induce either the DMD or the milder BMD 
phenotype. Less frequent mutations are gene duplications that account for only 5-15% 
of the cases of dystrophin mutations. There are two ‘hot spots’ where large deletions 
often take place, and these are found to cluster in exons 45-53 (which remove part of 
the dystrophin rod domain), and exons 2-20 (which remove some or all of dystrophin 
actin-binding domain, and part of its rod domain) causing the DMD phenotype 
(reviewed in Blake et al, 2002). Outside of these ‘hot spots’ however, there have been 
only a few cases, whereby gross deletions do not shift the normal open reading frame, 
and smaller but functional truncated dystrophin proteins are produced, leading to the 
milder BMD form (reviewed in Blake et al, 2002; reviewed in Muntoni et al, 2003). 
 
                        The “reading frame hypothesis” represents 90% of DMD gene mutations 
observed to date, and is commonly used both as a diagnostic confirmation of 
dystrophinopathies and for the differentiation of DMD and BMD (reviewed in Muntoni 
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et al, 2003). In DMD, deletion and duplications have been observed which disrupt the 
reading frame (frame-shift, also known as out of frame), resulting in unstable RNA that 
eventually leads to the production of nearly undetectable concentrations of truncated 
proteins, hence leading to the more severe dystrophy named DMD (reviewed in Muntoni 
et al, 2003). In BMD, mutations have been observed which maintain the reading frame 
(in-frame), generally resulting in abnormal but partly functional dystrophin, hence 
leading to the less severe dystrophy named BMD (reviewed in Muntoni et al, 2003). 
There is no relation between the size of the deletion and the resultant clinical disease, as 
shown in a BMD patient that possessed a large deletion that involve nearly 50% of the 
gene (England et al, 1990). On the contrary, deletion of exon 44 only, was found in a 
patient with DMD. Generally, the outcome on the severity of the disease is manifested 
by the in-frame or out-of-frame nature of the mutation, rather than the size of the deletion 
(reviewed in Muntoni et al, 2003). When studying the effects that mutations have on the 
dystrophin protein, Legardinier et al (2009) and Singh et al (2010) showed that 
mutations alter the stability and folding processes of the protein, leading to a decrease in 
the net functional dystrophin concentration. These mechanisms shed light as to how 
mutations trigger muscular dystrophy. 
 
                        There are exceptions to “the reading frame hypothesis”, however, where 
frame-shift mutations yield a BMD phenotype rather than the expected DMD 
phenotype (reviewed in Muntoni et al, 2003). These mutations can either be a result of 
deletions or duplications in the 5’ end of the DMD gene (exons 3-7; 5-7; 3-6) or further 
downstream (exons 51, 49-50, 47-52, 44 or 45). If these children have no family 
history of such a disease, diagnosis of the severity of the disease with a purely 
molecular genetic approach (for example, forward genetics) may be difficult in these 
patients. In fact, only some will develop DMD or BMD (reviewed in Muntoni et al, 
2003). It is not clear why, it may be down to the efficiency in exon skipping, creating 
in-frame deletions which lead to the production of functional dystrophin. Therefore, 
the best method to diagnose whether the disease necessarily develops or not, would be 
to carry out a muscle biopsy in this patient in order to verify whether dystrophin is 
produced or not. Only at this point can the severity of the disease be predicted 
(reviewed in Muntoni et al, 2003). Exon skipping events, whereby the cellular 
machinery is encouraged to “skip over” specific exons, are limited to a few fibers and 
are routinely found in the dystrophin deficient mdx mice and in about 50% of children 
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with DMD. The induction of exon skipping (by using small pieces of DNA called 
antisense oligonucleotides (AO) in order to mask the exon that needs to be skipped) is 
currently being investigated for gene therapy by several researchers, in the hope that it 
will provide a possible therapeutic strategy in the future for patients with DMD 
(reviewed in Muntoni et al, 2003; Wilton et al, 2008). 
 
                        A second exception to “the reading frame hypothesis” involves the 
diagnosis of in-frame mutations that yield DMD rather than then the expected BMD 
phenotype. Normally the disease phenotype is related to the ability to produce 
dystrophin. But this is not always the case. There are exceptions whereby the disease 
phenotype is dictated by the location of the mutation along the gene. For instance, in-
frame deletions of the rod domain generally seem to cause BMD, as long as the amino 
and carboxy-termini of dystrophin are maintained. On the other hand, when the 5’ ABS 
domain has an in-frame deletion of say, exons 3-13, this is usually associated with 
DMD. Disruption of the ABS domain, severely affects the ability of the dystrophin 
protein to link the cytoskeleton of the cell with neighboring cells, via the DPC 
complex. Thus it would resemble a situation where no dystrophin protein is expressed 
(reviewed in Muntoni et al, 2003). 
 
                        As highlighted earlier, the brain and the muscle exhibit differences in 
the severity of the disease. One of the causes is due to the different physiological 
stresses they are faced with. Secondly, the differences between the brain and the 
muscle is further accentuated by the location of the mutation along the gene. In the 
muscle, mutations at the 5’-end of the dystrophin protein disrupt the ABS domain of 
full-length dystrophin, the only dystrophin expressed in the muscle, thus blocking the 
intercellular linkage of neighboring cells leading to muscle wasting. The situation in 
the brain is completely the opposite. In fact, mutations in the 5’-end of the dystrophin 
protein reduce the severity of the mental impairment in brain (reviewed in Muntoni et 
al, 2003). This is because mutations found at the 5’-end only affect the full-length 
dystrophin isoforms, but the brain also contains shorter dystrophin isoforms that lack 
the exon containing the mutation of full-length dystrophin, hence leaving intact the 
transcription and function of all remaining shorter isoforms, and hence the DPC-like 
complexes they are found in brain are able to function as normal.  Consistent with this, 
DMD patients that possess 5’ mutations have been diagnosed with just a mild form of 
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cognitive impairment. On the other hand, DMD patients found to have mutations in 
proximity to the 3’-end of dystrophin gene, causes a disruption of all classical 
dystrophin isoforms in the brain, and as a consequence, these DMD patients have been 
diagnosed with more severe cognitive impairment (reviewed in Muntoni et al, 2003). 
The availability of a greater number of dystrophin isoforms in the brain may partly 
explain why the mental disorders in DMD patients are less severe than the outcomes in 
the muscle. 
 
                        DMD patients display a range of cognitive deficits including memory 
impairments, and these have been attributed to a lack of dystrophin in brain structures 
involved in cognitive functions, such as the hippocampus and neocortex (Anderson et 
al, 2002). Classical dystrophin is a major candidate protein considered to participate in 
cognitive deficits of DMD, but with the discovery of several shorter C-terminal 
isoforms of the full-length protein, the complexity of studies directed at understanding 
the molecular and cellular bases of the cognitive impairment in brains of DMD has 
increased in complexity. It is believed that the absence of classical full-length 
(427kDa) brain dystrophin affects cognitive function to a variable extent, although 
most patients exhibit some degree of memory deficits (Hinton et al, 2000), whereas 
mutations also affecting the shorter forms of dystrophin lead to more severe cerebral 
dysfunction (Moizard et al, 1998). However, the nature, magnitude and biological 
support of the cognitive deficits involving classical full-length dystrophin still remain 
unclear, and it is still just partly addressed by studies in the dystrophin-deficient mouse 
(see the subsequent section), a genetic model of DMD commonly named the mdx 
mouse (Anderson et al, 2002; Vaillend et al, 2002; Vaillend et al, 2004). This mouse 
model shows that total deficiency of full-length dystrophin alone, leads to abnormal 
brain responses recorded via a number of electrophysiological studies. It is important 
to note that in the brain of mdx mice, all remaining shorter dystrophin isoforms remain 
intact, as the mutation is not in the sequence containing shorter dystrophin isoforms. 
Hence the brain malfunctions in mdx mice is exerted and can therefore be attributed to 
the full-length dystrophin alone, rather than the truncated isoforms. In this thesis, I 
therefore focus on full-length dystrophin protein only. 
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                    1.1.6 A naturally occurring mutation in mice to study the 
function of dystrophin in brain: the mdx mouse 
 
                        Studies on dystrophin CNS function have benefited from the mdx 
mouse, a naturally occurring animal model for DMD that has been available for over 
20 years (Allamand et al, 2000). Mdx mice arise via a naturally occurring point 
mutation in exon 23 of the DMD gene that creates a premature stop codon. The 
pathological dystrophin transcripts lack the normal N-terminus and therefore are 
unable to attach to the plasma membrane and are degraded in the cytoplasm, leading to 
total deficiency of full-length dystrophin protein in muscle (Vainzof et al, 2008). This 
total deficiency of full-length dystrophin protein is also observed in the brain of these 
mdx mice (Muntoni et al, 1991). On the other hand, the brain contains additional 
shorter dystrophin isoforms whose expression remains intact in these mdx mice models 
(Sicinski et al, 1989). At the early stages of life, mdx mice show no obvious muscle 
weakness and their lifespan is not grossly reduced unlike human DMD, however 
simple in vivo tests have confirmed that mdx mice do resemble DMD, but exhibit such 
resemblance at later times relative to the life span in humans DMD. The reasons for 
these differences between humans and mice are not known. The accessibility of the 
mdx mice model has meant that more invasive biochemical measurements have been 
possible in order to study the function of dystrophin, to screen for strategies to treat the 
disease, and also to test the treatments on these mice (Allamand et al, 2000).  
 
                        The major clinical issue in DMD is the skeletal muscle pathology, 
however there is now a sufficient body of data to appreciate that the brain functions of 
these patients are impaired (Anderson et al, 2002). Cognitive defects are non-
progressive in these brains (Emery et al, 1993), and have been linked to the absence of 
classical full-length dystrophin that is otherwise expressed in cerebral structures 
involved in cognitive functions, such as the hippocampus and neocortex (Lidov et al, 
1996). The functional importance of classical full-length dystrophin in the brain has 
been reported in numerous studies in mdx mice. The mdx mutant shows morphological 
alterations of pyramidal neurons (Sbriccoli et al, 1995), specific learning and memory 
deficits (Muntoni et al, 1991, Vaillend et al, 1995; Vaillend et al, 1998), facilitated 
synaptic plasticities (Vaillend et al, 2002), altered neuronal calcium homeostasis (Hopf 
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et al, 1992), and enhanced sensitivity of CA1 hippocampal neurons to hypoxia (Mehler 
et al, 1992). 
 
                        The mdx mouse is not the only mouse model created to represent DMD, 
but it is the most commonly used mouse model to study the brain and muscle. Only 
briefly, a number of mdx strains will be described. The mdx2cv mouse model contains a 
point mutation in the splice acceptor sequence of intron 42 that abolishes the 
expression of Dp427 and Dp260 only, whilst the remaining shorter dystrophin isoforms 
continue to be expressed (Im et al, 1996). The mdx3cv mouse model contains a mutant 
splice acceptor site in intron 65 that abolishes the expression of all dystrophins (Sesay 
et al, 1996; Im et al, 1996; Vaillend et al, 1998). The mdx4cv mouse model contains a 
point mutation in exon 53 that abolishes the expression of Dp427, Dp260 and Dp140, 
thus allowing only the expression of Dp116 and Dp71 isoforms (Im et al, 1996). The 
mdx5cv mouse model contains a 53bp deletion in exon 10 generating a premature stop-
codon that impedes the expression of Dp427, whilst the remaining shorter dystrophin 
isoforms continue to be expressed (Im et al, 1996). The mdx5cv mice have been 
reported to display essentially the same muscle pathology as mdx mice, with additional 
phenotypes observed (Im et al, 1996). 
 
                        Recently, and most importantly, a DMD-null mouse model has been 
produced via a 2.4Mb deletion of dystrophin gene (the entire DMD gene) through the 
use of Cre-loxP recombination system (Kudoh et al, 2005). The DMD-null mouse 
model is important as it is the only mouse model where there is absolutely no 
expression of the dystrophin protein or isoforms. In contrast, a range of reversion 
frequencies has been reported in the various mdx strain mouse models listed above 
(Danko et al, 1992). Given that the production of multiple dystrophin isoforms through 
alternative splicing or exon skipping is totally prevented in the DMD-null mouse, these 
new mutants will provide an improved model system for functional studies of 
dystrophin and its isoforms. With this recombination system, it is possible to 
specifically inactivate the expression of specific isoforms in the brain, and study their 
individual functions. Regardless the availability of different DMD mouse models, the 
mdx alone remains the most widely used mouse model to study the neurodegenerative 
and muscle disease in DMD (Allamand et al, 2000; Durbeej et al, 2002; Collins et al, 
2003). This is because the phenotypic discrepancies between all the mouse strains 
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currently available have not been explained clearly, furthermore, they all show similar 
phenotype and little advantage over the original mdx model (Allamand et al, 2000; 
Durbeej et al, 2002; Collins et al, 2003).  
 
                        Through the availability of the mdx mouse brains, there is histological 
evidence connecting cognitive impairment with the lack of classical full-length 
dystrophin in the brain. First of all, the cell packaging of the mdx mouse is varied when 
compared to control mice. For example, some mdx brains have been found to have a 
higher cell packing density than controls, whereas other mdx brains contained a lower 
cell density than controls (Anderson et al, 2002). What is more, these brains often 
exhibit neuronal loss, gliosis, neurofibrillary tangles, Purkinje cell loss, dendritic 
abnormalities, disordered architecture, astrocytosis and perinuclear vacuolation 
(Anderson et al, 2002). The Red nucleus, a structure in the restral (anterior) midbrain 
involved in motor coordination, revealed significantly lower cell counts in mdx 
animals when compared to controls (Carretta et al, 2001). Sbriccioli et al (1995) 
demonstrated a reduced number of cortico-spinal neurons in the major motor pathway 
of the cortico-spinal (CS) system when compared to controls, suggesting an 
involvement of the CNS in DMD (Sbriccioli et al, 1995; Carretta et al, 2001; Carretta 
et al, 2003; Carretta et al, 2004; Venoux et al, 2008). In analogy to mdx mice, in DMD 
brains examined pathologically, there is evidence of disordered cortical architecture, 
predominantly in frontotemporal regions, altered neuronal migration, and abnormal 
neuronal orientation with attenuated terminal dendritic arborizations (Mehler et al, 
2000). Variable decreased cortical excitation is also a feature in patients with DMD 
(Mehler et al, 2000).  
 
                        Muntoni et al (1991) was the first to report cognitive deficit in the mdx 
mice following mass training in the water maze, and noticed a reduced memory of the 
passive avoidance response in mdx mice when compared to controls. Vaillend et al 
(1998) also found that following massed training in the water maze, mdx mice are not 
impaired in task acquisition, procedural memory, behavioral exploration of a novel 
object, nor the encoding of a new experience or short-term memory for objects (Sesay 
et al, 1996, Vaillend et al. 1998). However, the consolidation or expression of long-
term recognition memory and long-term spatial memory was impaired in mdx mice, 
whilst their acquisition abilities remained unaffected (Vaillend et al, 1995; Vaillend et 
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al, 2004). The impairments described above are very similar to the brain dysfunctions 
observed in DMD patients (Kim et al, 1992). 
 
                        To identify the cellular mechanisms that may underlie the deficits in 
DMD brains, a number of electrophysiological studies have been carried out in the 
brains of mdx mice. Although no single region of the brain is solely responsible for the 
formulation or recall of memories, numerous observations implicate the hippocampus 
(Deng et al, 2009). For example, a human patient who received a bilateral 
hippocampectomy lost all ability to remember recent events, although long-distant 
memories and higher, abstract cognitive skills remained intact (Scoville et al, 1957). 
Similarly, rodents with hippocampal lesions show impaired memory (Morris et al, 
1982). Together, these observations indicate that the hippocampus may be a site in the 
central nervous system in which functional defects result from the loss of full-length 
dystrophin (Deng et al, 2009), and is therefore used by electrophysiologists to study 
the altered functions of mdx brains. 
 
                        Electrophysiological studies show that although basal synaptic 
transmission in mdx mice is similar to that observed in wild type (wt) (Vaillend et al, 
2002), dystrophin deficiency in CA1 hippocampal neurons facilitates the induction of 
short-term potentiation (STP) and depression (STD), early long-term potentiation 
(LTP) and depression (LTD) of glutamatergic neurotransmission in mdx mice 
(Vaillend et al, 1998; Vaillend et al, 1999; Vaillend et al, 2002; Vaillend et al, 2004; 
Kueh et al, 2008). These forms of synaptic plasticity in CA1 hippocampal neurons are 
known to be via the NMDA receptor of glutamatergic synapses (Vaillend et al, 2002). 
The enhanced NMDA receptor-mediated synaptic plasticity in mdx mice may be due to 
a reduced GABAergic neurotransmission due to dystrophin deficiency (Vaillend et al, 
2002). In fact, Knuesel et al (1999) found classical full-length dystrophin co-localizes 
with GABAA receptors clusters at inhibitory synapses in wild type (wt) mice. The 
author (Knuesel et al, 1999) reports a 50% decrease in the number of GABAA receptor 
clusters in the hippocampus of mdx mice, which may reduce GABAergic 
neurotransmission, thus increasing the capacity of NMDA receptor to be activated. 
This is possible because Vaillend et al (2002) showed that by application of a GABAA 
receptor antagonist bicuculline, both mdx and wt respond with the same magnitude of 
potentiation. Hence, the abnormal organization of GABAA receptor clusters is involved 
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in facilitating synaptic activities, and may do so by reducing GABAergic 
neurotransmission (Vaillend et al, 2002; Vaillend et al, 2004; Kueh et al, 2008), 
leading to the various facilitated forms of plasticity observed in mdx mice. Vaillend et 
al (2002) further showed that it is the reduced Mg2+ ion block in NMDA receptors of 
mdx that enhances the NMDA receptor mediated synaptic plasticity in mdx mice. This 
is because when they reduced the Mg2+ ion concentration in the bath, the facilitated 
induction in mdx was blocked and became similar to wild type. All in all, the lack of 
classical full-length dystrophin disrupts the GABAA receptor cluster size, which may 
reduce inhibitory neurotransmission. Thus, although the mechanism is not known, it 
may modulate the voltage-dependent block of NMDA receptor by Mg2+, hence, 
facilitating synaptic activities in mdx mice (Vaillend et al, 2002). 
 
                        The absence of dystrophin may have important consequences in cellular 
signal integration, in addition to the already stated membrane integrity, ion channel 
physiology, and structural reorganization of the synapse (Mehler et al, 2000). This too 
may underlie some of the behavioural problems and cognitive impairment reported in 
DMD (Kueh et al, 2008). DMD and mdx exhibit an 80% loss of an enzyme named 
nitric oxide synthase (NOS) because dystrophin deficiency leads to a secondary loss of 
a specific form of NOS in muscle, named nNOS (neuronal NOS) (Brenman et al, 1995; 
Chang et al, 1996; Deng et al, 2009). Interestingly, the concentration of nNOS in the 
brain is not affected in mdx mice (Deng et al, 2009). The consequences for a loss in 
NOS activity are numerous. NOS activity produces NO, and the muscle-derived NO is 
not only used by the muscle but it is also delivered elsewhere via the systemic 
circulation for use by other organs, such as the brain. The brain produces its own NO 
but also makes use of systemic NO, and NO is said to normalize cell proliferation and 
neuronal differentiation in the dendate gyrus (DG) of the hippocampus (Deng et al, 
2009). In fact, muscle-derived NO regulates adult neurogenesis in the brain and loss of 
muscle nNOS has been shown to abnormally increase cell number and cell density in 
DG (Deng et al, 2009). Therefore, loss of muscle-derived NO in mdx mice may 
underlie the cognitive defects in the CNS of DMD patients (Deng et al, 2009). 
Dystrophin is therefore important for preventing the loss of nNOS in muscle.  
 
                        Through the availability of mdx, Wehding-Henricks et al (2009) 
showed that there is a reduction in the glycolytic metabolism and an increased 
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fatigability in dystrophin muscle. They propose that loss of nNOS may underlie the 
defects in glycolytic metabolism observed in mdx mice. This is because their studies 
demonstrate that mdx mice containing nNOS transgene, the glycolytic metabolism is 
enhanced and the endurance of mdx mice increased. What is more, they demonstrate 
that nNOS can modulate the glycolytic pathway by directly interacting with a rate-
limiting enzyme of the glycolytic pathway, named phosphofructokinase (PFK). They 
also show that PFK activity is increased upon binding to nNOS transgene. They 
conclude that a loss of positive allosteric interaction between nNOS and PFK may 
partly underlie the defects in glycolytic metabolism observed in mdx muscle. 
Dystrophin is therefore somehow important in promoting such interaction between 
nNOS and PFK. 
 
                        The metabolic profile in mdx is easily distinguishable from wild type 
(wt). In mdx brain, a number of metabolic processes are affected, and these include β-
oxidation, the TCA cycle, phosphocreatine/ATP cycle, lipid metabolism and 
osmoregulation (Griffin et al, 2001). Mdx mice have also been shown to be more 
sensitive to brief periods of severe hypoxia compared to wt, as synaptic transmission in 
the CA1 region of mdx mice is markedly more sensitive to hypoxia-induced damage 
compared to wild type. This suggests dystrophin plays an important role in protecting 
neurons from hypoxia-induced damage (Mehler et al, 1992), but the precise 
mechanism is yet to be established. It is being suggested that the altered response to 
hypoxia may also be influenced by the reported reduced GABAA receptor clustering in 
mdx mice (Knuesel et al, 1999), as GABAA receptor activation has been shown to 
exacerbate oxygen deprivation-induced neuronal injury (Muir et al, 1996). What is 
more, mdx neurons have increased intracellular calcium when compared to wt (Hopf et 
al, 1992), due to a calcium-specific regulatory defect in granule neurons. Changes in 
neuronal calcium homeostasis could have profound implications for the proper 
elaboration of a number of integral cellular functions, including excitability, 
associativity, neurotransmitter release, synaptic plasticity, gene transcription and the 
graded regulation of neuronal firing patterns (Mehler et al, 2000).  A 
compartmentalized elevation of calcium could have a consequence of activating 
proteolytic enzymes and or apoptotic pathways (Burdi et al, 2009). Altogether, all 
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these mechanisms are likely to participate in generating the mental impairments 
observed in DMD patients, due to the absence of functional dystrophin. 
 
                        As therapeutic approaches to DMD are being developed, mutant 
animals represent good models in which they can be tested (Allamand et al, 2000). It is 
the ease with which the murine genome can be manipulated that has made it 
particularly useful in testing functional hypotheses. Early transgenic experiments, using 
full-length as well as mini-dystrophin constructs, have demonstrated that expression of 
20% of the dystrophin protein is sufficient to prevent the development of muscle 
pathology in mdx mice, thus generating great hope for a treatment for DMD (Allamand 
et al, 2000). Proteosome inhibitors as a therapy for DMD has been tested in mdx mice 
and results emphasise the effectiveness of the pharmacological approach as a potential 
treatment for DMD (Bonuccelli et al, 2007). 
 
                        The mdx mouse is the most effective model for characterizing the 
structural and functional properties of dystrophin and therapeutic interventions 
(Chamberlain et al, 2007). The study of animal models for genetic diseases, in spite of 
the existence of differences in some phenotypes, can provide important clues to the 
understanding of the pathogenesis of these disorders and are also very valuable for 
testing strategies for therapeutic approaches (Vainzof et al, 2008). For clinical trials, it 
is being suggested to move one step forward from the mdx mouse, and use the canine 
golden retriever MD model, as it represents a more clinically similar model of DMD 
due to the animals larger size and significant muscle weakness (Vainzof et al, 2008).  
 
                        In conclusion, studies carried out on mdx mice have demonstrated that 
brain full-length dystrophin performs diverse developmental and mature cellular 
functions. In the mature state these cellular functions are limited to a highly restricted 
subset of anatomically distributed neuronal subpopulations. These particular 
populations may mediate the specific cognitive functions and subsystems that are 
impaired in patients with DMD. There is contradicting evidence on the function of full-
length dystrophin during development. Some say (Mehler et al, 2000) that full-length 
dystrophin may be involved in neuronal migration, cellular maturation and 
synaptogenesis during neural development (Mehler et al, 2000), whereas other 
researchers (Tretter et al, 2008) suggest that full-length dystrophin is unlikely to induce 
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synaptogenesis. It is being suggested that dystrophin may orchestrate the dynamic 
organization of neuronal microdomains by regulation of the orientation, spatial array 
and complement of multiple cellular proteins (Mehler et al, 2000). It is important to 
note that the mdx mutation of full-length dystrophin in the brain leads to the abolition 
of classical full-length dystrophin, as well as delta full-length dystrophin. It is therefore 
important to establish the functions of delta full-length protein. As previously stated, 
one of the major aims of this thesis was to study the molecular associations and 
subcellular localization of delta full-length dystrophin to determine its potential 
involvement in the pathology of DMD. 
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                    1.1.7 Protein interactions of the DMD gene product: the 
DPC complex 
 
                        Through a series of co-immunoprecipitation, yeast two-hybrid 
interactions and co-localization studies, classical full-length dystrophin has been found 
to interact with a range of proteins, which in analogy to the muscle, make up the DPC 
complex in the brain (figure 1.1.7.1).  The brain contains a variety of DPC-like 
complexes whose composition varies according to the cell-type it is found in and the 
dystrophin isoform it associates with (Blake et al, 1999; Culligan et al, 2002; Graf et 
al, 2004; Blake et al, 2009; Pilgram et al, 2009; Waite et al, 2009). In this thesis, only 
the DPC complex containing the classical full-length dystrophin is described and 
investigated. In the brain, the DPC complexes containing classical full-length 
dystrophin are exclusively localized at PSD structures of inhibitory synapses (Brunig et 
al, 2002) whereas DPC complexes containing the shorter dystrophin isoforms are said 
to localize in glial cells (Blake et al, 1999; Culligan et al, 2002; Graf et al, 2004; Blake 
et al, 2009; Pilgram et al, 2009). DPC complexes containing classical full-length 
dystrophin comprise of: a transmembrane and extracellular domain (α, β-
dystroglycan), a cytoplasmic complex (classical full-length dystrophin, syntrophin-
(α1, γ1, γ2), β-dystrobrevin and neuronal nitric oxide (nNOS) ) and an extracellular 
domain (figure 1.1.7.1). While some say (Blake et al, 2009; Pilgram et al, 2009) that 
α-neurexin is the extracellular component that links to the DPC, others state that only 
β1-neurexin, rather than α-neurexin, is present at inhibitory synapses and associates 
with the DPC (Culligan et al, 2002; Graf et al, 2004). Classical dystrophin is always 
found associated with the DPC complex only, and it never appears to be on its own 
(Brunig et al, 2002), therefore, based on studies on mdx mice, this implicates the entire 
DPC complex, and not just classical full-length dystrophin, to participate in brain 
impairments found in DMD brains. 
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Figure 1.1.7.1: The established molecular organization of the DPC complex in 
neurons. 
This figure shows the suggested model for the DPC complex present at PSDs of 
GABAergic synapses. Post-synaptic density (PSD), β-Neurexin (β-NX), α-
dystroglycan (α-DG), β-dystroglycan (β-DG), syntrophin (α1 and γ1), Neuronal 
nitric oxide synthase (nNOS), β-dystrobrevin (β-DB), classical full-length 
dystrophin (cDp427), GABAA receptor (GABAAR). For the purpose of clarity, only 
a subset of syntrophin isoforms has been added. This figure is adapted from Culligan 
et al (2002), Pilgram et al (2009) and Waite et al (2009). 
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                        The molecular interactions between the DPC components are as 
follows. The extracellularly exposed side of α-DG (the N-terminus) binds with high 
affinity (figures 1.1.7.1 & 1.1.7.2) to pre-synaptic β1-neurexins (LNS domain) (Graf et 
al, 2004), and the latter associates with post-synaptic neurologin 2 (Clarris et al, 2002; 
Graf et al, 2004). The C-terminal domain of α-DG (figure 1.1.7.2) forms non-covalent 
contacts with the N-terminus ectodomain of β-DG (Sciandra et al, 2001). β-DG has a 
transmembrane domain, hence it anchors the entire DPC complex into the postsynaptic 
membrane of GABAergic synapses (figures 1.1.7.1 & 1.1.7.2). The intracellular 
domain of β-DG contains a 15 amino acid C-terminus WW domain  (Hnia et al, 2007) 
that binds to the WW-domain of classical dystrophin (Cavaldesi et al, 1999; Huang et 
al, 2000). The EF hand and the ZZ-type-zinc finger domains (figure 1.1.2.2) in the 
classical dystrophin protein stabilize and strengthen this interaction  (reviewed in Blake 
et al, 2002). Classical dystrophin utilises the CH domain to enable a tight interaction 
with actin, such that the protein and the entire DPC complex is anchored to the 
cytoskeleton that underlies the membrane of neurons (figure 1.1.7.1). The coiled coil 
region of β-dystrobrevin (figure 1.1.7.3) is required to associate with the coiled coil 
region of classical dystrophin (Peters et al, 1997). Classical dystrophin has an unknown 
domain that separates the ZZ-type domain from the coiled-coil region, found at the C-
terminus of dystrophin, and is made of two heptad repeats of leucine that make up 
helical coils (reviewed in Blake et al, 2002) with which it can bind to syntrophins 
(figure 1.1.7.4). R16 and 17 in classical full-length dystrophin anchor nNOS to the 
membrane (Lai et al, 2009) whereas β-dystrobrevin contains two syntrophin binding 
domains within the ZZ domain, which enables its interaction with the PH2 and SU 
domains of syntrophin (Blake et al, 2002; Blake et al, 2009) (figure 1.1.7.4). The 
syntrophins utilize their PDZ domain to interact with the PDZ domain of nNOS 
(Brenman et al, 1995; Albrecht et al, 2002). 
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Figure 1.1.7.2: Domain structure of α and β-dystroglycan.  
 
The figure shows the domain structure of α and β-dystroglycan. The two proteins 
initially arise as a single dystroglycan product followed by a post-translational 
cleavage site (serine), generating two dystroglycan products: α and β-dystroglycan.  
The N-terminal (residues 35-315) globular domain of α-dystroglycan is utilised for 
binding to the LNS domain of pre-synaptic β1-Neurexin. The mucin-like region 
separates the N-terminus from the C-terminus of the α-dystroglycan protein. The C-
terminal (residues 485-651) globular domain of α-dystroglycan forms non-covalent 
contacts with the N-terminus ectodomain of β-dystroglycan. The transmembrane 
domain (TM) of β-dystroglycan anchors the entire dystroglycan complex to the 
membrane, whereas the WW domain of β-dystroglycan binds to the WW domain of 
classical dystrophin. This figure is adapted from Zaccaria et al (2001) and Hnia et al 
(2007). 
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Figure 1.1.7.3: Domain structure of β-dystrobrevin.  
The figure shows the domain structure of β-dystrobrevin. Two EF hands and one ZZ 
domain comprise the cysteine-rich domain. The EF hands domain contains hairpins of 
α-helices that can bind Ca 2+, while the ZZ domain, a putative zinc finger, may 
function as a calmodulin-binding site. The carboxy-terminal domain comprises of a α-
helical region and two sets of helical leucine-heptad motifs (H1 and H2). The α-
helical region contains two syntrophin binding sites (asterisks), one of which is within 
the vr3 (alternatively spliced variable region 3) region. The two helical leucine-heptad 
motifs (H1 & 2) are predicted to combine to form the coiled-coil region, which binds 
to the coiled-coil region located on dystrophin. This figure is adapted from Newey et 
al (2000), Albrecht et al (2002).  
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Figure 1.1.7.4: Domain structure of syntrophin isoforms.  
The figure shows the domain structure of syntrophin isoforms. Syntrophins are 
molecular adapter proteins found at the cytoplasmic side of the peripheral 
membrane. They contain at least one plekstrin homology (PH) domain utilized to 
bind phosphoinositol 4,5-phosphate. The PDZ domain is utilized to interact with 
other PDZ-containing proteins, such as signaling molecule nNOS (Brenman et al, 
1995). Syntrophin utilizes PH2 and the syntrophin unique (SU) domain to associate 
with the ZZ domain of β-dystrobrevin (Blake et al, 2002; Blake et al, 2009), and 
utilizes these same domains to associate with dystrophin (Piluso et al, 2000, Chen et 
al, 2006; Blake et al, 2009). The SU domain is slightly different in each syntrophin 
isoform and this ensures each syntrophin isoform to have different specificities to 
the protein it associates with. The figure is adapted from Albrecht et al (2002). 
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                   1.1.8 The functions of the DPC complex in brain 
 
                        DPC complexes containing classical full-length dystrophin localize at 
PSD structures of GABAergic synapses and are said to be important for cell-cell 
adhesion. Such adhesion is provided by the dystroglycan (DG) complex (figure 
1.1.7.2), the core component of the DPC complex of the PSD, as it is capable of 
associating with the pre-synaptic nerve ending, hence linking neighboring cells to one 
another (Ervasti et al, 1993; Moore et al, 2010). Precisely, dystroglycan associates with 
the pre-synaptic protein neurexin, and concominantly associates with the post-synaptic 
protein dystrophin, which in turn binds to actin. Altogether these DPC components 
provide cell-cell adhesion, by linking the intracellular actin-binding dystrophin protein 
to the extracellular pre-synaptic β1-neurexin of a neighboring cell.  There is definite 
evidence that disruption of dystroglycan expression in brain impairs neuronal adhesion 
at some sites (Moore et al, 2002; Satz et al, 2010). In fact, Cre-inducible conditional 
mutation in the dystroglycan gene of mouse neuronal cultures showed that the knock-
out of the dystroglycan gene eliminated the entire DPC complex from GABAergic 
synapses (Luscher et al, 2004), and impaired neuronal adhesion at these synapses 
(Moore et al, 2002).  
 
                        The DPC is also important for post-synaptic differentiation (Clarris et 
al, 2002; Graf et al, 2004), based on the association between the pre-synaptic protein 
β1-neurexin and post-synaptic neurologin-2, which initiates the clustering of post-
synaptic GABAA receptors at inhibitory synapses. Upon the formation of GABAA 
receptor clusters, the DPC complex prevents disassembling, or shifting of GABAA 
receptors around the synapse. Hence the DPC complex is also important for stabilizing 
the newly formed GABAA receptor clusters. Maintaining the stability of GABAA 
receptor clusters is important, as these are then able to respond to a major inhibitory 
neurotransmitter named GABA, which translates into inhibitory synaptic responses 
(Clarris et al, 2002; Graf et al, 2004). In DMD patients, the DPC complex is unable to 
stabilize GABAA receptors (Knuesel et al, 1999), therefore the GABAA receptor 
clusters disassemble, the inhibitory responses of the neuron become altered, this may in 
part underlie the mental impairments exhibited in these patients. Hence, the DPC 
complex may participate in mental impairments of DMD patients. 
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                        The DPC complex may participate in memory formation. In fact, mice 
that have dystroglycan selectively deleted in the brain only, but whose expression 
continues and is unaltered outside the brain, showed that defects in the dystroglycan 
gene, a core component of the DPC complex, is central to the pathogenesis of 
structural and functional brain abnormalities (Moore et al, 2002; Satz et al, 2010). 
High frequency stimulation (HFS) induced in hippocampal neurons of mice brains 
lacking dystroglycan, induced only a short-term potentiation (STP) rather than the 
expected long-term potentiation (LTP) as obtained in control mice (Moore et al, 2002). 
This suggests dystroglycan is required for HSF-induced LTP at CA3-CA1 synapses in 
the hippocampus (Moore et al, 2002). Satz et al (2010) studied in more detail the 
functions of dystroglycan in the brain, and provided genetic evidence that dystroglycan 
functions in the adult and developing CNS are cell-type specific. In fact, when Satz et 
al (2010) selectively deleted dystroglycan expression from neurons only, whilst 
dystroglycan expression in glial cells was allowed to continue, he found that the 
cytoarchitecture of these mice appeared normal. Satz et al (2010) therefore suggested 
that loss of dystroglycan expression in glial cells is the primary mechanism responsible 
for the abnormal cytoarchitecture of the cerebral cortex observed in dystroglycan null 
mouse brain. Hence, dystroglycan in glial cells, but not in neuronal cells, is involved in 
generating the normal cytoarchitecture of the cerebral cortex. What is more, Satz et al 
(2010) was also able to demonstrate that deletion of dystroglycan expression in 
neurons blunted hippocampal LTP, indicating that in neurons, dystroglycan is involved 
in synaptic activity. Given that dystroglycan is part of the DPC complex in neurons and 
glial cells (Blake et al, 1999; Brunig et al, 2002), these results suggest that the 
structural and functional brain abnormalities in DMD may be a consequence of DPC-
like complexes in astrocyte cells in addition to the DPC complex found at the PSD of 
neuronal synapses. 
 
                        The precise mechanisms by which β-dystroglycan may lead to brain 
pathogenesis is unknown. Studies in Cos-7 cells have shown that β-dystroglycan 
associates with signaling molecules such as ERK, MEK2 (Spence et al, 2004) and 
Grb2 (Russo et al, 2000; Spence et al, 2004), thus β-dystroglycan appears to be 
implicated in more than one signaling pathway. This would therefore also implicate the 
DPC complex in signaling cascade events. The precise role of dystroglycan in the 
transduction and modulation of various signaling cascades is not yet clear. In muscle 
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cells it has been established that dystroglycan and integrin are both able to bind to the 
extracellular matrix laminin component, and they are said to have opposing roles in 
laminin-mediated extracellular signal-regulated kinase activation (Ferletta et al, 2003). 
In other words, upon β-dystroglycan association with laminin, the former is then able 
to target MEK to membrane ruffles rather than to focal adhesions, consistent with the 
ability of dystroglycan to suppress the activation of MEK and ERK in response to 
integrin engagement (Ferletta et al, 2003). In these muscle cells, dystroglycan may 
therefore simply sequester MEK away from the rest of the MAP kinase cascade, 
preventing the efficient phosphorylation of ERK by MEK. Whether or not 
dystroglycan exhibits the same role in neurons, still needs to be established. However 
these experiments shed light to novel functions that dystroglycan may have in neurons 
as well. MAP kinases mediate specific cellular responses, including morphogenesis, 
cell death and stress responses. Dystroglycan, via its association to laminin may be 
important in participating in the regulation of these signaling responses in the brain. 
 
                        In addition to classical full-length dystrophin and the dystroglycan 
complex, β-dystrobrevin and syntrophin (α, γ1, γ 2) are also components of the core 
DPC that are expressed in the PSD of neurons in the brain. β-dystrobrevin (figure 
1.1.7.3) is a 71kDa dystrophin-related protein cytosolic component of the DPC 
complex in the PSD, and it is suggested to participate in the transportation of some 
DPC components to specific sites of the cell (Macioce et al, 2003). The suggested 
transporting abilities of β-dystrobrevin came from a yeast two-hybrid experiment, 
which identified KIF5A as a binding partner of β-dystrobrevin. Kif5A is a neuronal 
member of the Kif5 family of proteins that consists of heavy chains of conventional 
kinesin, and is known for its role in transport of proteins along neuronal processes. The 
C-terminal region of Kif5A binds to β-dystrobrevin via the heavy-chain-mediated 
kinesin interaction (Macioce et al, 2003). There are separate studies that support the 
transportation capabilities of β-dystrobrevin, as studies show β-dystrobrevin 
translocates from the neuronal membrane and back to the nucleus. It lacks a nuclear 
localization signal and instead possesses a ZZ-domain, a feature typical of nuclear 
proteins. This nucleus to membrane translocation mechanism has also been described 
as important not just for transportation capabilities, but it also reflects a number of 
proteins that are involved in the acquisition of long-term memory (LTP) (Blake et al, 
 50 
1999).  β-dystrobrevin associates with classical dystrophin in the DPC complex, it is 
therefore possible that classical dystrophin is transported via the KIF5A-kinesin-β-
dystrobrevin complex (Ceccarini et al, 2005). The route and mechanism by which β-
dystrobrevin may transport some or perhaps all DPC components still needs to be 
established.  
 
                        β-dystrobrevin binds directly to classical full-length dystrophin through 
reciprocal coiled-coil interactions (Peters et al, 1997; Beesley et al, 1999; Albrecht et 
al, 2002). In addition, β-dystrobrevin and classical full-length dystrophin bind to the 
syntrophin protein family (figure 1.1.7.4). In the brain, there exist 3 syntrophin 
isoforms (α1, γ1, γ2) of approximately 57-60 kDa (Piluso et al, 2000). Each syntrophin 
has a characteristic domain organization in mammalian brain (figure 1.1.7.4). Two 
pleckstrin homology (PH1 and 2) domains and one PDZ domain are present, with the 
first PH domain split into two regions (PH1a and PH1b) by the PDZ domain and its 
flanking regions. Syntrophin utilizes PH2 and the SU (syntrophin unique) domain to 
associate with the ZZ domain of β-dystrobrevin (Blake et al, 2002; Waite et al, 2009), 
PH2 and SU domains are also used to associate with dystrophin (Piluso et al, 2000; 
Chen et al, 2006; Waite et al, 2009). However, in the majority of studies reporting 
these syntrophin-dependent interactions, the effect on the DPC has not been explored. 
Even so, a number of functions have been attributed to syntrophin based on its 
cytosolic binding partners. Syntrophins, like many PDZ-domain-containing proteins, 
have been shown to play a key role in targeting, anchoring and stabilizing proteins to 
the cell membrane, leading to a cascade of cellular events that would otherwise be 
unable to occur. Syntrophins may therefore implicate the DPC complex in aggregating 
and stabilizing protein complexes at the PSD. 
 
                        Syntrophins have been shown to associate with neuronal nitric oxide 
(nNOS) via reciprocal PDZ domains (Brenman et al, 1995; Brenman et al, 1996), 
anchoring nNOS to specialized cellular domains in the PSD (Thomas et al, 1998; 
Sander et al, 2000). Neuronal NO synthase (nNOS), the enzyme that consistently 
produces NO in brain (Southan et al, 1996; Deng et al, 2009), is a component of the 
DPC complex (Yoshida et al, 1994) and contributes to transmission from one neuron to 
another (Deng et al, 2009). In addition to syntrophins, other proteins bearing a PDZ 
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domain can interact directly with the PDZ domain of nNOS (Brenman et al, 1996), 
thus influencing the subcellular distribution and activity of the enzyme (Sander et al, 
2000; Thomas et al, 1998). nNOS modulates physiological functions such as learning 
and memory, neurogenesis and is involved in a number of diseases (Hindley et al, 
1997; Cheng et al, 2003; Parcker et al, 2003; Moreno-Lopez et al, 2004). The DPC is 
involved in regulatory mechanisms that control nNOS expression (Deng et al, 2009), in 
fact, loss of dystrophin from the DPC complex leads to decreased NO levels in 
dystrophic neurons (Deng et al, 2009). This in turn leads to alterations in synaptic 
plasticity normally mediated by NO (Deng et al, 2009). In conclusion, the DPC 
complex is important for affecting the subcellular distribution and function of nNOS, 
and therefore the DPC complex indirectly modulates physiological functions such as 
learning, memory, neurogenesis and more (Hindley et al, 1997; Cheng et al, 2003; 
Parcker et al, 2003; Moreno-Lopez et al, 2004).  
 
                        NO plays an important role during development (Deng et al, 2009). In 
fetal brains, nNOS concentration is significantly higher than in adults, suggesting an 
important role of NO during neuronal development (Moukhles et al, 2001). It has been 
demonstrated that NO may be involved in the regulation of process outgrowth and 
remodeling and may be capable of changing the morphology of growth cone 
(Moukhles et al, 2001). Thus lower amounts of NO in developing brains of dystrophic 
neurons may lead to altered neuron maturation and to the establishment of abnormal 
connections by developing neurons. Although syntrophin and dystrophin, and therefore 
the DPC complex, can together modulate the functions of nNOS, the cell has 
established a mechanism that can block such interaction (Moukhles et al, 2001). This is 
achieved by splicing-out exons 71-74 found within dystrophin, which removes the 
syntrophin-binding site, hence blocking the interaction between dystrophin and 
syntrophin, and any downstream signaling normally carried out by the syntrophin 
protein (Mehler et al, 2000). Thus the DPC can modulate the function of nNOS as well 
as syntrophin in neurons. 
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                                              1.1.9 Summary 
 
                        It is evident that the functions of the DPC complex in brain neurons 
containing full-length dystrophin are important for development, appropriate cell 
targeting, stability of the synapse as well as of GABAA receptors, and for bringing in 
proximity various signaling proteins which would otherwise be mislocalized and 
therefore unable to carry out their functions. Immunoprecipitation experiments and 
immunocytochemistry identify classical full-length dystrophin to always associate with 
the DPC in the PSD of the brain, and to exclusively localize at inhibitory synapses. 
There is no knowledge on the cellular localization and function of delta full-length 
dystrophin. Studies on mdx mice however, reflect the function of classical as well as 
delta full-length dystrophin in these mice, as both proteins originate from the same 
gene and are absent in the mdx mouse. To date, mental impairments have been 
attributed to the absence of full-length dystrophin protein only. With the recent 
discovery of delta full-length dystrophin (Blake et al, 1999), it is now becoming 
evident that delta full-length dystrophin, in collaboration with classical full-length 
dystrophin, may also contribute to the mental impairments observed in these mice. 
Therefore, one major aim of this thesis was to determine whether delta full-length 
dystrophin may replace classical full-length dystrophin in the formation of novel delta 
DPC complexes at the PSD of inhibitory synapses, hence participating in brain 
alterations found in the mdx mouse. As described earlier, classical and delta dystrophin 
only differ by a single exon, therefore, unless this change affects delta dystrophin’s 
localization, function or structure, it is highly likely that the latter replaces classical 
full-length dystrophin to yield novel DPC-like complexes in PSDs of inhibitory 
synapses in the brain.  
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                    1.3 ε-sarcoglycan and the DPC complex in the Brain 
        
                                      1.3.1 Introduction and major aims  
 
 
                        Recently, a protein that is known to associate with the DPC complex in 
the muscle has also been identified in the brain, but its association with the DPC 
complex in the brain remains to be established. This protein is known as ε-sarcoglycan. 
ε-sarcoglycan is a member of the sarcoglycan protein family (Chan et al, 2005), 
composed of α, β, γ, δ, and ζ-sarcoglycan (Fanin et al, 1997; Wheeler et al, 2002), 
each encoded by a separate gene. Most members of the sarcoglycan family, including 
ε-sarcoglycan, have been shown to contribute to the formation of the dystrophin-
associated protein complex (DPC) in muscle (Liu et al, 1999; Durbeej et al, 1999; 
Straub et al, 1999; Imamura et al, 2000), which serves to link the extracellular matrix 
to the cytoskeleton of the cell (Holt et al, 1998). Unlike other sarcoglycan family 
members, which are largely or exclusively restricted to muscle, ε-sarcoglycan is highly 
expressed in many tissues including brain (Roberds et al, 1994; Noguchi et al, 1995; 
Zimprich et al, 2001; Xiao et al, 2003), therefore in chapter 5 I determine whether ε-
sarcoglycan may associate with DPC-like complexes in the brain, in analogy to the 
muscle, or whether it is part of separate molecular complexes. Antisera against ε-
sarcoglycan were raised in order to further purify and characterize ε-sarcoglycan 
complexes. The aim of the second part of this thesis was to increase the knowledge on 
the molecular complexity and functional roles of ε-sarcoglycan in rat brain.   
 
                        The cellular function of ε-sarcoglycan remains unknown. Unlike other 
sarcoglycans whereby recessive mutations result in various types of limb-girdle 
muscular dystrophies (LGMDS), mutations of the ε-sarcoglycan protein are not 
associated with muscular dystrophy, instead it leads to a different disorder known as 
Myoclonus Dystonia (MDS), a syndrome of neurological origin (Estrada et al, 2006; 
Hjermind et al, 2008). MDS is a non-degenerative neurological disorder (Grabowski et 
al, 2003) principally characterized by myoclonic jerks and dystonia (Asmus et al, 
2002; Chan et al, 2005; Tai et al, 2009) but also exhibits mild psychiatric symptoms 
(Tai et al, 2009; Chan et al, 2005; Asmus et al, 2002). The study of the cellular 
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localization and molecular associations of ε-sarcoglycan in mammalian brain is 
therefore important for the identification of molecular partners, candidate neuronal 
groups and circuits through which ε-sarcoglycan mutations lead to the dystonic and 
specific psychiatric symptom complex associated with MDS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 56 
                   1.3.2 Molecular genetics of the ε-sarcoglycan gene and 
encoded protein 
 
                        The ε-sarcoglycan gene (SGCE; OMIM: 604149) has been identified 
only relatively recently by an electronic database searching for sequences homologous 
to α-sarcoglycan (Ettinger et al, 1997; McNally et al, 1998; Kobayashi et al, 2003). It 
is being suggested that both genes may have originated from a common ancestor by 
gene duplication (Ozawa et al, 2005), given their high similarity in gene structure. The 
human gene for ε-sarcoglycan consists of 12 exons (figure 1.3.2) corresponding to 
71kb of genomic DNA in human chromosome region 7q21.3 (McNally et al, 1998; 
Grabowski et al, 2003), whilst the murine gene for ε-sarcoglycan maps to mouse 
chromosome 6 (McNally et al, 1998). A potential promoter region upstream of the 
initiation codon facilitates the transcription of the SGCE gene into a major 1.7 kb 
mRNA product (www.dMDS.nl/), subsequently translated into a 47kDa glycosylated 
protein in a variety of tissues, including the brain.  
  
                        According to studies carried out in the mouse, the brain is the only 
tissue where the mRNA product derived from the SGCE gene is alternatively spliced to 
yield more than one ε-sarcoglycan isoform, whilst all other tissues tested only express 
the conventional 47kDa protein (Nishiyama et al, 2004). There are however, 
inconsistencies as to the number of ε-sarcoglycan protein isoforms detected in brain. 
Ettinger et al (1997) identified a total of three ε-sarcoglycan protein isoforms in the 
mouse brain, with molecular weights 45kDa, ~47kDa and ~48kDa. However, later 
publications by different research groups (Nishiyama et al, 2004; Chan et al, 2005; 
Esapa et al, 2007) consistently detected only two ε-sarcoglycan isoforms (figure 
1.3.2A) that correspond to approximately 47 kDa and 49kDa proteins in mouse whole 
brain. The third isoform is never visible in their western blots, and these authors 
(Nishiyama et al, 2004; Chan et al, 2005; Esapa et al, 2007) do not justify the inability 
to identify the third alternatively spliced isoform that has been previously reported by 
Ettinger et al in 1997.  Only Yokoi et al (2005) proposed a third alternatively spliced ε-
sarcoglycan mRNA (type 3 isoform), however they do not verify whether the type 3 
mRNA isoform is also translated into a protein. More studies are clearly required to 
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verify the number of isoforms expressed in the brain, at the protein level. In chapter 5 I 
present the number of ε-sarcoglycan isoforms I have identified in rat adult brains. 
 
                        Nishiyama et al (2004) searched for variations in the alternatively 
spliced ε-sarcoglycan transcripts, to determine the exonic sequences that distinguish 
the 47kDa protein from the 49kDa protein (figure 1.3.2B). They found that alternative 
splicing occurs at the C-terminus. More precisely, when alternative splicing removes 
exon 11b only, whilst exon 8 is kept, the 47kDa ε-sarcoglycan isoform is obtained 
(figure 1.3.2B). Whereas when alternative splicing removes exon 8 only, and maintains 
exon 11b, the 49kDa ε-sarcoglycan isoform is obtained (figure 1.3.2B). Both ε-
sarcoglycan isoforms, therefore, clearly differ in their alternatively spliced C-terminal 
end (figure 1.3.2), whilst they exhibit identical N-terminal ends. Yokoi et al (2005) 
describes the novel potential alternative splice mRNA variant (type 3 isoform) having a 
new exon named 11c, from which two subtypes of clones encoding type 3 C-terminal 
mRNA sequences have been isolated. These either contain or lack exon 8, similar to 
what has been reported for the 47kDa and 49kDa isoforms by Nishiyama et al (2004). 
Again, these potential mRNA variants described by Yokoi et al (2005) remain to be 
confirmed at the protein level, and therefore have not been included in figure 1.3.2. 
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A. Protein domains of mouse brain 47kDa and 49kDa ε-sarcoglycan 
isoforms, respectively. 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
B. Exonic composition of mouse brain 47kDa and 49kDa ε-
sarcoglycan isoforms, respectively. 
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Figure 1.3.2: ε-sarcoglycan protein structure and relative exonic composition  
Α. Τhis figure shows the domain structure of two ε-sarcoglycan isoforms expressed in 
the brain, 47kDa and 49kDa, respectively. Both isoforms contain a 46 amino acid (AA) 
N-terminus signal sequence, followed by a 262 AA extracellular domain. The 262 AA 
domain contains a cadherin and calcium-binding domain and the potential N-
glycosylation site on the asparagines (Asn) 200. The 262 AA domain also contains four 
cysteine residues (Cys235, Cys248, Cys258 and Cys271), which enable the protein to 
form intramolecular S-S interactions. Adjacent to this domain is a 23AA 
transmembrane domain, and a 98 AA intracellular domain (www.dmd.nl/; Ettinger et 
al, 1997).  The 98 AA cytoplasmic domain differs between the two isoforms, as 
highlighted by the yellow and red boxes.  
B. This figure shows the exonic composition of the two ε-sarcoglycan isoforms 
expressed in the brain. The 47kDa protein contains exon 8 (yellow) whilst it lacks exon 
11b (red), whereas the cytoplasmic domain of the 49kDa protein isoform contains exon 
11b (red) whilst it lacks exon 8 (yellow). These differences suggest that the two 
isoforms bind different partners. Both murine isoforms contain three consensus sites 
for phosphorylation at their cytoplasmic domains; Ser343, Thr377 and Thr408 
(www.dmd.nl/; Nishiyama et al, 2004). Exon 10 of the SGCE gene has not been found 
in the mouse genome database (Nishiyama et al, 2004), hence it is not included in the 
figure. This figure is adapted from Ettinger et al (1997) and Nishiyama et al (2004). 
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                    1.3.3 Localization and developmental expression of  
ε-sarcoglycan  
 
                        The precise expression pattern of ε-sarcoglycan in the human CNS has 
not been studied (Kinugawa et al, 2009). On a wider scale, western blot analyses 
demonstrate that ε-sarcoglycan is widely distributed in the body. In fact, its expression 
has been detected in whole brain homogenate samples as well as in whole heart 
samples, striated muscle, smooth muscle, vascular smooth muscle, kidney, liver, 
spleen, testis, sciatic nerve, capillary blood vessels, Schwann cells in peripheral nerves, 
and lung samples (alveoli and bronchioles) (Mahloudji et al, 1967; Ettinger et al, 1997; 
Imamura et al, 2000; Hack et al, 2000; Xiao et al, 2003; Nishiyama et al, 2004). The 
highest level of expression of ε-sarcoglycan appears to be within the heart and lung 
(Ettinger et al, 1998; McNally et al, 1998; Xiao et al, 2003; Nishiyama et al, 2004), 
although its expression in the brain is also abundant.   
 
                        Mouse brain slices containing various brain regions have been used to 
study ε-sarcoglycan distribution at the protein and mRNA levels by methods such as 
immunohistochemistry and fluorescence in situ hybridization (FISH), respectively. 
Results suggest that both mRNA and protein levels of ε-sarcoglycan exhibit a “distinct 
and inhomogeneous distribution” in many brains structures, but only a subset of cells 
in these brain structures have been found to contain ε-sarcoglycan both at the mRNA 
and protein level (Chan et al, 2005). The protein has been detected in neurons within 
pons, cerebral cortex, hippocampal formation, neocortex, olfactory bulb, cerebellar 
cortex, cerebellar Purkinje cell layer, in midbrain monoaminergic cell groups, 
brainstem nuclei, basal ganglia and spinal cord (Xiao et al, 2003; Nishiyama et al, 
2004; Chan et al, 2005; Kinugawa et al, 2009). Different neuronal groups express 
different levels of the protein (Chan et al, 2005). In fact, the highest level of expression 
was found in the “mitral cells of the olfactory bulb, Purkinje cells of the cerebellum 
and in monoaminergic cell groups of the brainstem and hypothalamus” (Chan et al, 
2005). This is followed by slightly lower levels of ε-sarcoglycan expressed in 
dopaminergic (DAergic) neurons, serotoninergic (5-HTergic) neurons and in 
noradrenergic (NAergic) neurons (Chan et al, 2005). In the hippocampal formation, 
there are moderate levels of the ε-sarcoglycan protein. It is also found in moderate 
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levels in several hypothalamic nuclei, the amygdala, and the molecular cell layer of the 
cerebellum (Chan et al, 2005). Low expression level of the protein has been detected 
within the neocortex, globus pallidus and thalamic nuclei (Chan et al, 2005).  
 
                       ε-sarcoglycan is anchored at the plasma membrane of neuronal bodies 
and processes in the CNS, and is found within intracellular inclusions and the Golgi 
apparatus (Nishiyama et al, 2004;Chan et al, 2005; Esapa et al, 2007; Kinugawa et al, 
2009). According to western blot analysis by Nishiyama et al (2004) using various 
subcellular fractions of mouse whole brain, ε-sarcoglycan appears to be predominantly 
extrasynaptic rather than at PSD structures (Nishiyama et al, 2004), because both ε-
sarcoglycan isoforms enrich in the membrane fraction but neither isoform is enriched 
in the PSD fraction of total mouse brain homogenates, although their results highlight 
it certainly exists within the PSD (Nishiyama et al, 2004). These studies also 
demonstrate that the two ε-sarcoglycan isoforms (47kDa and 49kDa) differentially 
localize within the synaptosomal membranes isolated and attribute these differences to 
the structural differences of the two isoforms found at their alternatively spliced 
cytoplasmic domains (figure 1.3.2B).  
 
                        To date, there is no immunocytochemical data singularly describing the 
localization of the 47kDa isoform or the 49kDa ε-sarcoglycan isoform in the brain, 
because no antibody reacting to just the 47kDa or the 49kDa isoforms is currently 
available (Nishiyama et al, 2004). Nishiyama et al (2004) carried out an 
immunocytochemical study using an in-house antibody generated against the whole 
cytoplasmic region of ε-sarcoglycan, therefore unable to distinguish the 47kDa isoform 
from the 49kDa isoform, and shows that ε-sarcoglycan isoforms (47kDa and/or 47kDa 
isoforms) are not only expressed in neurons, but they are also expressed in astrocytes 
and capillary endothelial cells (Nishiyama et al, 2004). They further determined, via a 
western blot analysis, the expression of ε-sarcoglycan isoforms in an astrocyte-rich 
fraction. Only the 47kDa ε-sarcoglycan isoform, but not the 49kDa isoform, is closely 
associated with astrocytic cells. It would be interesting to obtain antibodies that can 
distinguish the two isoforms, enabling a detailed immunocytochemical study that can 
be carried out to study which isoform is expressed in which cell (neurons and/or 
astrocytes) and subcellular structures of the brain. It would also be interesting to 
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investigate whether the known DPC components found in astrocytic cells, such as the 
astrocyte-specific cDp140 dystrophin isoform (Blake et al, 1999; Waite et al, 2009), 
may associate with the 47kDa ε-sarcoglycan isoform.  
 
                     The developmental expression pattern of ε-sarcoglycan in the brain 
remains to be established. Instead, developmental studies carried out outside the brain 
highlight ε-sarcoglycan is a widely expressed protein, what is more, its developmental 
expression patterns and time-points have been shown to clearly differ from other 
sarcoglycan family members. Developmental studies using an immunohistochemical 
approach on mouse embryos have detected ε-sarcoglycan protein expression as early as 
embryonic day 8.5 (E8.5), whereas other sarcoglycan family members are absent 
(Straub et al, 1999; Xiao et al, 2003). At E12, ε-sarcoglycan is found in myoblasts, 
myotubes, cardiac myocytes, surrounding lung, bronchi and vascular endothelium 
(Straub et al, 1999; Xiao et al, 2003), whereas, other sarcoglycan family members are 
absent. By E15, ε-sarcoglycan is abundant in smooth muscle of lungs, in the smooth 
muscle of the bronchi, skeletal myotubes and cardiac myocytes, and other tissues from 
a variety of endodermal and ectodermal lineages (Straub et al, 1999), whilst other 
sarcoglycans are largely restricted to skeletal and cardiac muscle (Straub et al, 1999). 
In adult mouse, ε-sarcoglycan is expressed in smooth muscle cells of gastrointestinal 
tract, bladder, lung and uterus (Straub et al, 1999), whereas some sarcoglycan family 
members are absent (Straub et al, 1999). In skeletal muscle of adult mouse, ε-
sarcoglycan expression dramatically declines, whilst the expression of other 
sarcoglycan family members is high in the adult stage. In contrast, smooth muscle cells 
continue to express ε-sarcoglycan protein at high levels in adult mice (Xiao et al, 
2003). These are only a few examples to highlight the developmental profile and time-
points of ε-sarcoglycan, which clearly differ and precede that of other sarcoglycans. 
Early expression of ε-sarcoglycan during development suggests it may participate in 
the development of the organs it is found in.  
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                    1.3.4 Protein structure of 47kDa and 49kDa ε-sarcoglycan 
isoforms  
 
                        47kDa and 49kDa ε-sarcoglycan isoforms are considered type I 
transmembrane glycoproteins (Singer et al, 1990), because they are glycosylated 
proteins that transpass the membrane only once, with the N-terminal portion of the 
polypeptide exposed to the exterior of the cell and the C-terminal portion exposed to 
the interior of the cell, a typical feature of this class of proteins (Singer et al, 1990). 
Both isoforms share an identical N-terminal domain (figure 1.3.2) that is found at the 
extracellular interface of the cell. The N-terminal domain is composed of a 46 amino 
acid hydrophobic signal sequence (McNally et al, 1998), and a large 262 amino acid 
extracellular domain (amino acid 47-316). Within the 262 amino acid domain, there 
exists a cadherin-like domain (Dickens et al, 2002), one conserved site for asparagine-
linked N-glycosylation (Asn 200) (McNally et al, 1998) and four conserved cysteine 
residues (Cys235, Cys248, Cys258 and Cys271) (Nishiyama et al, 2004; 
www.dmd.nl). Adjacent to the extracellular domain is a stretch of 23 amino acids that 
constitute the hydrophobic transmembrane (TM) region (aa317-339) that enables either 
isoform to transpass the membrane of the cell once. This TM region is also identical in 
the two isoforms. Adjacent to the TM is the 98 amino acid cytoplasmic domain (aa339-
437), whereby the two isoforms exhibit differences in their exonic composition (figure 
1.3.2), giving rise to two well distinguished isoforms of 47kDa and 49kDa. The 
functional significance of the exons (exon 8 and exon 11b) that distinguish the two 
isoforms from one another has yet to be established. The cytoplasmic domain of both 
isoforms contains three phosphorylation consensus sites at Ser 343 (next to TM region 
exon 7), Leu 377 and Thr408 (exon 9, cytosolic domain) (Nishiyama et al, 2004; 
Ettinger et al, 1997). 
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                     1.3.5  ε-sarcoglycan mutations lead to MDS                             
 
                         Myoclonus-dystonia syndrome (MDS, DYT11) is caused by a non-
degenerative neurological disorder (Grabowski et al, 2003; Estrada et al, 2006; 
Hjermind et al, 2008) that generates myoclonic jerks and dystonia (Asmus et al, 2002; 
Chan et al, 2005; Tai et al 2009). In some cases, mild psychiatric symptoms are also a 
feature of this syndrome (Asmus et al, 2002; Chan et al, 2005; Tai et al, 2009). MDS 
can either be inherited in an autosomal dominant manner (Zimprich et al, 2001) or may 
occur sporadically, such as birth-related or other physical trauma or infection (Valente 
et al, 2003; Hedrich et al, 2004; Schüle et al, 2004). The disease becomes apparent 
during the first or second decade of life (Gerrits et al, 2009). Myoclonus is usually the 
main and most disabling feature in MDS patients, by predominantly affecting the upper 
limbs and axial muscles and is alcohol responsive (Kinugawa et al, 2009). Dystonia is 
also a feature of the disease, but it is in a much milder form and often manifests as 
cervical dystonia or writer’s cramp (Kinugawa et al, 2009). The symptoms presented 
by MDS patients are not related to age or sex (Kinugawa et al, 2009).  
 
                        Myoclonus Dystonia Syndrome is considered to be genetically 
heterogeneous (Kock et al, 2004) because some MDS patients have been diagnosed 
with allelic heterogeneity, whilst other MDS patients have been diagnosed with locus 
heterogeneity (Asmus et al, 2002). Allelic heterogeneity has been observed within the 
SGCE gene, a major culprit gene in MDS patients (Kinugawa et al, 2009; Grabowski 
et al, 2003; Zimprich et al, 2001; Klein et al, 2002). This is because various families 
having the MDS phenotype do not exhibit the same mutation within the SGCE gene, 
instead, many families differ in the region of mutation within the SGCE gene (Asmus 
et al, 2002; Grabowski et al, 2003). MDS also exhibits locus heterogeneity because the 
SGCE gene is not the only gene whose mutation has been linked to MDS. In fact, other 
loci have been found to yield the MDS phenotype, and these patients do not exhibit 
mutations within the SGCE gene. One example is the DYT15 gene (OMIM number; 
607488), located in chromosome region 18p11, whose mutation gives rise to an MDS 
phenotype identical to that of patients with mutations in the SGCE gene (Grimes et al, 
2002). In these patients, no mutation in the SGCE gene was detected. In a separate 
study, Asmus et al (2005) also found that 30% of familial cases exhibiting MDS had 
no mutation in the SGCE gene, suggesting that mutation of a different locus may also 
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give rise to MDS. Valente et al (2003) describes 16 patients with either sporadic or 
familial MDS, with no mutations in the SGCE gene identified. It is clear from these 
studies that a lot more work is required to characterize the causes of MDS. The 
mutations in the genes that lead to MDS vary from a nonsense mutation, missense 
mutation, deletion, insertion, duplication, or splicing mutations (Kinugawa et al, 2009). 
  
              Pedigree analysis shows reduced penetrance of the phenotype upon 
maternal inheritance of the mutated SGCE allele, which is a consequence of maternal 
imprinting (Grabowski et al, 2003). In the brain, the CpG island containing the 
promoter region of the maternal SGCE allele, together with the first exon of the SGCE 
gene, is completely methylated (Muller et al, 2002; Grabrowski et al, 2003). This leads 
to silencing of the maternal allele and consequently the transcription of the ε-
sarcoglycan gene from the maternal allele is prevented, whilst the paternal allele is 
always expressed (Asmus et al, 2006; Tezenas du Montcel et al, 2005). In other words, 
when the paternal SGCE allele is in the wild-type state, whilst the maternal SGCE 
allele is mutated, the individual is healthy because the paternal allele yields the native 
ε-sarcoglycan protein. However, when the paternal SGCE allele is mutated, whilst the 
maternal SGCE allele is in the wild-type state, the individual will exhibit the MDS 
syndrome because the maternal wild-type SGCE allele cannot be transcribed and 
translated due to methylation.  
 
                        The molecular mechanisms through which the detected mutations may 
contribute to MDS remain to be established (Klein et al, 2002). One possible route has 
only recently been suggested after comparing the subcellular localization of wild-type 
ε-sarcoglycan with several mutated ε-sarcoglycan proteins. The mutated proteins each 
carried a single mutation that has been previously reported in MDS patients (Esapa et 
al, 2007). According to their studies, these mutations lead to misfolding of the proteins 
and block their trafficking to the plasma membrane where the protein normally resides 
(Esapa et al, 2007). Therefore, impaired trafficking may be one of many mechanisms 
that contribute to the initiation of the disease. Separate studies also suggest high levels 
of expression of ε-sarcoglycan protein in wild-type monoaminergic midbrain neurons, 
thus mutation of the SGCE leading to the reduction of ε-sarcoglycan activity at the 
membrane of these neurons may provide a potential neurochemical explanation of both 
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movement disorders and psychiatric symptoms observed in MDS patients (Chan et al, 
2005). 
 
                        Pharmacological treatments such as clonazepam and valproate are 
currently available to treat the disease (Kurtis et al, 2010), and ethanol has been 
demonstrated to often ameliorate the symptoms (Cif et al, 2004). However, when MDS 
patients become refractory to pharmacological treatments, Deep brain stimulation 
(DBS) seems to be the only cure (Cif et al, 2004). DBS induces bilateral electrical 
stimulation of the Gpi (globus pallidus internus), an effective and safe treatment for 
MDS, which suppresses abnormal movements and improves quality of life (Cif et al, 
2004; Kurtis et al, 2010). This amelioration has been recognized in the long term as an 
efficient therapeutic strategy for MDS patients who are not necessarily immune to 
pharmacological treatments, as well as for patients who are immune to 
pharmacological treatments (Cif et al, 2004).  
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                    1.3.6 Proteins interacting with ε-sarcoglycan 
 
                        In the brain, the molecular associations of ε-sarcoglycan are not known. 
ε-sarcoglycan is part of a sarcoglycan family, composed of α, β, γ, δ and ζ-
sarcoglycan. Outside of the brain, the sarcoglycans are known to associate with one 
another to form a tetrameric sarcoglycan complex that frequently (Ervasti et al, 1990; 
Yoshida et al, 1990; Ozawa et al, 1998), but not always (Durbeej et al, 1999; Fort et al, 
2005), associates with DPC-like complexes in various types of tissues. The α, β, γ, δ-
sarcoglycan complex is restricted to skeletal muscle and associates with the DPC 
complex therein (Ervasti et al, 1990; Yoshida et al, 1990; Ettinger et al, 1997; Ozawa 
et al, 1998; Liu et al, 1999; Durbeej et al, 2000; Imamura et al, 2000). The ε, β, γ, δ-
sarcoglycan complex exists in both skeletal muscle (Liu et al, 1999) and smooth 
muscle (Straub et al, 1999; Imamura et al, 2000). In the smooth muscle, the ε ,β ,γ ,δ-
sarcoglycan complex associates with the DPC complex (Straub et al, 1999; Lapidos et 
al, 2004; Imamura et al, 2005; Shiga et al, 2006), and this is also true in skeletal 
muscle (Lapidos et al, 2004; Imamura et al, 2005). In the Schwann cell outermost 
membrane, a sarcoglycan complex composed of ε, β, δ, ζ sarcoglycans associates with 
dystroglycan and a Schwann cell-specific dystrophin isoform (Dp116) (Imamura et al, 
2000; Cai et al, 2007). In the lung, a sarcoglycan complex containing ε-sarcoglycan is 
found associated with DPC components (Durbeej et al, 1999). Separate studies have 
transfected the various sarcoglycan components into Chinese Hamster Ovary cells 
(CHO), in order to determine the molecular combinations of sarcoglycan complexes 
that may form. Their results show four different and potential sarcoglycan complexes 
that may also form in vivo, and these include: 1.α, β, ζ, δ-sarcoglycan, 2.α, β, γ, δ-
sarcoglycan, 3.ε, β, ζ, δ-sarcoglycan and 4.ε, β, γ, δ-sarcoglycan, all of which have 
been shown to associate with the DPC complex (Shiga et al, 2006) in the plasma 
membrane of CHO cells. No studies have yet been carried out to determine whether 
any of these sarcoglycan complexes exist in the brain and whether any of these 
associate with the DPC complex in the brain.  
 
                        According to various publications studying sarcoglycans and their 
expression in the brain, it appears that if a sarcoglycan complex exists in neurons, it 
will differ significantly from the complex found in muscle. In fact, γ-sarcoglycan is 
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absent in brain (Bönnemann et al, 1995; Lim et al, 1995; Nigro et al, 1996; Hack et al, 
2000; Noguchi et al, 2000) whereas δ-sarcoglycan and ζ-sarcoglycan are both 
expressed in the brain at the mRNA level (Shiga et al, 2006), although their translation 
into a protein has yet to be confirmed. Only ε and β-sarcoglycan have been detected in 
the brain at the protein level (Wheeler et al, 2002; Shiga et al, 2006). According to 
studies by Shiga et al (2006), all four sarcoglycan components (ε,β,ζ and δ-
sarcoglycan) that have to date been detected either at the mRNA or protein level in the 
brain, have been shown to complex together in CHO cells, suggesting that a similar 
complex may also form in the brain. 
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                    1.3.7 The function of ε-sarcoglycan in the brain 
                      
                        The function of ε-sarcoglycan in the brain remains largely unknown 
(Chan et al, 2005; Tai et al, 2009; Kinugawa et al, 2009), however an important role 
for ε-sarcoglycan in the brain is defined by the appearance of the myoclonus dystonia 
syndrome (MDS) when the SGCE gene is mutated (Xiao et al, 2003). Biochemical 
fraction studies of rat/mouse forebrain highlight that ε-sarcoglycan is present in 
synaptic membranes, raising the possibility that ε-sarcoglycan might be involved in 
neuronal functions, particularly in dopaminergic transmission, given its high 
expression in dopaminergic neurons of the substantia nigra (Nishiyama et al, 2004). 
Other neuronal-types also express ε-sarcoglycan, but the identity of these still remains 
to be identified (Chan et al, 2005). Overall, the broad expression of ε-sarcoglycan 
within the brain suggests that it may influence a large part of the brain. 
 
                        Non-invasive studies have been carried out to study the 
neurophysiological profile in MDS patients, in order to begin to unravel the function of 
ε-sarcoglycan (Marelli et al, 2008). This methodology is known as transcranial 
magnetic stimulation (TMS). Studies using TMS have been able to show that MDS 
patients exhibit a reduction in the power of the GABAA receptor circuitry, because of 
primary dysregulation of the striato-pallido-thalamo-cortical loop (Marelli et al, 2008). 
Parallel studies on MDS patients further highlight that there exists a delayed event-
related synchronization (ERS) of the motor cortex interneuronal function, which they 
suggest it may be due to a defective post-excitatory inhibition in the motor cortex at the 
end of the movement, which may reflect a lack of physiological synchronization of the 
GABAergic interneuron network (Cassim et al 2001; Marelli et al 2008). Given that ε-
sarcoglycan is widely localized in various brain regions including the cortex and 
brainstem, Marelli et al (2008) suggested that neuronal dysfunction is likely to occur at 
multiple brain levels in MDS, rather than cortical impairment alone. What is more, the 
subcellular localization of ε-sarcoglycan in neuronal membranes suggests that it may 
play a role in synaptic functions, thus leading to an interneuronal system imbalance 
that sustains physiological inhibition in multiple brain regions (Marelli et al, 2008). No 
studies have yet been carried out to determine whether ε-sarcoglycan is localized 
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within GABAergic synapses, where classical full-length dystrophin-containing DPC 
complexes are exclusively localized (Brunig et al, 2002).  
 
                        In non-neuronal tissues the role for ε-sarcoglycan is less apparent and it 
may be because mutation of ε-sarcoglycan may lead to subtle consequences (Xiao et 
al, 2003). Although wild-type ε-sarcoglycan is highly expressed in both embryonic and 
neonatal rodent striated muscle, MDS patients carrying a mutation in the SGCE gene 
never exhibit muscular dystrophy or myopathies (Xiao et al, 2003). It is being 
suggested that either ε-sarcoglycan is not critical for striated muscle embryogenesis, or 
closely related sarcoglycans may be capable of compensating ε-sarcoglycan deficiency 
and therefore no counter effects upon ε-sarcoglycan mutation can easily be identified. 
Substantially higher levels of the protein are expressed in smooth muscle when 
compared to skeletal muscle, it is therefore being suggested that ε-sarcoglycan is likely 
to play a more important role in smooth muscle when compared to skeletal muscle 
(Xiao et al, 2003). To date, it is not known what this function may be.  
 
                        To begin to get a better understanding on the function of ε-sarcoglycan 
in neurons and MDS pathology, development studies on ε-sarcoglycan have been 
compared with other better-studied sarcoglycan family member proteins (Xiao et al, 
2003). Unlike the other sarcoglycan family members, ε-sarcoglycan is more widely 
expressed among adult and embryonic tissue (Ettinger et al, 1997). What is more, ε-
sarcoglycan expression is very early in development and precedes that of other 
sarcoglycans (Straub et al, 1999; Piras et al, 2000). According to these findings, it is 
being suggested that ε-sarcoglycan may therefore have a more widespread role in 
maintaining cell adhesion and tissue integrity, when compared with other sarcoglycan 
family members (Piras et al, 2000). In other words, it is being suggested that ε-
sarcoglycan may participate in early development of brain, muscle, liver, kidney and 
heart tissue, as levels are higher in the fetal muscle compared to adult muscle of rats 
(Hjermind et al, 2008).  
 
                        It is not known for the brain, but in muscle, ε-sarcoglycan is always 
associated with other sarcoglycan family members, that together form the sarcoglycan 
complex. There are two functions attributed to the sarcoglycan complex in the muscle, 
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the first is a mechanical function, and the second is a signaling function (Ozawa et al, 
2005). In terms of mechanical function, studies carried out in the muscle have shown 
that in the absence of the sarcoglycan complex, binding of both β-dystroglycan to 
dystrophin as well as β-dystroglycan to α-dystroglycan are weakened. That is, the 
components of the dystrophin bolt are apt to disconnect (Ozawa et al, 2005). 
Therefore, in muscle, the sarcoglycan complex serves to strengthen the connection 
between the core components of the DPC complex. In terms of signaling function, α-
dystrobrevin connects to the sarcoglycan complex at its N-terminus and to dystrophin 
at its C-terminus, which in turn binds to syntrophin. In turn syntrophin binds to nNOS 
and to voltage gated sodium channels, therefore involving the sarcoglycan complex in 
signaling functions. No evidence has yet been published to demonstrate whether ε-
sarcoglycan is involved in such functions in the brain. However, given its known 
sarcoglycan complex formation in the muscle and its association with the DPC 
complex therein, it is plausible to suggest that a similar scenario may also be occurring 
in the brain. 
 
                        According to biochemical analysis on sarcoglycan complex formation, 
results suggest that the loss-of function mutations in the SGCE gene, including the 
disruption of the sarcoglycan complex, does not produce detectable abnormalities in 
the peripheral nervous system (PNS) (Imamura et al, 2000), whereas it does induce 
vascular smooth muscle irregularities with consequences such as cardiomyopathy 
(Coral-Varquez et al, 1999). These results suggest that in sarcoglycan deficiency, 
differences exist between the pathophysiological mechanisms in smooth muscle and 
PNS (Nishiyama et al, 2004). It is therefore interesting and important to investigate the 
cellular associations and functions of ε-sarcoglycan within the brain as these may also 
differ to those observed in the muscle and other organs, and may reveal novel 
pathophysiological mechanisms that can be targeted with pharmacological treatments 
to cure patients with MDS. One major difference between the muscle and the brain is 
that the muscle undergoes mechanical stress whereas the brain does not. Therefore the 
functional requisites for ε-sarcoglycan in the muscle are likely to be different to those 
in the brain. 
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                        Ιn 2002, Dickens et al discovered a cadherin-domain homologue within 
the extracellular portion of ε-sarcoglycan (figure 1.3.2). The function of this domain is 
not known for ε-sarcoglycan. However, cadherin-domain-containing proteins are 
typically adhesion molecules that modulate a wide variety of processes including cell 
polarization and migration (Tepass et al, 2000; Dickens et al, 2002; Roemer et al, 
1996). Multiple cadherin domains have been shown to form Ca++-dependent rod-like 
structures with a conserved Ca++-binding pocket at the domain-domain interface, that is 
utilised to form homotypic or heterotypic interactions with other proteins. Most of the 
calcium-binding residues found in the domain-domain interface in the cadherin 
domains of ε-sarcoglycan are conserved and therefore may be utilised for interactions 
with other proteins (Dickens et al, 2002). However, it remains to be established what 
proteins interact with the various binding sites found along the ε-sarcoglycan protein. 
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     1.3.8 Summary 
 
             It is evident that mutations in the SGCE gene, in most cases, leads to 
MDS. Given the wide expression patterns exhibited by ε-sarcoglycan in and outside the 
brain, the mutated protein is likely to affect a variety of organs, and the consequences 
of such mutation will in part depend on the level of redundancy of that protein in a 
specific organ. Preliminary data suggest an extrasynaptic membrane-associated 
localization of ε-sarcoglycan, therefore indicating that the protein may not associate 
with DPC complexes localized at the PSD of inhibitory synapses. However, more 
detailed studies are required in order to determine the localization of ε-sarcoglycan 
within neurons of the brain and compare it to classical and delta dystrophin-containing 
DPC complexes, in order to determine whether it is part of these complexes or whether 
it associates with different protein complexes. This work has been researched in this 
thesis and is described in chapter 5.  
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                         2.0 Materials and Methods 
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2.1 Reagents and equipment 
 
 
2.1.1 General Reagents. 
 
General reagents, common to more than one protocol are listed in this section and 
under Appendix I, whereas those used only in specific procedures are mentioned 
throughout the method described and under Appendix II. All solutions and media 
were made using double deionised water (ddH2O). Stock solutions were sterilised by 
autoclaving, or passing through a 0.22µm filter, and then stored at room temperature 
(RT), unless specified otherwise. 
 
2.1.2 Chemicals 
 
All molecular biology grade laboratory chemicals were purchased from Sigma-
Aldrich and stored at room temperature, unless otherwise stated. Please see Appendix 
I, Box 1. 
 
2.1.3 Biological kits and systems 
        
Please see Appendix I, Box 2 
 
2.1.4 Markers and enzymes 
              
Please see Appendix I., Box 3 
 
2.1.5 Media, buffers and solutions 
  
Please see Appendix I, Box 4 (pH Buffers) and Box 5 (solutions used for specific 
protocols). 
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2.1.6 Equipment and suppliers 
  
Please see Appendix 1, Box 6.  
 
2.1.7 Reagents and Equipment for specific protocols 
  
Please see Appendix II, Box 1. 
  
2.1.8 Antibodies used in Western blotting and Immunocytochemistry     
      detection analysis 
        
Please see Appendix III, Table 1. 
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                  2.2 Isolation of subcellular fractions and protein detection 
 
 
2.2.1 Protease inhibitors 
   
All the samples obtained from homogenisations and cell fractionation procedures 
contained a combination of protease inhibitors. Previous colleagues in our lab have 
optimised the concentration of the protease inhibitors (PI) used (Susanne Flann et al, 
1999). 1µl PI was added for every 1ml of sample suspension. 
 
2.2.2 Preparation of subcellular fractions from rat forebrain or cerebellum 
 
Subcellular fractions from Wistar rat forebrains were prepared by a method based 
on that of Cotman et al, (1971) as previously described (De Silva et al., 1979) and 
summarised in figure 2.2.2. Five adult rat forebrain or ten adult rat cerebellum brains 
were homogenised in homogenisation buffer (0.32M sucrose containing 1mM MgCl2) 
using 12 strokes in a glass/Teflon homogeniser with 1mm clearance, at 500 rpm. The 
resultant homogenate was diluted to 10% (w/vol) in homogenisation buffer, and 
centrifuged 3,000 rpm (Sorval, SS34 rotor) for 10 minutes. The pellet was 
resuspended in homogenisation buffer and re-centrifuged as before. The supernatants 
of both centrifugations were combined and centrifuged at 12,700 rpm (Sorval, SS34 
rotor) for 15 minutes, to form the P2 pellet.  
 
The P2 pellet was washed twice in 0.32M sucrose and centrifuged at 17,000 rpm 
(Sorval, SS34 rotor) for 20 minutes after each wash, in order to remove any 
microsomal contamination. The supernatant obtained from the 20 minutes spin was 
spun at 42,000rpm (Beckman, 42.1 rotor) for 60 minutes, after which the microsomes 
(P3) and cell soluble (S3) was isolated (figure 2.2.2). Whereas the pellet obtained 
from the 20 minutes spin was resuspended and lysed in 125ml of 50 µM CaCl2 pH 
7.0, and allowed to stand on ice for 20 minutes. Subsequently, 25ml of 0.2M sodium 
phosphate buffer, pH 7.5, containing 0.05mM CaCl2 and 5mM p-iodonitrotetrazolium 
violet (INT) and 0.4M sodium succinate was added and allowed to incubate for 25 
minutes at 30 ºC. This step led to the formation of a formazan precipitate in 
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mitochondria, increasing the buoyant density. In this way, mitochondrial 
contamination of the synaptic membrane (SM) fraction, in particular, was reduced. 
The suspension was centrifuged at 10,000 rpm (Sorval, SS34 rotor) for 7 minutes. 
The resulting P2 INT pellet was washed twice with 0.16 M sucrose containing 0.05mM 
CaCl2, in order to remove any residual INT, and centrifuged at 20,000 rpm (Sorval, 
SS34 rotor) for 18 minutes after each wash.  
 
The washed P2 INT pellet was resuspended in 15ml of 0.32M sucrose-containing 
0.05mM CaCl2. This solution was underplayed with 0.8M, 1.0M and 1.2M sucrose, 
each containing 0.05mM CaCl2. 
 
The gradients were centrifuged for 120 minutes at 26,000 rpm (Beckman, SW28 
rotor) and myelin, light membranes (LM) and synaptic membranes (SM) were 
harvested from the 0.32M / 0.8M, 0.8M / 1.0M and 1.0M / 1.2M interfaces 
respectively (figure 2.2.2). The mitochondrial fraction formed a pellet at the bottom 
of the tube. The harvested fractions were diluted in 0.05mM CaCl2 and centrifuged at 
42,000 rpm for 30min (Beckman, Ti60 rotor). The pellets were resuspended in 50µl 
of 0.32M sucrose containing PI (1µl/ml) and stored at -80 ºC. 
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Figure 2.2.2: Subcellular fractions prepared by the Cotman et al (1971) 
method. 
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2.2.3 Preparation of PSD in rat Forebrain/Cerebellum by the Gurd et al (1982) 
method 
 
A fresh SM fraction prepared by the Cotman et al (1971) method (refer to section 
2.2.2) was used to isolate PSDs by a method based on Gurd et al (1982). The SM 
fraction was harvested and mixed with 30ml 0.05mM CaCl2 and centrifuged at 
42,000 rpm (Beckman, Ti60 rotor) for 30 min. The SM pellets were resuspended in 
4ml of fresh deionised water and protease inhibitors (PI). To each of four new tubes, 
1.25g 20% w/w PEG 6000, 1.25g (20% w/w Dextran T-500), 0.5ml (0.2M Sodium 
Carbonate Buffer pH.9.6), 200µl (25% w/v n-octyl glucopyranoside) and 1ml of the 
SM suspension was homogenised with 12 straight strokes with the Dounce 
homogeniser. All four tubes were centrifuged at 5,000 rpm for 15 minutes. The PSDs 
appeared at the interphase. The PSDs were harvested, mixed with deionised water and 
centrifuged at 12,000rpm for 2 minutes. This was repeated twice. The water was 
removed and the PSD pellet resuspended in 250µl of 0.32M sucrose. Protease 
inhibitors were added to the PSD and stored at –80oC.  
 
2.2.4 Preparation of PSD in Forebrain by the Carlin et al (1980) method 
 
Subcellular fractions from Wistar rat forebrains were prepared by a method based 
on Cotman et al (1971), modified by Carlin et al (1980). Ten adult rat forebrain 
brains were homogenised in homogenisation buffer (0.32M sucrose containing 1mM 
MgCl2) using 12 strokes in a glass/Teflon homogeniser with 1mm clearance, at 500 
rpm. The resultant homogenate was diluted to 10% (w/vol) in homogenisation buffer 
and centrifuged at 3,000 rpm (Sorval SS34 rotor) for 10 minutes. The pellet was 
resuspended in homogenisation buffer and re-centrifuged as before. The supernatants 
of both centrifugations were combined and centrifuged at 10,430 rpm (Sorval, SS34 
rotor) for 15 min, to give a crude membrane P2 fraction.  
 
The brains in the P2 pellet were resuspended and diluted to 10% (w/vol) in          
homogenisation buffer and centrifuged at 10,430 rpm (Sorval, SS34 rotor) for 10 
minutes. The pellet obtained was resuspended in 15ml 0.32M Sucrose containing 
0.05mM CaCl2. This solution was underplayed with 0.8M sucrose, 1.0M and 1.2M 
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sucrose, each containing 0.05mM CaCl2 (figure 2.2.2). The gradients were 
centrifuged at 26,000 rpm (Beckman, Sw28 rotor) for 120 minutes. The myelin, light 
membranes (LM) and synaptic membranes (SM) were harvested from the 0.32M / 
0.8M, 0.8M / 1.0M and 1.0M / 1.2M sucrose interfaces respectively (figure 2.2.2), 
each containing 0.05mM CaCl2. The mitochondrial fraction formed a pellet at the 
bottom of the tube. The myelin and LM fractions found at different sucrose interfaces 
were isolated and subsequently added to two separate tubes, diluted in 0.05mM 
CaCl2, and centrifuged at 42,000 rpm (Beckman, Ti60 rotor) for 30 minutes. The 
pellets were resuspended in 500µl of 0.32M sucrose. PI was added to preserve the 
fractions. All fractions except the SM fraction, were stored at –80oC.  
 
PSDs were prepared by the Carlin et al (1980) method. The SM fractions 
(synaptosomes) harvested from the sucrose gradient were diluted with 60ml of 0.32M 
Sucrose 1mM NaHCO3 (1g of initial weight of brain material/6ml sucrose solution). 
The diluted SM preparation was centrifuged at 42,000 rpm (Beckman, Ti60 rotor) for 
30 minutes. The pellet obtained was resuspended in 6ml 0.32M Sucrose 1mM 
NaHCO3 (10g initial weight of brain material/6ml sucrose solution) and 6ml Triton 
X-100 (1:1), mixed well, and centrifuged at 39,900 rpm (Beckman Ti60 rotor) for 20 
minutes. The PSD pellet was resuspended in 0.32M Sucrose 1mM NaHCO3. PI was 
added to preserve the fraction. The PSD was stored at –80oC. 
 
2.2.5 Protein determination by the Folin-Lowry method 
 
 An appropriate volume of sample or BSA standard (Bovine Serum Albumin) was 
added to 200µl of 1M NaOH, and the protein was allowed to solubilise for 10 min. 
The volume of each tube was adjusted to 500µl with distilled water, followed by the 
addition of a 2ml Lowry solution (49ml 2 % (w / v) Na2CO3, 0.5ml 2.12 % (w / v) 
Na2 tartrate, 0.5ml 1 % CuSO4). The tubes were left to stand for 15 min at Room 
Temperature. 200µl aliquots of Folin Reagent (Lowry et al, 1951) diluted 1:1 with 
distilled water, were added to each tube and incubated 45 minutes at Room 
Temperature. The spectrophotometer was set to 750 nm. The instrument was zeroed 
with the blank containing the same preparation described above, replacing the volume 
of sample or BSA with the buffer containing the sample or BSA. The absorbance 
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measurements of the standards and unknown samples were measured. A BSA 
standard curve (0-200µg) was prepared by plotting the 750nm values (y-axis) versus 
their concentration in µg/ml (x-axis). The concentration of the unknown sample was 
determined using the standard curve. The final concentration of the sample was 
obtained by multiplying the concentration of the sample by the dilution factor, 
divided by the path length.  
 
2.2.6 Sample preparation for SDS-gel analysis 
 
 Sample buffer x 2 (4% SDS, 20% Glycerol, 10% 2-mercaptoethanol, 0.004% 
Bromophenol Blue, 0.125M Tris-HCl) was diluted 1:1 with the sample. The sample 
preparation was heated at 95oC for 5 minutes, followed by a 5 minute period on ice. 
The samples were then centrifuged in a microfuge at 12,000 g for 5 minutes, the 
supernatant was ready for loading on an SDS-polyacrylamide gel. 
 
2.2.7 SDS-polyacrylamide gel electrophoresis 
 
 SDS-polyacrylamide gel electrophoresis was carried out as described by Laemmli 
(1970) using the Bio-Rad mini Protean II mini-gel apparatus. Typically, 10% (w / v) 
polyacrylamide gels were used, except where specified otherwise. 10 % gels were 
made up with 6.4ml distilled water, 3.75ml of 1.5 M Tris-HCl, pH 8.8, 150µl of 10 % 
(w / v) SDS, 5ml of 30 % (w / v) acrylamide containing 0.8 % (w / v) bis-acrylamide 
(Protogel, National Diagnostics) with 55µl of polymerisation. 12 % gels containing 
5.5ml distilled water and 6ml Protogel, with all other constituents as described above. 
The stacking gel (5.5% w / v acrylamide) contained 2.9ml distilled water, 1.25ml of 
0.5 M Tris-HCl, pH 6.8, 0.95ml Protogel, 50µl of 10 % (w / v) SDS with 31.5µl 10 % 
(w / v) AMPS and 7.5µl Temed. 
 
 Samples were prepared (refer to section 2.2.6) and gels run at 200 V until the dye-
front reached the end of the gel. Pre-stained molecular weight markers were utilised 
(Appendix I, Box 3). 
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2.2.8 Coomassie Blue staining for protein-detection in polyacrylamide gels 
 
 The gel was placed in the Coomassie Blue stain (50 % (v / v) methanol, 10 % (v / v) 
acetic acid, 0.25 % (w / v) Coomassie Blue R250) for 45 min. The gel was removed 
and destained in 45 % (w / v) methanol and 5 % (w / v) acetic acid in water, until the 
gel background was no longer blue, and the protein bands could be clearly seen. The 
sensitivity of this stain is up to 0.2-0.5µg protein per band. 
 
2.2.9 Western blotting 
 
 All protein samples were blotted onto nitrocellulose with a pore size of 0.45µm 
(Amersham, Hybond-ECL). A wet Western blotting procedure, modified from the 
method described by Towbin et al (1979) was developed using the Bio-Rad mini 
trans-blot cell blotting apparatus. The nitrocellulose was equilibrated in Blotting 
Buffer for 1 h prior to blotting. Electrophoretic transfer was carried out for 1 hour at 
100 V constant voltage. 
 
2.2.10 Ponceau S staining for protein-detection on Western blotted nitrocellulose 
  
 Ponceau S staining on Western blots was carried out as described by Harlow and 
Lane (1988). The blot was washed in Ponceau S solution (0.2 % (w/v) Ponceau S, 3% 
(w/v) TCA, 3 % (w/v) sulphosalicylic acid) for 5 min. This is a temporary stain, 
which can be washed off by rinsing in PBS before blocking and subsequent 
immunodevelopment. This is not a sensitive method for detection of proteins. 
 
2.2.11 Development of Western blots: Enhanced chemiluminescence (ECL) 
detection system 
 
 Blocking was carried out in 5 % w / v Marvel dried milk in PBS. The Marvel was 
centrifuged for 5 minutes at 5,000 rpm before use. After allowing blocking for 30 
minutes, the blot was washed in PBS, once for 15 minutes and then twice, for 5 
minutes each. Incubation of primary antibody was carried out over night at 4 ºC. The 
dilution required of each batch of primary antibody was previously determined by 
testing the intensity of development of a standard blot. The blot was then washed in 
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PBS as before, once for 15 minutes and then twice for 5 minutes each time. 
Following this, incubation with a 1 in 2,000 dilution (in 5 % marvel in PBS) of 
secondary rabbit polyclonal antibody or mouse monoclonal antibody was carried out, 
for one hour at room temperature. The blot was washed for 15 minutes in PBS, 
followed by four additional 5-minute washes. 
 
 Equal volumes of solutions one and two from ECL detection kit or from supersignal 
WestDura ECL HRP substrate detection kit, were mixed to form the detection 
reagent. Surplus buffer was drained from the blot that was then incubated in the 
detection reagent for 1 minute. A piece of hyper-film ECL was placed over the 
wrapped blot and exposed for 15 seconds initially. Exposure time was varied 
dependent on the intensity of the reaction. After exposure, the film was developed for 
4 min in developer and 2 min in fixer. 
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2.3 Isolation and detection of ε-sarcoglycan binding partners 
 
 
2.3.1 Preparation of solubilised ε-sarcoglycan and binding partners from 
forebrain derived light membrane 
 
 Two rat forebrains were obtained and homogenised into 10mM Tris pH 7.0 Buffer 
and PI in a final volume of 20ml. The homogenate was centrifuged for 5 minutes at 
3,000 rpm (SS34, Sorval), the supernatant was obtained and was centrifuged 42,000 
rpm (Beckman, 42.1 rotor) for 1 hour at 4oC. The pellets were resuspended in RIPA 
Buffer pH 7.5 in a final volume of 39ml, incubated for 30 minutes at 4oC, stirring 
gently. The resuspension was centrifuged at 42,000 rpm for 1 hour at 4oC (Beckman, 
42.1 rotor). The pellet obtained represented the LM fraction containing ε-sarcoglycan 
isoforms solubilised from the membrane as part of any multi-protein complexes that 
exist within the membrane. The pellet was subsequently resuspended in 1ml of 
(50mM Tris-HCl pH 5.5 containing 1%SDS), ready for Immunoprecipitation 
 
2.3.2 Cross-linking of anti-ε-sarcoglycan antibody to Dynabeads Protein G 
 
100µl of Dynabeads Protein G (Invitrogen) were added to an eppendorf tube and 
placed on a magnet, to separate the beads from the solution. After removal of the 
solution, the dynabeads attracted to the magnet structure were released and washed 
three times with 0.5ml citrate-phosphate Buffer pH 5.0, and the solution was removed 
when the dynabeads were allowed to dissociate from the solution and bind to the 
magnet. 20µl of anti-ε-sarcoglycan antibody was mixed with the washed dynabeads 
Protein G, and incubated 40 minutes at Room Temperature in a test-tube rotator. 
Subsequently, the dynabeads are said to have captured the antibody, thus the 
eppendorf tube was placed near the magnet to isolate the dynabead-antibody 
complex, and the latter was washed a couple of times with 0.5ml citrate-phosphate 
Buffer 0.1% Tween 20 pH 5.0. Prior to cross-linking the dynabead-antibody complex, 
the latter was washed in 1ml 0.2M triethanolamine buffer pH 8.2.  
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The dynabead-antibody complex was resuspended in 20mM DMP in 0.2M 
triethanolamine pH 8.2, with gentle mixing for 30 min at 20oC, to allow cross-linking. 
Using the magnet to isolate the dynabead-antibody complex, the supernatant was 
discarded and the cross-linking reaction was interrupted with 1ml 50mM Tris pH7.5, 
with a 15 minute gentle incubation at Room Temperature. Using the magnet, the 
cross-linked antibody-dynabead complex was washed a couple of times using 1ml 
PBS/T. Two additional washes of the cross-linked beads in 30µl 0.1M Citrate pH 2.0 
were carried out and loaded on a gel to verify the efficiency of antibody binding and 
antibody cross-linking to the beads, respectively, during the procedure. The cross-
linked beads were stored in PBS pH 7.4, containing 0.1% Tween-20 and 0.02% 
sodium azide, at 4oC. 
 
2.3.3 Immunoprecipitation of ε-sarcoglycan binding partners 
 
 The solubilised ε-sarcoglycan product (refer to section 2.3.1) was mixed with non-
cross-linked Dynabead Protein G (Invitrogen) in a 1:40 ratio, incubated for 3 hours, 
with gentle rotation at Room Temperature. A magnet was subsequently used to 
separate the beads and unspecifically-bound proteins from the pre-cleared LM 
suspension. The pre-cleared LM suspension and Dynabeads Protein G cross-linked 
with the anti-ε-sarcoglycan antibody were mixed in a 1:40 ratio, respectively, 
incubated overnight with gentle rotation at 4oC. The magnet was used to separate the 
beads containing the immunoprecipitated (IP) complex from the solution, such that 
the suspension could be removed, and the beads were washed twice in PBS. The IP 
complex was eluted from the Dynabead Protein G complex by addition of 30µl 0.1M 
Citrate pH 2.0, allowing to rotate for 2 minutes. A magnet was subsequently utilised 
to isolate the Dynabead Protein G from the suspension containing the IP complex, 
and the latter isolated. The elution step was repeated twice more.  
 
 
 
 
 
 
 
 87 
                             2.4 Cell culture of cortical neurons 
 
 
2.4.1 Preparing the coverslips 
 
 24 well tissue culture plates were prepared with coverslips coated with poly-D-
lysine, under sterile conditions. Coverslips were autoclaved, washed with ethanol and 
allowed to dry prior to coating procedures. Each coverslip was added to a well and 
coated with 0.5ml of Coating material (100mg/l Poly-D-lysine in 0.15M Boric Acid, 
pH 8.4). The plates were incubated 2 hours at 37oC in a sterile incubator. Post-
incubation, each well was washed twice with Hanks’ Balanced salt solution without 
Ca2+ and Mg2+, and left in sterile PBS solution in a 37oC sterile incubator, until 
needed. 
 
2.4.2 Preparation of cortical neurons from E18 prenatal rats 
 
 Cortical neurons were prepared by a method based on Dresbach et al (2003). E18 
pregnant rats were anaesthetised and its embryos removed. The heads were removed 
from the embryos, and the brain was dissected from the skull and transferred into a 
petridish with icecold Hanks’ Balanced salt solution (HBSS) without Ca2+ and Mg2+. 
The brains were cut along the midline and the forebrain was removed and 
immediately placed in another petridish with cold HBSS (without Ca2+ and Mg2+). All 
the forebrains isolated were transferred to a 15ml tube, washed three times with 5ml 
HBSS (without Ca2+ and Mg2+). Once all the HBSS media was removed, 1ml of pre-
warmed Day 1 Media (refer to Appendix II) was added to the forebrain and very 
gently triturated with a thin glass until the solution was clear. The suspension was 
filtered through a 70µm cell strainer. To the filtered supsension, 1ml Day 1 Media 
was added for each brain isolated, and a further 2ml Day 1 Media was added to this 
mixture.  
 
 Cells were counted by adding 10µl of cortical neuron preparation to 10µl of Trypan 
Blue, and viewed under a microscope. 60,000 cells/cm2 (high density) were plated on 
24 well plates for transfection experiments, whereas 30,000 cells/cm2 (low density) 
were plated on 24 well plates for immunocytochemistry. 24 hours after plating, the 
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Day 1 media was replaced with Day 2 Media (refer to Appendix II). Neurons were 
allowed to grow for two to three weeks in a sterile 37oC incubator, and half the media 
in each well was replaced with fresh pre-warmed Day 2 Media every seventh day. 
 
2.4.3 Preparation of DNA 
 
pET32b vectors containing the 33kDa ε-sarcoglycan peptide, and pEGFP-N3 
vectors containing Cexon78 or Dexon78 of classical and delta dystrophin isoforms 
respectively, were kind gifts by Derek DJ Blake and Christopher T Esapa of the 
Pharmacology Department, Oxford University.  
 
2.4.4 Transfection of cortical neurons with pEGFP-N3Cexon78 and pEGFP-
N3Dexon78 vectors 
 
For tissue culture media and reagents, refer to Appendix II. Using 24 well 
tissue culture plates coated with poly-D-lysine (refer to section 2.4.1), each well was 
plated with 60,000 cells/cm2 in 0.5ml of pre-warmed Neurobasal Media A, and 
incubated for 72 hours at 37oC, with 5% CO2 in 95% humified air. On day 3, half of 
the plating volume was removed and replaced with pre-warmed 250µl fresh 
Neurobasal Media B. Four days after plating, 1µg of DNA (refer to section 2.5.3) was 
prepared in a polypropylene tube and diluted into 50µl OPTI-MEM I. In a separate 
polypropylene tube, 4 µg of Lipofectamine 2000 (Invitrogen) was also diluted into 
50µl OPTI-MEM I, and incubated for 5 minutes at Room Temperature. The diluted 
DNA/Lipofectamine 2000 (total of 100µl) were mixed together and incubated 20 
minutes at Room Temperature. The supernatant from primary cultures was removed 
and replaced with 400µl/well of fresh Neurobasal Media B. 100µl of diluted 
DNA/Lipid complexes were added to each well, making a final volume of 500µl. The 
transfection was allowed to occur for 5 hours at 37oC, 5% CO2 with humified air. 
After 5 hours, the supernatant was removed and replaced with 0.5ml of Neurobasal 
Media B, and placed back in the incubator for 24 hours. The neurons were then fixed 
(refer to section 2.4.5 or 2.4.6) in order to visualise the protein of interest using a 
Nikon Eclipse TE300 microscope (refer to section 2.4.7). 
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2.4.5 PFA-Fixation (for cDp, dDp, ε-sg, MAP2, MANDAG, GABAAR, GAD65, 
β3-tubulin and synaptophysin antibodies) of mature cortical neurons 
 
 For tissue culture media and reagents, refer to Appendix II. Coverslips were washed 
with pre-warmed PBS. Neurons were fixed by adding 0.5ml of 4%PFA (pH 7.4) in 
PBS for 20 minutes at Room Temperature. The coverslips were then washed twice 
with 25mM Glycine in PBS and blocked one hour at Room Temperature in Blocking 
Solution with Triton X-100. The coverslips were placed in a humified chamber onto 
Parafilm, and 50µl of primary antibody in Blocking Solution was left over night at 
4oC. The next day the cover slips were washed twice in PBS followed by incubation 
with 50µl secondary antibody in Blocking Solution without Triton X-100 for 1 hour 
at Room Temperature in the dark. The coverslips were then washed twice with PBS, 
followed by water washes, and then mounted with Vectashield Mounting Medium.  
  
2.4.6 Methanol-Fixation (for dDp, PSD95 and NR1 antibodies) of mature 
cortical neurons 
 
 For tissue culture media and reagents, refer to Appendix II. Neurons were fixed 
with –20oC cold Methanol for 5 min at –20oC, followed by permealisation in 0.25% 
Triton X-100 for 5 min. Upon washing with PBS, unspecific binding was blocked for 
1 hour at Room Temperature in 10%BSA in PBS. 50µl of primary antibody in 
Blocking Solution with Triton X-100 was added to each well and incubated over 
night in a humified chamber. The next day, the coverslips were washed twice in PBS, 
followed by 1 hour incubation with 50µl secondary antibody in Blocking Solution 
without Triton X-100 at Room Temperature, in the dark. After washes with PBS, and 
water, the coverslips were mounted with Vectashield Mounting Medium.  
 
2.4.7 Viewing fixed neurons under the microscope 
 
      The stained cells were visualised using a Nikon Eclipse TE300 inverted 
microscope equipped with a Hamamatsu digital camera and images visualised using 
simple PCI (Digital Pixel) software. 
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                                    2.5 Antibody production 
 
 
2.5.1 Endofree Maxiprep Plasmid Kit for amplification of the epitope-containing 
DNA 
 
For buffer solutions, refer to Appendix I, Box 4. For biological kits and systems, 
refer to Appendix I, Box 2. An Endofree Maxiprep Plasmid Kit (Qiagen) was utilised 
to amplify the DNA containing the epitope against which the antibody had to be 
raised against. Prior to starting, RNAse A was added to P1 buffer, and P3 buffer was 
chilled at 4oC. A single colony was picked (refer to section 2.5.5) from a selective 
plate and used to inoculate a starter culture of 2-5ml LB medium containing the 
appropriate selective antibiotic. The colony in the LB medium was incubated for 8 
hours at 37oC with vigorous shaking (300 rpm). The starter culture was diluted to 
1:500 into 150ml selective LB medium and incubated 16 hours at 37oC with vigorous 
shaking (300 rpm). The bacterial cells were harvested by centrifugation at 6,000g for 
15 minutes at 4oC. The bacterial pellets were combined and resuspended in 10ml 
Buffer P1. 10ml Buffer P2 was subsequently added, mixed thoroughly by vigorously 
inverting the sealed tube 6 times, and incubated for 5 minutes at Room Temperature. 
10ml of chilled Buffer P3 was added to the lysate and immediately mixed thoroughly 
by vigorously inverting the sealed tube 6 times or until the solution became 
neutralised. The lysate was poured into the barrel of the Qiafilter cartridge, incubated 
10 minutes at Room Temperature. The cap from the Qiafilter Cartridge outlet nozzle 
was removed and the plunger was gently inserted into the Qiafilter maxi Cartridge 
and the cell lysate was filtered into a 50ml tube. 2.5ml of Buffer ER was added to the 
filtered lysate and mixed by inverting the tube approximately 10 times followed by a 
30-minute incubation on ice. To equilibrate the QIAGEN-tip 500, 10ml of Buffer 
QBT were applied to the column, and the Buffer was allowed to exit the column by 
gravity flow.  The filtered lysate was applied to the equilibrated QIAGEN-tip 500 and 
allowed to enter the resin by gravity flow. The QIAGEN-tip was washed twice with a 
30ml Buffer QC. The DNA was eluted with 15ml Buffer QN. The DNA was then 
precipitated by adding 10.5ml (0.7 volumes) of isopropanol to the eluted DNA, mixed 
and centrifuged immediately at 15,000g (Beckman, SW28 rotor) for 30 minutes at 
4oC. The supernatant was carefully decanted. The DNA pellet was washed by 
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resuspending with 5ml of endotoxin-free Room Temperature 70% ethanol, and 
centrifuged at 15,000g (Beckman, SW28 rotor) for 10 minutes. The resulting 
supernatant was carefully decanted without disturbing the pellet. The pellet was 
allowed to air-dry for 10 minutes, and redissolved in a suitable volume of endotoxin-
free Buffer TE (~300µl).  
 
2.5.2 Analysis of DNA by sequencing 
 
 DNA sequencing by the dideoxy-mediated chain termination method was routinely 
automated and performed in Oswell Laboratories. 5µg of purified plasmid DNA to a 
1.5ml microfuge tube were normally sent over for sequencing analysis after adjusting 
the volume to 50ml with ddH2O (C = 100ng/µl). Sequencing data were analysed 
using ABI PRISMA software compatible with a Power Macintosh G3. 
 
2.5.3 Spectrophotometric determination of DNA 
 
 The spectrophotometer was calibrated at 260nm by adding 1ml TE (Tris-EDTA 
buffer) in a cuvette. 10µl of each DNA sample was added to 900µl TE buffer and 
mixed well. The OD260 values were obtained from the spectrophotometer. The 
amount of DNA was quantified from the following formula: 
 
DNA concentration (µg/ml) = OD260 x 100 (dilution faction) x (50 µg/ml)* 
                                                                             1000 
* (conversion factor for ds DNA)   
 
2.5.4 Preparation of Lysogeny broth (LB) agar ampicillin plates 
 
 The LB agar media was prepared in a 1L flask. The flask was covered with an 
aluminium foil and autoclaved for 20 minutes using the liquid cycle. 100µg/ml 
ampicillin was added to the autoclaved medium and mixed. A flame was passed on 
the beaker to remove any bubbles in the medium, and on the beaker mouth for 
sterilisation purposes. The LB agar was poured into sterile plates, and these were 
 92 
allowed to stand at Room Temperature for a day. The plates were then stored upside 
down inside a bag to prevent drying out, at 4oC. 
 
2.5.5 Transformation protocol of E. coli with pET32b ε-sarcoglycan peptide 
 
For cells, buffers, solutions and reagents, refer to Appendix I, box 5. BL21 (DE3) 
competent cells were thawn on ice. Separate 100µl aliquots of the competent cells 
were added to different 14ml BD Falcon polypropylene round-bottom tubes, whilst a 
100µl aliquot of competent cells was obtained for use as a transformation control. To 
increase transformation efficiency, a 1:10 dilution of a 14.2M stock solution of β-
mercaptoethanol (β-ME) was added to all cells, for a final concentration of 25mM β-
ME, and gently swirled every 2 minutes. 25ng of pET32bε-sarcoglycan peptide was 
added to each transformation reaction and swirled gently. For the control 
transformation reaction, 1µl of pET32b plasmid lacking ligation was added to a 
separate 100µl aliquot of the competent cells and swirled gently. All transformation 
reactions were incubated on ice for 30 minutes. Each transformation reaction was 
heat-pulsed in a 42oC water bath for 45 seconds, followed by a 2-minute incubation 
on ice. 0.9ml of a preheated (42oC) SOC medium (2M filter-sterilised glucose 
solution) was added to each transformation reaction and subsequently incubated the 
reactions for 1hr, in a shaker (220rpm) and 37oC. 100µl of the transformed cells 
containing the ligated pET32b vector were spread on to LB agar ampicillin plates 
using a sterile spreader. 200µl of the control transformants were plated onto an LB-
ampicillin agar plate. The plates were incubated overnight at 37oC. The single 
colonies of transformants were picked for either “Endofree Maxiprep Plasmid Kit” or 
for “Induction of target protein using IPTG on a large scale”. 
 
2.5.6 Induction of target protein using IPTG on a large scale 
 
For cells, buffers, solutions and reagents, refer to Appendix I, box 5. Single 
colonies of transformants were picked and inoculated each in a different 20ml aliquot 
of LB medium containing 100µg/ml ampicillin, left overnight in a shaker (220rpm) at 
37oC. A 1 liter culture (LB, 100µg/ml ampicillin) was inoculated 1:50 with the 
noninduced overnight culture under vigorous shaking (220rpm) at 37oC, until an 
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OD600 of 0.5 was reached. A 1ml samples was taken just prior to induction, and the 
cells in the sample were pelleted using a microcentrifuge and resuspended in 50µl 5x 
SDS-PAGE sample buffer, for gel analysis. Overexpression of the peptide of interest 
was induced by addition of IPTG to a final concentration of 1mM. Once the OD600 of 
0.5 was reached, a 1ml sample was collected and the cells were pelleted in a 
microcentrifuge and resuspended in 100µl 5x SDS PAGE sample buffer, for gel 
analysis. The induced cells in the 1 liter culture were then harvested by centrifugation 
at 4,000 g for 20 minutes, stored overnight at –20oC. 
 
2.5.7 Preparation of cleared BL21 (DE3) lysates under denaturing conditions for 
purification of the target protein 
 
For buffer solutions, refer to Appendix I, box 4. The induced cell pellet was 
thawn for 15 min on ice and resuspended in Buffer B at 5ml per gram-wet weight. 
The cells were gently stirred for 30-60 minutes at Room Temperature. Once the 
solution became translucent, lysis was complete and the lysate was centrifuged at 
10,000 g (Sorval, SS34 rotor) for 30 min at Room Temperature in order to pellet the 
cellular debris. The supernatant was ready to undergo protein purification under 
denaturing conditions. A 5µl aliquot of the supernatant was mixed with 5µl of 2x 
SDS-PAGE sample buffer and stored at –20oC for SDS-PAGE analysis. 
 
2.5.8 Batch purification of 6xHis-tagged proteins from BL21 (DE3) cells under 
denaturing conditions 
 
For buffer solutions, refer to Appendix I, box 4. 1ml of the 50% Ni-NTA 
(Qiagen) slurry (binding capacity 5-10mg/ml) was equilibrated with Buffer B, and 
centrifuged at 2,000 rpm for 2 minutes. 1-2mg lysate was loaded onto an equilibrated 
column and mixed gently on a shaker (200rpm) for 60 min at Room Temperature. 
The lysate-resin mixture was carefully loaded into an empty column with the bottom 
cap still attached. Once the mixture settled in the column, the bottom cap was 
removed and the flow-through was collected and kept for gel analysis. The column 
was washed twice with 4ml Wash buffer pH 6.3, and the flow-through was collected 
for gel analysis. The recombinant 32.6kDa ε-sarcoglycan peptide was eluted 4 times 
with 0.5ml Elution buffer pH 5.9, followed by 4 times with 0.5ml Elution buffer pH 
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4.5. The fractions were collected and analysed by SDS-PAGE. The Ni-NTA Resin 
matrix was stored in Buffer B containing 30% ethanol, to inhibit microbial growth. It 
is recommended a maximum of 5 runs per column. 
 
2.5.9 Selection and preparation of Dialysis Membrane 
 
A 30 cm dialysis membrane with “molecular weight cut-off” (MWCO) 1000 was 
utilised. The membrane was boiled for several minutes in a large excess of 10mM 
sodium bicarbonate, followed by boiling for several minutes in 10mM Na2EDTA. 
The boiling step in 10mM Na2EDTA was repeated. The membrane was then washed 
several times in distilled water and stored at 4oC in 20% to 50% ethanol, to prevent 
growth of cellulolytic microorganisms. 
 
2.5.10 Dialysis of ε-sarcoglycan peptide 
 
The MWCO 1000 dialysis membrane was removed from ethanol storage solution 
and rinsed with distilled water. A secure clamp was utilised to close one end of the 
membrane. The membrane was filled with ε-sarcoglycan peptide and the open end 
was also clamped avoiding any air above the sample. The sample was squeezed to 
check the integrity of the membrane and clamps. The dialysis membrane was 
immersed in a beaker containing 2 liter of cleavage buffer, allowing stirring gently 
overnight at 4oC.  The next day, the cleavage buffer was replaced with 1.5 liter of 
fresh cleavage buffer pH 7.4, allowing stirring gently for 2 hours at 4oC.  This last 
step was repeated. The dialysis membrane was removed from the buffer and the 
membrane was held vertically to remove excess buffer trapped near the clamp. The 
sample was removed with a Pasteur pipet. 
 
2.5.11 Concentrating the purified ε-sarcoglycan peptide 
 
Up to 2ml of the dialysed ε-sarcoglycan peptide was added to a Centricon YM-10 
centrifugal filter device, and allowed to spin for 1 hour, at 25oC, at 5,000 g (Sorvall, 
H1318 rotor). The dialysed ε-sarcoglycan peptide was concentrated to as little as a 
25µl sample volume in cleavage buffer.  
 
 95 
2.5.12 Recombinant Enterokinase (rEK) treatment on the 33kDa ε-sarcoglycan   
peptide 
 
For buffer solutions, refer to Appendix I, box 4. The concentrated ε-sarcoglycan 
peptide containing the enterokinase (EK) tag was digested using Recombinant 
Enterokinase. Serial dilutions of 50U rEK in rEK Dilution/Storage Buffer were 
prepared to produce solutions containing 0.1, 0.2 and 0.5U enzyme per µl. These 
were assembled with the following components into 4 separate tubes, in order to 
estimate the appropriate range of enzyme:target protein ratio and incubation times. 
5µl of 10x rEK Cleavage/Capture Buffer A, 10µg target protein, 1µl diluted rEK (the 
fourth tube received 1µl Dilution/Storage Buffer only), and x µl of deionised water to 
make a 50 µl total volume. The reactions were incubated at room temperature, taking 
10 µl aliquots into 10µl of 2x SDS sample buffer after 2, 6 and 17 hours, such that the 
extent of cleavage of the samples could be determined by SDS-PAGE analysis. The 
optimum rEK:protein ratio for this study was 1:100, with a 17 hour incubation time. 
A total of 2mg ε-sarcoglycan peptide digested with rEK was obtained, and was 
concentrated in Centricon YM-10 centrifugal filter device. For details, refer to section 
2.5.11. 
 
2.5.13 Isolation of the ε-sarcoglycan peptide from the S-tag-containing peptide 
 
For buffer solutions, refer to Appendix I, box 4. The 14kDa ε-sarcoglycan 
peptide and 18.6kDa tag, obtained by rEK digestion of the 32.6kDa ε-sarcoglycan 
peptide, were equilibrated in Wash/Bind buffer pH 7.5. The 4ml slurry S-tag Agarose 
Beads (Novus Biologicals), which can bind up to 1mg of S-tag, were also equilibrated 
in Wash/Bind buffer by gently mixing the beads with Wash/Bind buffer for 2 
minutes, followed by a 2 minute centrifugation at 2,000 rpm. The supernatant was 
discarded and the 2ml settled Agarose beads were mixed with 2mg protein capacity 
(1mg of 14kDa ε-sarcoglycan peptide + 1mg of 18.6kDa tag), 2 hours at Room 
Temperature, with gentle rotation (14 rpm). The sample was added to 5ml spin-filter 
columns, and centrifuged 10 minutes at 500g. The supernatant contained the 14kDa ε-
sarcoglycan peptide of interest. The beads were gently mixed on a rotator (14 rpm) 
for 5 minutes with 3M Magnesium Chloride, followed by a 2minute centrifugation at 
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2,000 rpm. The supernatant contained the 18.6kDa S-tag peptide. The beads were 
resuspended and gently mixed (14 rpm) in Wash/Bind buffer pH 7.5 for 5 minutes, 
followed by a 2 minute centrifugation, and stored in phosphate buffer, pH 7.3 
containing 0.5M NaCl, 0.02% Thimerosal at 4oC, for further use. 
 
2.5.14 Bradford Protein Assay (for protein and antibody) 
 
 A BioRad protein assay kit was used to estimate the concentration of proteins. 20µl 
of different dilutions of the BSA (2mg/ml) protein standard were pipetted into 
separate 1ml cuvettes. 20µl of unknown samples were also pipetted into separate 1ml 
cuvettes. 1ml of 1x Dye reagent was added to each cuvette. All samples were 
incubated for 10 minutes at Room Temperature. The spectrophotometer was set to 
280nm. The instrument was zeroed with the blank sample containing 1ml of 1x Dye 
reagent and 20µl of the same buffer found in the sample/BSA. The absorbance 
measurements of the standards and unknown samples were measured. A standard 
curve was prepared by plotting the 280nm values (y-axis) versus their concentration 
in µg/ml (x-axis). The concentration of the unknown sample was determined using 
the standard curve, and the final concentration was adjusted by multiplying by the 
dilution factor, and divided by 1cm (path length). 
 
2.5.15 Lyophilisation 
 
      Prior to lyophilisation, the switches for both the vacuum and refrigeration were 
set to “auto”(switches are both down), the lights for vacuum and refrigeration were 
checked to make sure they were both on, the temperature was allowed to reach ~ 
40oC, and the pressure was allowed to reach ~100x10-3 M Bar. The sample was 
frozen in a –80oC freezer until the sample was completely frozen. The open container 
containing the sample was covered with tin foil. A few small holes were punched in 
the tin foil in order to allow for more efficient pressure equalisation. The frozen 
sample was placed in a round bottom lyophiliser tube, and this in turn was placed into 
a rubber gasket attached to the lyophiliser. The valve attached to the rubber gasket 
was turned 180oC clockwise to open the chamber to the pump. The vacuum reading 
should momentarily go down and then come back up as the vacuum pumps down the 
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tube. After a 2 hour to overnight incubation time, depending on the volume of each 
sample and the time it takes for each sample to completely dry-out, the valve was 
turned counter clockwise 180oC and the lyophiliser tube containing the sample could 
be removed.   
 
2.5.16 Antibody production 
 
The lyophilised sample (refer to section 2.5.15) was sent to Sigma-Genosys for 
antibody production in rabbit hosts. 
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          2.6 Isolation of anti-ε-sarcoglycan antibody from immunised   
          Rabbit serum 
 
 
2.6.1 Cross-linking of ε-sarcoglycan peptide to the AminoLink Column 
 
Following the dialysis of the ε-sarcoglycan peptide in 1L PBS solution (refer to 
section 2.5.10), the peptide was concentrated (refer to section 2.5.11), prior to cross-
linking to the AminoLink Column. The AminoLink Plus Resin was suspended by 
end-over-end mixing. Subsequently, top cap and then the bottom tab were 
sequentially removed, in order to avoid drawing air into the column. The column was 
centrifuged at 1,000g for 1 minute in order to remove the storage buffer. 2ml of 
Coupling Buffer pH 7.2 was added to the column, followed by centrifugation at 
1,000g for 1 minute. This last step was repeated. The bottom cap was replaced and 2-
3ml of ε-sarcoglycan peptide (1-2mg content) dissolved in pH 7.2 Coupling Buffer 
was added to the AminoLink Plus Column. 0.1ml of the prepared sample was saved 
for subsequent determination of coupling efficiency. In a fume hood, 40µl of 5M 
Sodium Cyanoborohydride Solution was added to the reaction slurry, and the top cap 
was replaced to allow the mixing of the column by end-over-end mixing at Room 
Temperature for 4 hours. The top and bottom cap were removed respectively, then the 
column was placed into a new tube where it could be centrifuged at 1,000g for 1 
minute, and the non-bound protein was collected and saved, in order to determine the 
coupling efficiency by comparing the protein concentration of the non-bound fraction 
to the starting sample. The top cap was removed, followed by the removal of the 
bottom cap, and the column was placed into a new tube and centrifuged at 1,000g for 
1 minute to remove Coupling Buffer. The column was washed with 2ml of 
Quenching Buffer and centrifuged. The washing step was repeated. The bottom cap 
was replaced, and in a fume hood, 2ml of Quenching Buffer were added to 40µl of 
Sodium Cyanoborohydride Solution, and the resulting solution was added to the 
column. The top cap was replaced to allow gentle mixing of the column for 30 
minutes by end-over-end rocking. The top cap was carefully removed, as some gas 
pressure may have formed during the reaction. The bottom column cap was 
subsequently removed, and the column was placed into a new tube and centrifuged in 
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order to remove Quenching Buffer. The reactants and the non-coupled protein were 
washed away with 2ml of Wash Solution (1M NaCl, 0.05% NaN3) and centrifuged at 
1000g for 1 minute. This step was repeated four times. The column was equilibrated 
by adding 2ml of Storage Buffer B and centrifuged. This step was repeated two more 
times. The bottom cap was replaced and 2ml of Storage Buffer B were added to the 
top of the resin bed. The top cap was replaced and the equilibrated column was stored 
upright at 4oC until further use.  
 
2.6.2 Affinity purification of anti-ε-sarcoglycan antibody from immunised 
Rabbit serum 
 
 The AminoLink Column containing the 33kDa ε-sarcoglycan peptide covalently 
attached to the beaded agarose support by primary amine-containing proteins was 
equilibrated to Room Temperature. The top column cap, followed by the bottom cap, 
was removed and the column was centrifuged at 1,000g for 1 minute to remove any 
storage solution. The column was equilibrated with 6ml of Phosphate-Buffered saline 
(PBS) pH 7.4. The rabbit serum was diluted with PBS in a 1:1 ratio, and 2ml volumes 
of the diluted serum were added in succession to the column. 12ml of Coupling 
Buffer pH 7.2 was added to the column, the flow-through containing the non-bound 
serum antibody was collected and saved, in order to determine the coupling efficiency 
by comparing the antibody concentration of the non-bound fraction to the starting 
sample. The rabbit serum anti-ε-sarcoglycan antibody that bound to the affinity 
column was eluted with 8ml Elution Buffer (0.1M Glycine pH 2.5). The eluted 
samples were saved in separate 1ml fractions, each containing 50µl of Neutralization 
Buffer (1M Tris-HCl pH 9.0). pH strips were utilised to verify the elution containing 
the antibody was neutralised. The elution(s) containing the antibody was identified 
via spectrophotometric analysis at 280nm (refer to section 5.23). 100µl liquots of 
anti-ε-sarcoglycan antibody were added to separate eppindorff tubes and stored at      
–80oC.  
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   Chapter 3:  
 
 
            3.0 Classical and delta dystrophins are differently localized 
in brain and hence likely to form different DPC complexes. 
 
 
                  3.1 Introduction 
  
               In brain, the molecular composition of the DPC complex at inhibitory 
synapses of hippocampal neurons is becoming well established and includes: classical 
full-length dystrophin, β-dystrobrevin, α and β-dystroglycan, syntrophins, and β-
neurexin (Brunig, et al, 2002; Culligan et al, 2002) (see chapter 1, figure 1.1.7.1). A 
decade ago, Blake et al (1999) identified a novel alternatively spliced isoform of 
classical dystrophin, which I name delta dystrophin (see Chapter 1, figure 1.1.2.2B). 
Although the expression of delta dystrophin in the brain has already been demonstrated 
(Blake et al, 1999), no studies on the function or localization of delta dystrophin in the 
brain have been published to date, and very little information is known about its 
molecular interactions in brain (Blake et al, 1999). The amino acid sequence of 
classical and delta dystrophin differs by only one exon located at the C-terminal end of 
each protein (chapter 1, figure 1.1.2.2). Classical dystrophin contains classical exon 78 
that can be replaced by a longer and unique sequence I name delta exon 78, to yield 
delta dystrophin. Classical dystrophin contains a number of different domains (chapter 
1, figure 1.1.2.1) that allow the protein to associate with various DPC components and 
intracellular proteins. Classical exon 78 is not part of any of these domains in classical 
dystrophin. In fact, the significance of classical exon 78 still remains to be established. 
Given that classical exon 78 does not appear to participate in molecular interactions 
with the DPC complex, its replacement with delta exon 78 suggests delta dystrophin 
possesses all the requisites to serve a similar function to classical dystrophin. Hence it 
may replace classical dystrophin to form novel delta DPC-like complexes in the brain. 
If so, this raises a number of interesting questions. Do delta dystrophin DPC complexes 
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co-localize to the same subcellular compartments as classical dystrophin DPC 
complexes? Do they have the same protein composition and the same functions? 
 
               I present here a database search (BLAST database) on classical exon 78 
and delta exon 78, in order to verify whether any recently identified conserved domain 
published on this database whose function is known, matches these two short amino 
acid sequences. I then use a biochemical approach to compare the subcellular 
distribution of classical and delta dystrophin in two different brain regions (forebrain 
and cerebellum), to determine if the two dystrophin isoforms have the same or different 
distributions in the brain, in order to begin to determine whether delta dystrophin may 
replace classical dystrophin in DPC formation and its functions. The distribution of 
classical and delta dystrophin presented is also compared with the subcellular 
distribution of other well-established DPC components in the brain. These experiments 
aim to determine the similarities and/or differences delta dystrophin complexes may 
have with the well-established classical dystrophin-containing DPC complexes in 
forebrain and cerebellum, and provide information on the ability of delta dystrophin to 
replace classical dystrophin in the formation of novel delta DPC-like complexes in the 
cerebellum as well as in the forebrain. The cerebellum was selected because of the 
abundance of inhibitory GABAergic neurons (Leto et al, 2008), given that classical 
dystrophin is associated with GABAergic nerve terminals (Brunig et al, 2002). 
 
               According to a number of publications, DPC complexes of neurons 
contain only classical full-length dystrophin and are highly enriched in PSD structures 
(Culligan et al, 2002; Blake et al, 1999; Waite et al, 2009; Pilgram et al, 2009). Its 
localization at PSD structures has been shown via a number of biochemical approaches 
(Blake et al, 1999) as well as by immunocytochemical studies of hippocampal cultures 
(Brunig et al, 2002). Classical dystrophin and associated DPC components are co-
localized with PSD markers (Brunig et al, 2002), therefore, PSDs and a range of 
subcellular fractions from rat brain have been prepared in order to determine whether 
delta dystrophin is also enriched in PSDs. There are two common and widely used 
methods to isolate PSDs (see materials and methods) either using Triton X-100 
extraction (Cohen et al, 1977; Carlin et al, 1980) or phase partitioning using n-octyl 
glucopyranoside (Gurd et al, 1982). Given that the composition of PSDs extracted by 
the two methods may vary, and, given that the Triton X-100 preparation seems to 
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contain only tightly bound PSD components (Matus et al, 1978; Kraus and Beesley 
unpublished results), both methods have been utilized and compared with one another, 
to examine the distribution of delta and classical dystrophins in PSD structures in both 
the forebrain and cerebellum.  
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3.2 Results: 
 
 
                  3.2.1 BLAST database search 
 
            To establish the significance of classical and delta exon 78, I examined 
these sequences by using the BLAST database (http://blast.ncbi.nml.nih.gov/Blast.cgi).  
I introduced the sequence of classical exon 78 (Table 3.2.1), and the database found 
homologies of the sequence in classical dystrophin proteins only, but did not match 
with any putative conserved domains present in other proteins, thus the significance of 
classical exon 78 remained unresolved. When I introduced the sequence of delta exon 
78 (Table 3.2.1), the database found homologies with delta dystrophin proteins only, 
but again, it did not match with any putative conserved domains present in other 
proteins, thus the significance of delta exon 78 also remained unresolved. In order to 
establish whether there may exist distant sequence similarities between these exons and 
the protein sequence database, I carried out a different BLAST database search, named 
PSI-BLAST. Unlike the BLAST database, the PSI-BLAST has been demonstrated to be 
useful in detecting such similarities even after considerable modification of their 
sequence during evolution (Bergman et al, 2007). When I introduced these sequences 
in the PSI-BLAST database, the results obtained were identical to those described in 
Table 3.2.1. I therefore began to examine and compare the subcellular distribution of 
classical and delta dystrophin in forebrain, to establish whether the differences 
exhibited by classical and delta exon 78 may or may not affect the subcellular 
distribution of delta dystrophin, when compared to classical dystrophin. This in turn 
was important for determining whether delta dystrophin may be able to replace 
classical dystrophin in the formation of novel delta DPC-like complexes at these brain 
regions, or whether the substitution of exon 78 results in the production of different 
protein complexes with different subcellular localization and with different properties 
and functions. 
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Query Protein sequence Comparison 
with the cdd 
         
Classical exon 78 
    (dystrophin) 
 
RNAPGKPMREDTM 
 
No putative 
conserved 
domain has 
been detected 
other than in 
dystrophin 
isoforms. 
 
Delta exon 78 
     (dystrophin) 
           
HNVGSLFHMADDLGRAMESLVSVMTD
EEGAE 
 
No putative 
conserved 
domain has 
been detected 
other than in 
dystrophin 
isoforms. 
 
 
 
Table 3.2.1: classical and delta exon 78 contain no putative conserved domain. 
A BLAST database was used to align exon 78 with sequences whose conserved 
domains are already established. The BLAST hit resulted negative. The significance of 
these exons to date remains unknown. Cdd, conserved domain database. 
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                  3.2.2 Isolation of brain subcellular fractions 
 
            Different subcellular fractions were obtained as described in M&M, 
chapter 2. These fractions were then probed with a number of antibodies to determine 
the distribution of the antigen proteins in the different subcellular fractions. The 
following subcellular fractions were obtained from forebrain and cerebellum of adult 
rat brains: brain homogenate (BH), P2 pellet, myelin (My), microsomes (Mc), light 
membrane (LM), synaptic membrane (SM) and mitochondria (Mt). The SM fraction 
was fractionated further to give the PSD fraction. The PSD fraction consists of a large 
number of proteins, including scaffolding proteins, receptors, signaling proteins and 
adhesion molecules. The BH obviously contains all the complete protein complement 
present in brain. The P2 pellet contains mainly nuclei or non-solubilised material of 
neurons and glia. Microsomes mostly consist of artifactual vesicles formed from the 
endoplasmic reticulum (ER), ribosomes, partially lysed cells, and occasional small 
nerve-ending particle contamination. Myelin mostly consists of myelin fragments 
together with fragments of axon membrane. LM mainly contains membrane fragments 
largely of non-synaptic origin; the SM contains mainly synaptic membrane material as 
well as some contaminants from other fractions, including membranes of non-synaptic 
origin. The mitochondria consists almost entirely of mitochondrial membrane and 
matrix material, as well as some DNA contamination.  
 
                        Forebrain PSDs were isolated using either n-octyl glucopyranoside or 
Triton X-100. Fractions were assayed for protein concentration by the Folin-Lowry 
method, and then subjected to a number of tests to show they are not cross-
contaminated. A Sodium Dodecyl Sulfate (SDS) polyacrylamide gel containing an even 
loading of the subcellular fractions isolated, was stained with Coomassie blue (figure 
3.2.2.1) to reconfirm the protein loading is even throughout each lane. Figure 3.2.2.1 
shows that the gels were evenly loaded, but as expected, the protein composition of 
each fraction was distinctly different and evenly loaded. Three separate markers 
(neuroplastin65, Gp50 and PSD-95) were used to test for cross-contamination between 
the subcellular fractions isolated. 
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26.4kDa 
 Figure 3.2.2.1: SDS PAGE separation of forebrain subcellular fractions.  
Aliquots of subcellular fractions prepared from forebrain were separated on a 10% 
SDS PAGE gel. Proteins were visualised with Coomassie blue. Protein loading is 
20µg/lane. Lane 1, Molecular Weight Markers; lane 2, Brain Homogenate (BH); 
lane 3, Myelin (My); lane 4, Mitochondria (Mt); lane 5, Light Membrane (LM); lane 
6, Synaptic Membrane (SM); lane 7, Post Synaptic Density (PSD), isolated by the n-
octyl glucopyranoside (N) method. Molecular weight standards are indicated.  
PSD 
(N) 
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                        I first examined the purity of forebrain subcellular fractions by 
determining the distribution of neuroplastins (np55 and np65, 55 and 65kDa 
respectively), using anti-neuroplastin antibody (Gp65) (figure 3.2.2.2). Previous work 
carried out in our lab has shown that both neuroplastins are enriched in the SM fraction, 
whereas only np65 is present in the PSD fraction (Hill et al, 1988). Np65/55 were 
therefore considered to be suitable markers for testing cross-contamination of the PSD 
fraction with membrane fractions. All subcellular fractions were loaded on to an SDS 
gel, followed by western blotting with anti-neuroplastin antibody (Gp65) (figure 
3.2.2.2). The neuroplastin distribution was as expected. Neuroplastins 65 and 55 were 
visible in the Brain Homogenate, P2 pellet, LM fraction and appeared enriched in the 
SM lane. Only very low amounts of np65 and np55 were present in myelin and 
mitochondria fractions, suggesting there is very little cross-contamination with the 
fractions containing both neuroplastins.  
 
 Next I investigated the distribution of the neuroplastins within PSD 
fractions obtained by two different detergent methods, and compared it to the SM 
fractions (figure 3.2.2.3). Regardless of the method used for isolating the PSD fraction, 
np55 was consistently absent from the PSD fractions, and as expected, np65 was 
present in PSD fractions isolated by both methods. What is more, both neuroplastins 
were enriched in the SM fraction, as expected. The neuroplastin distribution showed 
that the subcellular fractions were successfully isolated. It is important to note that the 
level of np65 in the Triton X-100 extracted PSDs is much less than for the n-
octylglucoside prepared PSDs. This is a novel result and important as it suggests that 
np65 may only be loosely bound to the PSD. In both preparations, the PSDs appear to 
be pure, as np55 did not contaminate the PSD fraction.   
 
 To further test cross-contamination of the PSD fraction with membrane 
fractions, the distribution of Gp50 (figure 3.2.2.4) was investigated. The Gp50 antibody 
detects the 50kDa β2-subunit of the ATPase subunit, known to be present in synaptic 
membranes (SM), but absent from the PSD and other fractions (Beesley et al, 1987). 
Upon western blotting of subcellular fractions and incubation with the anti-Gp50 
antibody, I observed that only the LM and SM fractions contained the Gp50 protein, 
whereas the PSD fraction did not contain any Gp50 protein, in agreement with Beesley 
et al (1987). In fact, the 50kDa protein is highly enriched in the LM fraction, less 
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prominent in the SM fraction. In conclusion, the PSD fraction appears to be pure, as 
Gp50 did not contaminate the PSD fraction. No Gp50 was found in the remaining 
subcellular fractions, suggesting that there is no cross-contamination with the fractions 
containing Gp50. 
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Mt BH SM P2 LM My 
Figure 3.2.2.2: Western Blot of forebrain subcellular fractions immunodeveloped 
with anti-neuroplastin antibody (Gp65).   
Neuroplastin 65 (np65) and neuroplastin 55 (np55) are abundant in the BH, P2 and 
LM fractions, and appear enriched in the SM fraction. Negligible quantities are found 
in the myelin and mitochondrial fractions. Protein loading is 20µg/lane. Lane 1, Brain 
Homogenate (BH); lane 2, Pellet 2 (P2); lane 3, Myelin (My); lane 4, Light 
Membrane (LM); lane 5, Synaptic Membrane (SM); lane 6, Mitochondria (Mt). 
Molecular weight standards are indicated.  
65kDa 
55kDa 
np65 
np55 
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PSD 
(T) 
PSD  
Figure 3.2.2.3: Western Blot of forebrain synaptic fractions immunodeveloped 
with anti-neuroplastin antibody (Gp65). PSDs were isolated by the Triton X-100 
(T) or n-octyl glucopyranoside methods.   
Neuroplastin 65 (np65) and neuroplastin 55 (np55) are enriched in the SM fraction. 
Only np65 is present in the PSD fractions. Triton X-100 extracted PSDs contain much 
less np65 than n-octyl glucopyranoside extracted PSDs. Protein loading is 20µg/lane. 
Lane 1, SM; lane 2, Post Synaptic Density (PSD), isolated by the n-octyl 
glucopyranoside (N) method; lane 3, Post Synaptic Density (PSD), isolated by the 
Triton X-100 (T) method. Molecular weight standards are indicated.   
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Figure 3.2.2.4: Western blot of forebrain subcellular fractions 
immunodeveloped with anti-Gp50 antibody. PSDs were prepared by the n-
octyl glucopyranoside method. Gp50 is enriched in the LM and SM fractions only. 
Protein loading is 20µg/lane. Lane 1, Brain Homogenate (BH); lane 2, Myelin 
(My); lane 3, Mitochondria (Mt); lane 4, Light Membrane (LM); lane 5, Synaptic 
Membrane (SM); lane 6, Post Synaptic Density (PSD) isolated by the n-octyl 
glucopyranoside (N) method. Molecular weight standards are indicated. 
My Mt  
 
LM  
 
SM  
 
 
PSD BH 
50kDa Gp50 
      
(N) 
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 For the third and final test for the purity of these subcellular fractions I 
determined the distribution of the PSD marker PSD-95 (figure 3.2.2.5). PSD-95 is a 
95kDa scaffold protein that is very highly enriched in the PSD fraction of the forebrain 
(Kim et al, 1992; Hunt et al, 1996). Western blots including all subcellular fractions 
were incubated with anti-PSD-95 antibody. The 95kDa protein was successfully 
enriched in the PSD fraction and absent from all other fractions, suggesting there is no 
cross-contamination between the PSDs and the other subcellular fractions. In 
conclusion, my data show that the subcellular fractions do not show cross-
contamination.  
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Figure 3.2.2.5: Western blot of forebrain subcellular fractions immunodeveloped 
with anti-PSD-95 antibody. The PSD fraction was prepared by the Triton X-100 
(T) method.  
As expected, PSD-95 is enriched in the PSD fraction only. Protein loading is 
20µg/lane. Lane 1, Brain Homogenate (BH); lane 2, Microsomes (Mc); lane 3, 
Synaptic Membrane (SM); lane 4, Post Synaptic Density (PSD), isolated by the Triton 
X-100 (T) method. Molecular weight standards are indicated. T, Triton X-100.  
 
BH Mc SM  
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PSD-95 95kDa 
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                    3.2.3 Classical and delta dystrophin are differently 
distributed in the forebrain 
 
                        Having established that the subcellular fractions were of comparable 
purity to that described in the literature (Beesley et al, 1987; Hill et al, 1988; Kim et 
al, 1992; Hunt et al, 1996), I then examined the subcellular distribution of delta 
dystrophin in the forebrain, and compared it to that of two crucial DPC components 
of the brain that are known to be enriched in the PSD: classical full-length dystrophin 
and β-dystrobrevin (Blake et al, 1999). Each forebrain subcellular fraction was 
loaded on an SDS gel for Coomassie Blue stain (figure 3.2.3.1) to ensure even 
loading of each subcellular fraction in every lane. After establishing even loading of 
forebrain subcellular fractions, the subcellular distribution of β-dystrobrevin, classical 
dystrophin and delta dystrophin was determined by immunoblotting a range of 
subcellular fractions, including SMs and PSDs prepared from rat forebrain. 
Immunoblots containing n-octyl glucopyranoside isolated PSDs were incubated with 
a panel of antibodies specific for β-dystrobrevin, classical dystrophin and delta 
dystrophin (figures 3.2.3.2, 3.2.3.3 & 3.2.3.4).   
 
               As expected, β-dystrobrevin was found to be enriched in the PSD 
fraction (figure 3.2.3.2) when compared with the LM, SM and BH fractions, as 
expected, in agreement with Blake et al, (1999). This result was reconfirmed using 
another set of freshly isolated subcellular fractions (data not shown). The enrichment 
of α-dystrobrevin 1 and 2 in the PSD fraction when compared to the LM, SM and BH 
fractions was also observed (figure 3.2.3.2), as expected (Blake et al, 1999). Higher 
molecular weight immunoreactive bands were present in all fractions (asterisks) 
except in myelin and mitochondria. Given that there are no known promoters in the 
dystrobrevin gene to account for these molecular weight bands, they could be non-
dystrobrevin proteins that cross-react with the antibody.  
 
               In order to determine the subcellular distribution of classical dystrophin 
in the forebrain, a duplicate blot was prepared and incubated with anti-classical 
dystrophin antibody. The antibody recognized four separate classical dystrophin 
isoforms of different molecular weights (figure 3.2.3.3) in the PSD fraction, all of 
which are known to be expressed in the brain: cDp427, cDp140, cDp116 and cDp71 
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(Pilgram et al, 2009). As expected, classical full-length dystrophin (cDp427) was 
found to be highly enriched in the PSD fraction, when compared with the LM, SM 
and BH fractions (figure 3.2.3.3). By contrast, the shorter classical dystrophin 
isoforms cDp140, cDp116 and cDp71 were only moderately enriched in the PSD, 
when compared to the LM, SM fractions (figure 3.2.3.3). The myelin and 
mitochondrial fractions lacked all classical dystrophin isoforms, except for much 
reduced levels of cDp71, when compared to BH, LM, SM and PSD fractions. The cell 
soluble fraction contained much reduced levels of cDp427, cDp140, cDp116 and 
cDp71 when compared to the PSD, SM, LM and BH lane. The cell soluble fraction 
should not contain classical dystrophin isoforms, as these have been shown to be 
tightly associated with the cytoskeletal structures, predominantly the PSD, therefore 
they are highly insoluble (Blake et al, 1999). One possible explanation may be that 
during the fractionation procedure, some of the dystrophin isoforms become released 
from the membrane into the homogenization medium. Thus, the presence of classical 
dystrophin isoforms in the cytosol may represent small cross-contamination. A 
similar scenario was observed by Blake et al (1999) in the cell soluble fraction. It is 
important to note that immunoblots in this thesis were optimized for full-length 
dystrophin and thus are overexposed for some of the lower bands such as Dp71. 
These lower bands have saturated the film and thus are not giving a linear response in 
terms of comparing enrichments. There were two additional shorter isoforms with a 
molecular weight inferior to 71kDa present in most fractions (asterisks). Given there 
are no known promoters for these molecular weight bands, the latter may represent 
degradation products. In conclusion, figure 3.2.3.3 reconfirms that cDp427 is highly 
enriched in the PSD fraction, as expected (Blake et al, 1999). 
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Figure 3.2.3.1: SDS PAGE separation of forebrain subcellular fractions, together 
with PSDs isolated by either the Triton X-100 detergent method or the n-octyl 
glucopyranoside method.  
Aliquots of subcellular fractions prepared from forebrain were separated on a 10% SDS 
PAGE gel. Proteins were visualised with Coomassie blue. Lanes 1-9 show samples 
from duplicate experiments using subcellular fractions isolated using the n-octyl 
glucopyranoside method. Lanes 10 and 11 show PSDs isolated by the n-octyl 
glucopyranoside (N) method. Lane 12 shows the PSD fraction isolated by the Triton X-
100 (T) method. Protein loading is 20µg/lane. Lanes 1-2, Brain Homogenate; lanes 3-4, 
Myelin; lanes 5-6, Mitochondria; lanes 7-8, Light Membrane; lane 9, Synaptic 
Membrane; lanes 10-11, Post Synaptic Density (PSD), isolated by the n-octyl 
glucopyranoside (N) method; lane 12, Post Synaptic Density (PSD), isolated by the 
Triton X-100 (T) method.  Molecular weight standards are indicated. N, n-octyl 
glucopyranoside. T, Triton X-100. M, Molecular Weight Marker. 
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Figure 3.2.3.2: Western blot of forebrain subcellular fractions immunodeveloped 
with anti-β-dystrobrevin antibody.   
As expected α1,α2, and particularly β-dystrobrevin are enriched in the PSD lane. 
Protein loading is 20µg/lane. Lane 1, Brain Homogenate (BH); lane 2, Cell soluble 
(Cs); lane 3, Myelin (My); lane 4, Mitochondria (Mt); lane 5, Microsomes (Mc); lane 6, 
Light Membrane (LM); Lane 7, Synaptic Membrane (SM); lane 8, Post-Synaptic 
Density (PSD), isolated by the n-octyl glucopyranoside (N) method. Molecular weight 
standards are indicated.  
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Figure 3.2.3.3: Western blot of forebrain subcellular fractions immunodeveloped 
with anti-classical dystrophin antibody.  
Classical full-length dystrophin (cDp427) is enriched in the PSD fraction. cDp140, 
cDp116 and cDp71 are moderately enriched in the PSD fraction. Myelin and 
mitochondria lack all isoforms except for much reduced levels of cDp71, when 
compared to the BH and PSD fraction. The cell soluble fraction contains much reduced 
levels of all classical dystrophin isoforms, when compared to the BH and PSD fraction. 
Protein loading is 20µg/lane. Lane 1, Brain Homogenate (BH); lane 2, Cell Soluble 
(Cs); lane 3, Myelin (My); lane 4, Mitochondria (Mt); lane 5, Microsomes (Mc); lane 6, 
Light Membrane (LM); lane 7, Synaptic Membrane (SM); lane 8, Post Synaptic 
Density (PSD), isolated by the n-octyl glucopyranoside method (N). Molecular weight 
standards are indicated.  
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            To determine whether delta dystrophin was enriched in the PSD, a 
duplicate blot was incubated with anti-delta dystrophin antibody (figure 3.2.3.4). In 
contrast to classical full-length dystrophin, delta full-length dystrophin was highly 
enriched in the microsomal fraction and only moderately enriched in the PSD fraction, 
when compared with the LM, SM and BH fractions. dDp140 was moderately enriched 
in the microsomal and PSD fraction, when compared to the membrane fractions (LM 
and SM), whereas dDp116 and dDp71 were found in most fractions, with dDp71 being 
generally more abundant than dDp116. Contrary to classical dystrophin in figure 
3.2.3.3, the cell soluble fraction of figure 3.2.3.4 contains a moderate amount of 
dDp427, when compared to the BH, LM, SM and PSD fractions, followed by negligible 
amounts of dDp140, dDp116 and dDp71, when compared to the BH, LM, SM and PSD 
fractions. In addition to the four well-established delta dystrophin isoforms just 
described, the anti-delta dystrophin antibody recognized a number of additional bands 
(asterisks). A band in the PSD fraction that is slightly higher than dDp427 could 
represent an alternatively spliced isoform of dDp427. However, it remains to be tested 
whether such alternative delta dystrophin transcript exists or not. Given that there are 
no known promoters for the production of the remaining bands (asterisks) in the various 
subcellular fractions, they either represent degradation products of dystrophin proteins, 
or simply be immunoreactive bands of unrelated protein artifacts observed on the blot. 
Altogether, figures 3.2.3.3 and 3.2.3.4 suggest that delta full-length dystrophin 
(dDp427) has a different subcellular distribution to that of classical full-length 
dystrophin (cDp427) within the forebrain. 
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Figure 3.2.3.4: Western blot of forebrain subcellular fractions immunodeveloped 
with anti-delta dystrophin antibody.  
Delta full-length dystrophin (dDp427) is highly enriched in the microsomes and only 
moderately enriched in the PSD fraction. dDp140 is moderately enriched in the 
microsomal and PSD fraction, whereas dDp116 and dDp71 are found in most fractions, 
with dDp71 being generally more abundant than dDp116. Protein loading is 20µg/lane. 
Lane 1, Brain Homogenate (BH); lane 2, Cell Soluble (Cs); lane 3, Myelin (My); lane 
4, Mitochondria (Mt); lane 5, Microsomes (Mc); lane 6, Light Membrane (LM); lane 7, 
Synaptic Membrane (SM); lane 8, Post Synaptic Density (PSD), isolated by the n-octyl 
glucopyranoside (N) method. Molecular weight standards are indicated.  
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                    3.2.4 Classical and delta dystrophin are differently 
distributed in the cerebellum 
 
                        The subcellular distribution of a protein in the forebrain may not always 
reflect the subcellular distribution found in the cerebellum. For example, PSD-95 is 
highly enriched in the PSD of the forebrain (Hunt et al, 1996, Kim et al, 1992), 
whereas it is less concentrated in the PSD fraction of the cerebellum. On the other hand, 
the cerebellum exhibits intense concentration of PSD-95 immunoreactivity in axon 
terminals, which is not observed in forebrain neurons (Hunt et al, 1996). Therefore, in 
order to establish whether delta dystrophin may replace classical dystrophin in the 
formation of novel delta DPC-like complexes at the PSD of the cerebellum, I 
determined and compared the subcellular distribution of classical dystrophin and delta 
dystrophin in the cerebellum, and also compared it to the forebrain.    
 
                        I compared side by side the subcellular localization of classical 
dystrophin in the forebrain with the cerebellum because the concentration of this 
protein in the two brain regions has never been compared, although its localization at 
PSD structures of the forebrain and cerebellum has long been established (Kim et al, 
1992). This is important as classical dystrophin is known to selectively localize at 
GABAergic synapses in the forebrain (Brunig et al, 2002), and given that 
approximately 50% of the cerebellar neuronal phenotypes are GABAergic interneurons 
(Leto et al, 2008), whilst only 20% of forebrain neurons are inhibitory (Xu et al, 2010), 
I decided to determine whether classical dystrophin was more enriched in the 
cerebellum PSDs when compared to forebrain PSDs, as this would allude to the 
possibility that in the cerebellum also, classical dystrophin may restrict to PSDs of 
inhibitory synapses, similar to what has been observed for the forebrain.  
 
                        I immunoblotted a range of subcellular fractions prepared from rat 
cerebellum and compared these with forebrain subcellular fractions. The immunoblot 
was incubated with an antibody specific for classical dystrophin (figure 3.2.4.1). In 
figure 3.2.4.1, classical full-length dystrophin was found highly enriched in the PSD 
fraction of both brain regions, with cDp427 appearing more concentrated in the 
cerebellar PSDs when compared to forebrain PSDs. cDp140 was more concentrated in 
the cerebellar PSDs when compared to the forebrain PSDs, and was more concentrated 
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in the SM and cell soluble fractions of the cerebellum, when compared to the respective 
fractions of the forebrain (figure 3.2.4.1). Generally, there was more cDp140 in 
cerebellum than in forebrain throughout all the subcellular fractions. cDp116 and 
cDp71 were moderately enriched in the PSD fraction of the forebrain and cerebellum, 
when compared to the LM and SM fractions of the forebrain and cerebellum 
respectively (figure 3.2.4.1). Overall, all classical dystrophin isoforms were more 
concentrated in the cerebellum when compared to the forebrain, and they all enriched in 
the PSD fraction of either brain region. What is more, PSD enrichment in the 
cerebellum was greater than in the forebrain. It is important to note, however, that 
immunoblots were optimized for full-length dystrophin and thus are overexposed for 
some of the lower bands such as Dp71. These bands, unlike cDp427, are saturated and 
thus are not giving a linear response in terms of comparing enrichments. There were 
two additional shorter isoforms (asterisks) with a molecular weight inferior to 71kDa. 
Given there are no known promoters for these molecular weight bands, they may either 
represent degradation products, or non-classical dystrophin proteins that cross-react 
with the antibody. 
 
            To test whether delta dystrophin may replace classical dystrophin and 
form novel delta DPC-like complexes in PSD structures of the cerebellum, duplicate 
immunoblots were incubated with anti-delta dystrophin antibody (figure 3.2.4.2) such 
that these could also be compared with the subcellular distribution of classical 
dystrophin. Results showed low expression of dDp427 throughout the cerebellum, as 
opposed to the higher level of expression of dDp427 in the forebrain, although dDp427 
was found to be enriched in the cerebellar PSD and microsomal fractions when 
compared to the cerebellar LM fraction. In contrast, forebrain dDp427 was highly 
enriched in the microsomal fraction of the forebrain and moderately enriched in the 
PSD of the forebrain, when compared to forebrain LM and SM fractions, in agreement 
with figure 3.2.3.4. dDp427 was more concentrated in the cell soluble fraction of 
forebrain when compared to the cell soluble fraction in the cerebellum. dDp140 and 
dDp116 were weakly distributed throughout forebrain and cerebellar fractions, and 
highly enriched only in the PSD fraction of the forebrain. dDp71 was found in most 
fractions of the forebrain and cerebellum (figure 3.2.4.2), but much depleted in the cell 
soluble and myelin fractions. The presence of delta dystrophin in the cell soluble 
fraction was reproduced in every experiment (figures 3.2.3.4 and 3.2.4.2), contrasting 
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with the knowledge that dystrophin is an insoluble protein (Blake et al, 1999). As will 
be shown in chapter 4 (figure 3.2.4.1), delta dystrophin specifically co-localizes with 
microtubules and therefore it may be that dissociation of microtubules during the 
fractionation procedure has resulted in solubilisation of a portion of the delta 
dystrophins into the cell soluble fraction. In forebrain and cerebellum there exist 
additional bands (asterisks) below the dDp427 point. These bands could either 
represent degradation products or they could also represent non-delta dystrophin 
proteins that cross-react with the antibody. Altogether, these results (figure 3.2.4.1 and 
3.2.4.2) show two striking novel findings: firstly that the subcellular distribution of 
classical full-length and delta full-length dystrophins is markedly different; secondly, 
the regional distribution of these two molecules in brain is markedly different. 
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Figure 3.2.4.1: Western blot of forebrain and cerebellar subcellular fractions 
immunodeveloped with anti-classical dystrophin antibody.  
cDp427 is highly enriched in the PSD fraction of the forebrain. cDp140, cDp116 and 
cDp71 are moderately enriched in forebrain PSDs. The same enrichment pattern is 
observed in the PSD of the cerebellum, with the latter exhibiting more classical 
dystrophin than the forebrain. The fractions are run in pairs with the left and right hand 
samples being forebrain and corresponding cerebellar fractions respectively. Protein 
loading is 20µg/lane. Lanes 1-2, Brain Homogenate (BH); lanes 3-4, Cell Soluble (Cs); 
lanes 5-6, Myelin (My); lanes 7-8, Mitochondria (Mt); lanes 9-10, Microsomes (Mc); 
lanes 11-12, Light Membrane (LM); lanes 13-14, Synaptic Membrane (SM); lanes 15-
16, Post Synaptic Density (PSD), isolated by the n-octyl glucopyranoside (N) method. 
Molecular weight standards are indicated.  F, forebrain. C, cerebellum. 
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Figure 3.2.4.2: Western blot of forebrain and cerebellar subcellular fractions 
immunodeveloped with anti-delta dystrophin antibody.  
Results show low expression of dDp427 throughout the cerebellum, as opposed to the 
higher level of expression of dDp427 in the forebrain. dDp427 is highly enriched in the 
microsomal fraction of the forebrain, exhibiting only moderate enrichment in the PSD 
fraction of the forebrain. In contrast, cerebellar dDp427 is generally weakly expressed 
when compared to the level of expression throughout the forebrain, although dDp427 is 
enriched in cerebellar microsomes and PSD. dDp140 and dDp116 are weakly 
distributed throughout forebrain and cerebellar fractions and are highly enriched only in 
the PSD fraction of the forebrain. dDp71 is ubiquitously expressed. The fractions are 
run in pairs with the left and right hand samples being forebrain and corresponding 
cerebellar fractions respectively. Protein loading is 20µg/lane. Lanes 1-2, Brain 
Homogenate (BH); lanes 3-4, Cell Soluble (Cs); lanes 5-6, Myelin (My); lanes 7-8, 
Mitochondria (Mt); lanes 9-10, Microsomes (Mc); lanes 11-12, Light Membrane (LM); 
lanes 13-14, Synaptic Membrane (SM); lanes 15-16, Post Synaptic Density (PSD), 
isolated by the n-octyl glucopyranoside (N) method. Molecular weight standards are 
indicated.  F, forebrain. C, cerebellum. 
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                        3.2.5 Dystrophin is an integral PSD protein of the 
forebrain  
 
 Determining whether a protein is part of the PSD apparatus via a 
biochemical approach may sometimes yield an artefactual result compared to the in 
vivo scenario in the cell. For example, a number of biochemical studies have indicated 
that Bassoon is a PSD component (Dieck et al, 1998; Li et al, 2004). The true 
localization of Bassoon however is presynaptic, as revealed by double-fluorescence 
immunocytochemistry between Bassoon and various presynaptic markers (Dieck et al, 
1998). Dieck et al (1998) then went on to assess the nature of Bassoon during the PSD 
extraction studies with two detergents, Triton X-100 and n-octyl glucopyranoside, and 
noted that neither detergent was able to solubilise significant amounts of Bassoon, but 
noticed that Triton X-100 was able to solubilise larger amounts of Bassoon compared to 
n-octyl glucopyranoside. I have also demonstrated in figure 3.2.2.3 that the Triton X-
100 protocol (Carlin et al, 1980) may remove loosely bound PSD components that are 
not removed by the n-octyl glucopyranoside phase partitioning method (Gurd et al, 
1982). The data in figure 3.2.2.3 shows that np65 is enriched in PSDs prepared by the 
phase partitioning method, whereas it is present only in low amounts in PSDs prepared 
using the Triton X-100 protocol (figure 3.2.2.3). This is consistent with previously 
published data (Smalla et al, 2000), which suggests that np65 can rapidly translocate 
out of the PSD and thus may be only loosely bound to the PSD. Thus, the following 
section established whether dystrophin is loosely bound to the PSD or whether it is an 
integral protein of the PSD of the forebrain (figure 3.2.5.1).  
 
                        The subcellular distribution of dDp427 was determined by 
immunoblotting (figure 3.2.5.1) rat forebrain subcellular fractions, including PSDs 
prepared using the Triton X-100 and n-octyl glucopyranoside phase partitioning 
methods. The immunoblot was incubated with anti-delta dystrophin antibody. Delta 
full-length dystrophin was enriched in microsomes, in PSDs isolated by the Triton X-
100 protocol, and in PSDs isolated by the n-octyl glucopyranoside method, when 
compared with the SM fraction (figure 3.2.5.1). In fact, the enrichment of dDp427 in 
PSDs isolated by the Triton X-100 method was similar to the enrichment of dDp427 in 
PSDs isolated by the n-octyl glucopyranoside method. In the microsomal and n-octyl 
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glucopyranoside PSD fractions only, dDp427 was detected as a doublet band (asterisk). 
The explanation for this is not clear. dDp140 and dDp116 were moderately enriched in 
PSDs isolated by the Triton X-100 method and in PSDs isolated by the n-octyl 
glucopyranoside method when compared with the SM fraction. dDp71 was found in all 
fractions tested. As a control, a duplicate blot was incubated with anti-classical 
dystrophin antibody (figure 3.2.5.2). As expected, cDp427 was highly enriched in PSD 
fractions isolated by either detergent method, when compared with the BH and SM 
fractions (figure 3.2.5.2). By contrast, only the n-octyl glucopyranoside PSD fraction 
contained moderate enrichment of cDp140 and cDp116 when compared to BH and SM 
fractions, whereas the Triton X-100 PSD fraction showed moderate enrichment of 
cDp116, but not cDp140. Dp71 was ubiquitously expressed. In conclusion, the type of 
detergent used to prepare the PSD fraction did not affect the enrichment patterns of 
classical and delta full-length proteins, as both were found equally enriched in the PSD 
of the forebrain isolated by either detergent method. The results suggest that both 
classical and delta full-length dystrophin are integral rather than loosely bound PSD 
proteins. Although this study suggests that classical and delta full-length dystrophin 
proteins appear to be integral PSD proteins, delta dystrophin is consistently highly 
enriched in microsomes and only moderately enriched in the PSD fractions (figure 
3.2.5.1), hence the subcellular distribution of classical full-length and delta full-length 
dystrophins is markedly different and according to figures 3.2.4.1 and 3.2.4.2, the 
regional distribution of these two molecules is markedly different. The precise 
subcellular distribution of classical and delta dystrophin was further investigated 
immunocytochemically in chapter 4.   
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Figure 3.2.5.1: Western blot of forebrain subcellular fractions including PSDs 
prepared using the Triton X-100 or n-octyl glucopyranoside method and 
immunodeveloped with anti-delta dystrophin antibody. 
Delta full-length dystrophin is more highly enriched in microsomes, compared to PSDs 
obtained by either the n-octyl glucopyranoside method or the Triton X-100 method. 
The similar level of enrichment in the PSD fractions prepared by both methods suggests 
that dDp427 is an integral PSD protein. The microsomal and n-octyl glucopyranoside 
PSD fraction show dDp427 as a doublet band (asterisk). dDp140 and dDp116 are 
moderately enriched in the PSDs obtained by either detergent method, and are found in 
lower concentrations in the remaining fractions tested. dDp71 is ubiquitously 
expressed. Protein loading is 20µg/lane. Lane 1, Microsomes (Mc); lane 2, Synaptic 
Membrane (SM); lane 3, Post Synaptic Density (PSD), isolated by the Triton X-100 (T) 
method; lane 4, Post Synaptic Density (PSD), isolated by the n-octyl glucopyranoside 
(N) method. Molecular weight standards are indicated. T, Triton X-100. N, n-octyl 
glucopyranoside. 
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Figure 3.2.5.2: Western blot of forebrain subcellular fractions including PSDs 
prepared using the Triton X-100 or n-octyl glucopyranoside method and 
immunodeveloped with anti-classical dystrophin antibody.  
Classical full-length dystrophin (cDp427) is enriched compared to SM in PSDs 
obtained by the n-octyl glucopyranoside method and the Triton X-100 method. cDp140 
and cDp116 appear to be moderately enriched in PSDs obtained by the n-octyl 
glucopyranoside method, when compared to the SM and BH fractions, whereas the 
Triton X-100 PSD fraction shows moderate enrichment of cDp116, but not cDp140. 
cDp71 is ubiquitously expressed. Protein loading is 20µg/lane. Lane 1, Brain 
Homogente (BH); lane 2, Synaptic Membrane (SM); lane 3, Post Synaptic Density 
(PSD), isolated by the Triton X-100 (T) method; lane 4, Post Synaptic Density (PSD), 
isolated by the n-octyl glucopyranoside (N) method. Molecular weight standards are 
indicated. T, Triton X-100. N, n-octyl glucopyranoside.  
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  3.3 Discussion: 
 
 
          3.3.1 Classical and delta dystrophin exhibit different 
regional and subcellular distribution in forebrain and cerebellum, 
hence they are likely to form different DPC complexes   
 
 
            A BLAST database search on classical exon 78 and delta exon 78 
shows that other than classical and delta dystrophin isoforms, no other proteins 
contain these sequences. The functional significance of these exons remains unknown 
(Table 3.2.1), whereas the remaining domains of either classical and delta dystrophin 
are identical, and classical dystrophin is known to utilize these domains to form the 
DPC complex at PSDs of neurons (Culligan et al, 2002). I therefore compared the 
subcellular distribution of classical and delta dystrophin in forebrain and cerebellum, 
to establish whether their differences in exon 78 may or may not affect the subcellular 
distribution of delta dystrophin, when compared to classical dystrophin. This in turn 
was important for determining whether delta dystrophin was also a PSD protein and 
therefore able to replace classical dystrophin in the formation of novel delta DPC-like 
complexes in PSDs of forebrain and cerebellum, or, whether the substitution of exon 
78 results in the production of different protein complexes with different subcellular 
localization and with different properties. 
 
 The data in this chapter show clear differences in the pattern of 
subcellular distribution of classical and delta full-length dystrophin proteins, the 
former being most highly enriched in PSD structures, the latter in the microsomal 
fractions. Furthermore, there is a striking difference in the level of expression of the 
two isoforms between the two brain regions, with delta full-length dystrophin being 
expressed at low levels in the cerebellum when compared to the forebrain, whilst 
classical full-length dystrophin is more concentrated in cerebellar fractions when 
compared to forebrain. These studies show that although the two proteins are highly 
homologous, they are likely to form protein complexes with different subcellular 
localization and with different properties and function. Given that classical and delta 
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exon 78 are the only sequences distinguishing classical dystrophin from delta 
dystrophin, they are likely to affect the subcellular distribution of classical and delta 
dystrophin within the forebrain and cerebellum. The details are described below.  
 
            I determined and compared the subcellular distribution of classical 
dystrophin in both forebrain and cerebellum subcellular fractions. Classical full-
length dystrophin is highly enriched in the PSD fractions of the forebrain and 
cerebellum (figure 3.2.4.1), in agreement with publications (Kim et al, 1992; Culligan 
et al, 2002) and exhibits a subcellular distribution in the forebrain that is identical to 
that in the cerebellum (figure 3.2.4.1). Classical full-length dystrophin is strongly 
expressed in both brain regions, what is more, classical full-length dystrophin is more 
concentrated in cerebellar PSD, when compared to the corresponding forebrain PSD 
(figure 3.2.4.1). As classical dystrophin and DPC components selectively localize at 
GABAergic synapses in forebrain neurons (Brunig et al, 2002) and given that only 
20% of the forebrain comprises of GABAergic neurons (Xu et al, 2010) whilst 50% 
of the cerebellum is composed of GABAergic neurons (Leto et al, 2008), the higher 
cDp427 band intensity in cerebellar compared to forebrain PSDs suggests that in the 
cerebellum also, cDp427 may be restricted to PSDs of inhibitory synapses. All in all, 
these results demonstrate that classical dystrophin is expressed in both brain regions, 
it is highly enriched in the PSD fraction of forebrain and cerebellum, and is likely to 
localize at PSDs of inhibitory synapses in the cerebellum, as well as the forebrain. 
What is more, in the cerebellum, classical full-length dystrophin is reported to form 
DPC complexes within the PSD (Kim et al, 1992). Therefore I suggest that in analogy 
to the forebrain, cerebellum DPC complexes containing cDp427 may also localize at 
GABAergic synapses. Immunocytochemical studies are required to confirm the 
biochemical data. 
 
            When the subcellular distribution of delta full-length dystrophin in 
forebrain and cerebellum subcellular fractions was examined, it revealed two very 
different scenarios, and these are again very different to those described for classical 
full-length dystrophin. In the forebrain, delta full-length dystrophin is highly enriched 
in the microsomal fraction whilst it is only moderately enriched in the PSD (figure 
3.2.3.4). Whereas the expression of delta full-length dystrophin in the cerebellum is 
low when compared to the forebrain, although full-length delta dystrophin is enriched 
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in microsome and PSD fractions prepared from cerebellum. It is important to note 
that the cerebellum, although it comprises only 10% of the brain volume, it contains 
similar numbers of neurons when compared to the forebrain (Leto et al, 2008). 
Therefore, the low expression of delta full-length dystrophin throughout the 
subcellular fractions in the cerebellum is not due to a lower number of neurons in the 
cerebellum when compared to the forebrain, rather, it is probably due to a low level 
of delta dystrophin expression therein. Given that 20% of the forebrain is comprised 
of GABAergic neurons (Xu et al, 2010) whilst 50% of the cerebellum is comprised of 
GABAergic neurons (Leto et la 2008), the lower dDp427 band intensity in cerebellar 
PSDs when compared to forebrain PSDs suggests that dDp427 is not expressed 
specifically in GABAergic synapses. In conclusion, alternative splicing of the DMD 
gene product (classical and delta full-length dystrophin) is closely regulated in the 
two brain regions, with delta full-length dystrophin being expressed in forebrain as 
well as the cerebellum, albeit in lower amounts. What is more, these results also 
suggest that in the forebrain and in the cerebellum, delta full-length dystrophin may 
form novel delta DPC complexes outside the PSD (as suggested by the microsomal 
enrichment), as well as in PSD structures (as suggested by the PSD enrichment) of 
non-GABAergic synapses. This hypothesis is further verified in Chapter 4. 
 
            Based on the different regional and subcellular distributions exhibited 
by classical and delta full-length dystrophin isoforms, it is suggested that the 
molecular composition and function of delta full-length dystrophin-containing 
complexes that form within the forebrain and cerebellum, is likely to markedly differ 
from classical full-length dystrophin-containing complexes. Firstly, this is because 
my studies suggest delta full-length dystrophin may localize at PSDs of non-
GABAergic synapses, whilst classical full-length dystrophin and its associated DPC 
proteins exclusively localize at PSDs of inhibitory synapses (Brunig et al, 2002). In 
turn this suggests that delta full-length dystrophin may bind to different protein 
partners and hence, has a different function and molecular composition when 
compared to classical dystrophin-containing DPC complexes. Secondly, the higher 
enrichment of delta full-length dystrophin in the microsomal fraction when compared 
to the moderate enrichment in the PSD fraction (figures 3.2.3.4 & 3.2.4.2) suggests 
delta full-length dystrophin also forms novel DPC complexes outside the PSD, and as 
a consequence, delta full-length dystrophin-containing complexes outside the PSD 
 133 
may exhibit a different molecular composition compared to classical full-length 
dystrophin-containing proteins that exclusively localize at PSDs of inhibitory 
synapses. Thirdly, I show that β-dystrobrevin (figure 3.2.3.2), a component of 
classical full-length dystrophin-containing DPC complexes (Brunig et al, 2002; 
Culligan et al, 2002) also exhibits a different subcellular distribution to that exhibited 
by delta full-length dystrophin (figure 3.2.3.4). Therefore, all these studies 
demonstrate that the molecular composition of dDp427-containing DPC complexes is 
likely to be markedly different to the molecular composition of cDp427-containing 
DPC complexes, despite the fact that both classical and delta full-length dystrophins 
contain the same protein binding sequences. Therefore, regardless of the highly 
similar domain structure, classical and delta full-length dystrophin isoforms are likely 
to exert different functions in the different types of neuronal subcellular 
compartments in which they are found. These will include GABAergic and possibly 
non-GABAergic synapses, respectively. What is more, biochemical studies suggest 
delta full-length dystrophin appears to be more widely distributed in the brain when 
compared to classical-full-length dystrophin. This has been investigated further in the 
immunocytochemical studies described in chapter 4.  
 
            Classical and delta dystrophin both originate from the same gene, thus 
the low expression of delta full-length dystrophin in the cerebellum when compared 
to forebrain, as opposed to the higher expression of the classical full-length 
dystrophin in the cerebellum when compared to forebrain, is likely to occur by 
reducing alternative splicing mechanisms on the mRNA product derived from the 
DMD gene in the cerebellum, as this would ensure the continued production of 
classical dystrophin in the cerebellum whilst reducing the production of delta 
dystrophin therein. The differences in subcellular distributions exhibited by the 
classical and delta dystrophin isoforms, must be due to Cexon78 and Dexon78, as 
these are the only sequences that distinguish classical dystrophin from delta 
dystrophin respectively. In other words, a plausible hypothesis is that classical exon 
78 may participate in directing classical full-length dystrophin exclusively to PSD 
structures, whereas delta exon 78 may participate in directing delta full-length protein 
to other PSD types and/or in microsomes. Thus, classical and delta exon 78 may 
encode a trafficking signal that participates in directing the proteins to different 
subcellular compartments. In fact, Sakamoto et al (2008) found that the binding site 
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to the PSD is located at the C-terminus end between the WW domain and the C-
terminus of classical dystrophin, which is where classical and delta exon 78 are found 
(chapter 1, figure 1.1.2.2). What is more, Sakamoto et al, (2008) show that when this 
region is removed, the classical dystrophin isoforms are unable to associate with the 
PSD, instead, they localize in the cytoplasm, neurites and axons. Thus, Cexon78 and 
Dexon78 are clearly implicated in the trafficking of the classical and delta dystrophin 
proteins to or away from the PSD. In chapter 4 I investigate whether Cexon78 and 
Dexon78 alone, may encode different trafficking signals.  
 
            I have demonstrated in figure 3.2.2.3 that the Triton X-100 protocol is 
able to remove part of the loosely bound PSD components, as evidenced by np65 
levels, whereas the n-octyl glucopyranoside protocol cannot. Thus I was able to 
determine whether delta full-length dystrophin is loosely bound to the PSD, or 
whether it is an integral PSD protein of the forebrain. I demonstrate that delta full-
length dystrophin is enriched in the forebrain PSD fraction obtained by the Triton X-
100 protocol, and was also consistently enriched in the forebrain PSD fraction 
obtained by the n-octyl glucopyranoside method. I also demonstrate that classical 
full-length dystrophin is consistently enriched in forebrain PSDs isolated by either 
detergent method. Given that neither detergent affects the enrichment of the full-
length dystrophin isoforms in the PSD fractions, I suggest classical full-length 
dystrophin (Culligan et al, 2002) and delta full-length dystrophin are both integral 
proteins of the PSD apparatus of the forebrain. The negligible amount of classical 
full-length dystrophin in the cell soluble fraction of the forebrain (figure 3.2.3.3) is in 
agreement with this result. However, the relative enrichment of delta full-length 
dystrophin in the cell soluble fraction when compared to the PSD fraction (figure 
3.2.3.4) does not support the suggestion that delta full-length dystrophin may be an 
integral PSD protein. What is more, dDp427 exhibits highest enrichment in the 
forebrain microsomal fraction, whilst it is only moderately enriched in the forebrain 
PSD fraction. In contrast, cDp427 exhibits highest enrichment in the PSD fraction. 
Thus, the results clearly suggest that classical full-length dystrophin is an integral 
PSD component, whereas this may not be the case for delta full-length dystrophin. In 
chapter 4 I have used intact neurons in order to determine the exact localization of 
delta dystrophin within the cell, and determined whether or not dDp427 is an integral 
protein of the PSD.  
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            Mental impairment occurs in one third of DMD patients and is said to 
be due to a mutation of the DMD gene (Barbujani et al, 1990; Mehler et al, 2000; 
Blake et al, 2002; Anderson et al, 2002; Nowak et al, 2004) (chapter 1). Studies to 
date suggest that the CNS pathology in DMD patients is due to abnormal organization 
of the classical full-length dystrophin protein at selectively localized GABAergic 
inhibitory synapses, which in turn lead to faulty transmission with impaired cognitive 
impairments in young boys (Albrecht et al, 2002). The fact that delta full-length 
dystrophin is also a DMD derived protein and it is also expressed in neurons of the 
forebrain and cerebellum (figure 3.2.4.2), suggests a potentially alternative route by 
which a mutated DMD gene may contribute to the mild mental retardation observed 
in DMD boys. What is more, given that classical dystrophin-containing DPC 
complexes exclusively localize at GABAergic synapses (Brunig et al, 2002), whilst 
according to this chapter, delta dystrophin-containing DPC complexes are likely to 
localize more widely, and possibly including at non-GABAergic synapses, the CNS 
pathology may not only originate from GABAergic synapses, but non-GABAergic 
synapses and other parts of the neurone as well. The formation of novel delta 
dystrophin containing DPC complexes outside the PSD and within non-GABAergic 
synapses suggests that when the DMD gene is mutated it would alter the organization 
of delta dystrophin and associated proteins at these sites which, together with the 
mutated classical dystrophin isoform at GABAergic synapses, would altogether 
contribute to the CNS pathologies of DMD patients.  
 
            The shorter classical dystrophin isoforms identified, which include 
cDp140, cDp116 and cDp71, are only moderately enriched in the PSD of the 
forebrain (figure 3.2.3.3), and according to various publications, they are not 
considered PSD proteins, but have been shown to locate in perivascular astrocytes 
(Lidov et al, 1990, Lidov et al, 1995, Lidov et al, 1996), peripheral nerve (Lidov et 
al, 1995) and glial cells (Mehler et al, 2000), respectively. PSDs are known to absorb 
proteins of non-neuronal origin, examples of non-neuronal proteins absorbed in PSDs 
include α-dystrobrevin (Blake et al, 1999), and glial fibrillary acidic protein (Matus 
et al, 1980), which are clearly enriched in the PSD fraction of immunoblots, but in 
vivo they localize elsewhere. This may also be the case for cDp140, cDp116 and 
cDp71, as all three are known to locate outside neurons. However, it is also plausible 
that these classical dystrophin isoforms are genuine PSD components. Therefore, a 
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more detailed study is required in order to establish whether cDp140, cDp116 and 
cDp71 are part of another cellular compartment or cell. This is in part because the 
overexposure of the western blot caused the lower delta and classical dystrophin 
bands to be saturated and therefore not give a linear response in terms of comparing 
enrichments. 
 
            In conclusion, the expression of classical and delta dystrophin exhibit 
different regional and subcellular distribution in forebrain and cerebellum.  What is 
more, classical full-length dystrophin exhibits highest enrichment in PSDs of the 
cerebellum compared to PSDs of the forebrain, and given the abundance of 
GABAergic synapses available in the cerebellum (Leto et al, 2008), is consistent with 
classical full-length dystrophin localizing at the PSD of inhibitory synapses. For delta 
full-length dystrophin, the situation is totally different, as dDp427 shows much lower 
expression in cerebellum compared to forebrain PSDs, suggesting it may be 
expressed by non-GABAergic synapses. Immunocytochemical studies (see chapter 4) 
are necessary to confirm this. Given that dDp427 appears to localize in non-
GABAergic synapses (figure 3.2.4.2), whilst cDp427 and associated DPC 
components exclusively localize at GABAergic synapses (Brunig et al, 2002), it 
suggests that dDp427 forms novel DPC complexes plausibly at non-GABAergic 
synapses, but also more widely within neurons (see below). These complexes may 
well have a different molecular composition and function when compared to classical 
dystrophin-containing DPC complexes. Contrary to classical full-length dystrophin, I 
demonstrate that delta full-length dystrophin distribution in the forebrain is not only 
enriched in the PSD fraction, but exhibits highest enrichment in the microsomal 
fraction, suggesting delta full-length dystrophin is more widely distributed when 
compared to classical full-length dystrophin. Thus, delta full-length dystrophin may 
form complexes of different compositions outside the PSD, as well as in PSD 
structures, and indeed may have different functional roles in the CNS. In conclusion, I 
suggest that delta full-length dystrophin may not be able to replace classical 
dystrophin in the formation of novel delta DPC-like complexes at forebrain and 
cerebellum PSDs of inhibitory synapses, instead, it is likely to form different protein 
complexes with a different molecular composition, localization and function(s), when 
compared to classical full-length dystrophin-containing DPC complexes. Obviously it 
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would be expected that some components of classical and delta DPC complexes 
would be common to both. 
  
            The next chapter utilizes cortical neuronal cultures in order to 
investigate the subcellular distribution of delta dystrophin in relation to classical 
dystrophin and other well-established DPC components, in order to establish its 
function and precise localization in the cell. 
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                              Chapter 4:  
 
          
             4.0 Delta dystrophin does not replace classical dystrophin 
at GABAergic synapses to form novel delta dystrophin-containing 
DPC complexes. 
 
 
                              4.1 Introduction 
 
            The biochemical studies carried out in chapter 3 show classical and delta 
full-length dystrophin exhibit distinct patterns of localization. This is because classical 
full-length dystrophin is exclusively enriched in the PSD fraction (Chapter 3, figure 
3.2.3.3), whereas delta dystrophin is found to be more highly enriched in microsomes 
with only mild enrichment in the PSD fraction (Chapter 3, figure 3.2.3.4). It is this 
difference in subcellular localization coupled with the fact that they (classical and delta) 
both have the same protein binding motifs that suggest they form distinct sets of DPC 
complexes with different patterns of distribution. The difference in regional localization 
exhibited by classical and delta dystrophin in cerebellum versus forebrain (Chapter 3, 
figure 3.2.4.1 and 3.2.4.2) also supports this. In this chapter I therefore established 
immunocytochemically the cellular and subcellular localization of delta dystrophin and 
compared it with classical dystrophin and other DPC components that are known to 
localize at PSDs of GABAergic synapses. These studies were carried out to determine 
whether delta dystrophin may replace classical dystrophin in forming DPC complexes 
at PSDs of GABAergic synapses, or whether delta dystrophin indeed forms distinct sets 
of DPCs with different patterns of distribution, or both.  
 
            I used cortical neurons for the in vivo studies for two reasons. Firstly, 
various reports on cortical neurons of DMD brains have shown that these neurons 
exhibit disordered architecture, altered neuronal migration, abnormal neuronal 
orientation with attenuated terminal dendritic arbors (Mehler et al, 2000) and decreased 
cortical excitation. Hence cortical neurons are implicated in DMD brain disorders. 
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Secondly, the biochemical studies presented in chapter 3 revealed that delta dystrophin 
is more highly expressed in the forebrain, when compared to the cerebellum, hence the 
focus on cortical neurons. To confirm whether delta dystrophin is a PSD protein and 
whether it may replace classical dystrophin to form novel delta DPC complexes at the 
PSD of cortical inhibitory synapses, mature cortical neuronal cultures were used to co-
label delta dystrophin with a number of synaptic markers including GAD65, GABAAR, 
PSD-95 and NMDA receptors. This allowed me to determine whether delta dystrophin 
is synaptic and precisely which type of synapse it is found in, because molecularly 
specialized clusters of GAD65 and GABAAR are indicative of GABAergic terminals 
(Rao et al, 1998; Brunig et al, 2002), whereas NMDA receptors and PSD-95 are 
indicative of glutamatergic terminals (Craig et al, 1994; Hunt et al, 1996; Rao et al, 
1998). Furthermore, I also co-labelled β-dystroglycan, the crucial core protein of the 
DPC complex at the PSDs of inhibitory synapses (Brunig et al, 2002; Pilgram et al, 
2009; Waite et al, 2009), with delta dystrophin, in order to determine whether the two 
proteins co-localize, similarly to the well-established interaction and co-localization 
between classical dystrophin and β-dystroglycan (Ervasti et al, 1991; Grady et al, 2000; 
Brunig et al, 2002). I also co-labelled classical dystrophin with delta dystrophin, in 
order to directly compare the localization of the two isoforms and therefore establish the 
similiarities and/or differences in terms of localization exhibited by the two isoforms 
within these cultures. Concomitant with these studies, the significance of classical exon 
78 and delta exon 78  (the only sequences that distinguish classical from delta 
dystrophin) was examined in more detail, as the data presented in this thesis suggests 
that there is a different subcellular localization of classical and delta dystrophin. It is 
plausible that delta exon 78 encodes a trafficking signal. I therefore transfected neurons 
using pEGFP-N3 vectors containing either classical or delta exon 78, in order to 
determine whether delta exon 78 alone may encode a trafficking signal that would 
explain the differences in subcellular distribution observed in the biochemical studies 
presented in chapter 3. 
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                                    4.2 Results: 
 
         4.2.1 Comparison of delta dystrophin with PSD-95 in 
cortical neurons 
 
            In order to study the subcellular distribution of delta dystrophin within 
neurons of the forebrain, cortical neuronal cultures were prepared. These were grown 
for two weeks, because at this time point 92-95% of the neurons are reported to contain 
the highest density of spiny dendrites, a characteristic feature of in situ neurones (Papa 
et al, 1995; O’Brien et al, 1997; Rao et al, 1998). Once neurons have reached this state 
of maturity, cortical neurons were then fixed with PFA prior to immunolabeling. In 
order to determine whether delta dystrophin is present in the postsynaptic density 
(PSD), I began by testing whether delta dystrophin is present at PSDs of excitatory 
synapses. In figure 4.2.1, 14 div neurons were co-labelled for delta dystrophin and PSD-
95  (postsynaptic density protein 95), a major component of PSDs of excitatory 
synapses (Hunt et al, 1996; Rao et al, 1998). Anti-delta dystrophin antibody is directed 
against delta exon 78, hence, recognising all four delta dystrophin isoforms (see chapter 
1, figure 1.1.2.1). Figure 4.2.1 shows that neurons labelled with PSD-95 exhibited 
prominent punctate staining in dendritic spines (A1, 3), similar to that reported by 
Kornau et al (1995) and Rao et al (1998). Unlike PSD-95, delta dystrophin exhibited 
diffuse staining (A1, 2) throughout the dendrites of neurons containing PSD-95, but 
never co-localized with PSD-95 (white arrow, B1-3 and C1-3), hence suggesting delta 
dystrophin is not part of the postsynaptic density of excitatory synapses labelled with 
PSD-95. What is more, PSD-95 staining was often very close to the delta dystrophin 
stained processes (white arrow, C1-3), suggesting that these spines may originate from 
the delta dystrophin stained dendrites, but the delta dystrophin does not extend into the 
PSD. By comparing the pattern of PSD-95 staining with that of delta dystrophin (figure 
4.2.1), I also observed that PSD-95 clusters did not stain all processes containing delta 
dystrophin (grey arrow, C1-3). In contrast, delta dystrophin stained all dendrites 
containing PSD-95 staining (A-C). In conclusion, delta dystrophin staining is more 
widely distributed than PSD-95 staining, and it does not localize at PSDs of excitatory 
glutamatergic synapses. 
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Figure 4.2.1: Comparison of delta dystrophin with PSD-95. 
Rat cortical neurons were fixed at 2 weeks in culture and immunostained for delta 
dystrophin and PSD-95 (a marker for the PSD of excitatory synapses). Boxes show 
areas expanded in B and C. Neurons labelled with PSD-95 exhibited prominent 
punctate staining in dendritic spines (A3, B3, C3) whereas delta dystrophin exhibited 
diffuse staining throughout the dendrites labelled with PSD-95 (A1; white arrow, B1-3; 
white arrow, C1-3). The two proteins never co-localized (white arrow, B1; white 
arrow, C1). Delta dystrophin stained all dendrites labelled with PSD-95 (A1-3), hence 
it is present in neurons expressing this marker. In contrast, PSD-95 clusters did not 
stain all processes containing delta dystrophin (grey arrow, C1-3), hence delta 
dystrophin is also present in a wider set of neurons that do not express PSD-95. Given 
that delta dystrophin does not co-localize with PSD-95, delta dystrophin is likely 
absent from PSDs of glutamatergic synapses. Delta dystrophin (green), PSD-95 (red). 
Scale bar 10µm. 
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          4.2.2 Comparison of delta dystrophin with the NMDA R in 
cortical neurons            
   
            In order to conclude with more confidence that delta dystrophin is absent 
from the PSD of excitatory synapses, a second marker for the postsynaptic density of 
glutamatergic synapses, namely the NMDA receptor (Rao et al, 1998), was utilised. 
Figure 4.2.2 shows 14 div cortical neurons co-labelled with delta dystrophin and 
NMDA receptor. The anti-NMDA receptor antibody recognised the NR1 subunit of the 
NMDA receptor. NR1 exhibited punctate staining, generally in a clustered form 
(arrowhead, D3), and restricted to the somadendritic domain and the distal tips of 
dendrites (A1-3). Contrary to NR1 staining, delta dystrophin exhibited diffuse staining 
throughout the cell body and along proximal dendrites where NR1 staining was also 
present (A1-3), but they never co-localized (arrowhead, B1-3; arrow, C1-3; arrowhead, 
D1-3;). What is more, all proximal dendrites labelled with NR1 contained delta 
dystrophin (arrow, C1-3), but not all processes containing delta dystrophin were stained 
with NR1 (arrows, D1-3), suggesting delta dystrophin is more widely distributed 
compared to NR1 staining. On rare occasions, digital overlap is observed and this is due 
to the density of cultures at this point of the coverslip. Taken together, figures 4.2.1 and 
4.2.2 conclusively show that delta dystrophin is not found at the PSD of excitatory 
glutamatergic synapses. However, it is present along dendrites that express these 
markers. It is also present in a wider set of neurons, as it is present along the dendrites 
of neurons that do not express either of these (NR1 and PSD-95) markers. 
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Figure 4.2.2: Comparison of delta dystrophin with the NMDA receptor. 
Rat cortical neurons were fixed at 2 weeks in culture and immunostained for delta 
dystrophin and NMDA receptor NR1 subunit (a marker for the PSD of excitatory 
synapses). Boxes show areas expanded in B-D. NR1 exhibited punctate staining (A3), 
generally in a clustered form (arrowhead, D3), and restricted to the somadendritic 
domain and the distal tips of dendrites (A3). Contrary to NR1 staining, delta dystrophin 
exhibited diffuse staining throughout the cell body and along proximal dendrites (A2) 
where NR1 staining was also present (arrowhead, B1-3), but they never co-localized 
(arrowhead, B1-3; arrow, C1-3; arrowhead, D1-3). All proximal dendrites labelled with 
NR1 contained delta dystrophin (A1), suggesting delta dystrophin is expressed in 
neurons containing NR1. In contrast, not all processes containing delta dystrophin were 
stained with NR1 (arrows, D1-3), suggesting delta dystrophin is also present in a wider 
set of neurons that do not express NR1. Given that NR1 and delta dystrophin do not co-
localize, delta dystrophin is not part of PSD structures of excitatory glutamatergic 
synapses. Delta dystrophin (green), NR1 (red). Scale bar 10µm. 
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          4.2.3 Comparison of delta dystrophin with GABAA R in 
cortical neurons 
 
           Having established delta dystrophin is not a PSD component of excitatory 
synapses, I next investigated whether delta dystrophin is present at the PSD of 
inhibitory synapses. The GABAA receptor is a marker of the PSD of GABAergic 
synapses (Craig et al, 1994; Rao et al, 1998; Brunig et al, 2002) and is known to co-
localize with classical dystrophin and other DPC components at the PSD of inhibitory 
synapses (Brunig et al, 2002; Vithlani et al, 2009). Therefore, fixed cortical neurons 
were co-labelled with antibodies specific for the essential α2 subunits of the GABAA 
receptor and for delta dystrophin (figure 4.2.3), to determine whether delta dystrophin 
localized at GABAergic PSDs. At 14 days in culture, staining for the GABAA R α2 
subunit revealed a highly concentrated immunoreactivity distributed on the dendrites 
and a weaker staining on the soma at presumptive PSD structures of GABAergic 
synapses (A1, 3). On the contrary, delta dystrophin exhibited diffuse staining 
throughout the same soma and dendrites expressing GABAA R (A1, 2), but once again it 
does not co-localize with GABAA R (arrow, B1-3; arrow, C1-3). What is more, delta 
dystrophin is also present in processes where GABAA R staining is absent (arrow, A1-
3), therefore suggesting delta dystrophin is more widely distributed and is present in 
neurons which do not express GABAAR. An isolated process shows extensive GABAA 
R and delta dystrophin labelling (arrowhead, A1-3), these stretches are complementary 
and do not co-localize. In conclusion, delta dystrophin is not found in the PSD of 
GABAergic synapses although it is present in dendrites of neurons that express GABAA 
R. Furthermore, it is more widely distributed in neuronal subtypes that do not express 
GABAA R. 
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Figure 4.2.3: Comparison of delta dystrophin with GABAA R.         
Rat cortical neurons were fixed at 2 weeks in culture and immunostained for delta 
dystrophin and GABAA receptor α2 subunit (a marker for the PSD of inhibitory 
synapses). Boxes show areas expanded in B and C. GABAA R α2 subunit revealed a 
highly concentrated immunoreactivity distributed on the dendrites (arrowhead, A1-3; 
arrow, B1-3; arrow, C1-3), and a weaker punctate staining on the soma at presumptive 
PSD structures of GABAergic synapses (A1, 3). On the contrary, delta dystrophin 
exhibited diffuse staining throughout the same soma and dendrites stained by GABAA R 
(A1-3), but the two proteins never co-localized (arrow, B1-3; arrow, C1-3), hence delta 
dystrophin is present in neurons expressing GABAA R, but is not a PSD component of 
these inhibitory synapses. What is more, delta dystrophin is present in all dendrites 
labelled with GABAA R (A-C), whereas GABAA R is not found in all processes 
containing delta dystrophin (arrow A1-3), suggesting delta dystrophin is more widely 
distributed in other neuronal subtypes that do not express GABAA R. Delta dystrophin 
(green), GABAA R (red). Scale bar 10µm. 
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          4.2.4 Comparison of delta dystrophin with GAD 65 in 
cortical neurons 
 
            Given that delta dystrophin is not found at the postsynaptic apparatus of 
both GABAergic and glutamatergic synapses, I next determined whether delta 
dystrophin might be a component of the presynaptic apparatus in cortical neurons. In 
figure 4.2.4, 14 div neurons were fixed and co-labelled for delta dystrophin and GAD 
65, a key enzyme for GABA synthesis and a presynaptic marker of GABAergic 
synapses (Rao et al, 1998; Brunig et al, 2002). GAD 65 exhibited punctate staining at 
the periphery of the soma and proximal dendrites (A1-3), suggesting a presynaptic 
localization within presumptive GABAergic terminals. On the other hand, delta 
dystrophin exhibited diffuse staining throughout the soma and neuronal processes (A1-
2), as shown previously. Therefore, despite some digital overlap, the two proteins are 
differently distributed in the neuron (arrow, B1-3), suggesting delta dystrophin is not 
part of the presynaptic nerve terminals of GABAergic synapses. What is more, delta 
dystrophin always localized in dendrites innervated by GAD 65-containing terminals 
(A1-3), whereas the latter did not innervate all processes containing delta dystrophin 
(arrow, A1-3). In conclusion, delta dystrophin is not found in the presynapse of 
GABAergic synapses, although it is present in neurons that receive GABAergic 
innervation. Furthermore, delta dystrophin is present in a range of neuronal subtypes 
that do not receive GABAergic innervation. It is not uncommon to find random co-
localization between two proteins that in fact do not co-localize. For instance, Rao et al 
(2000) also reported some co-localization between PSD-95 and GAD 65, although it is 
well established that the two proteins are part of two very distinct sets of synapses, 
excitatory and inhibitory synapses, respectively. Therefore, in the next study, the 
significance of random co-localization observed between delta dystrophin and the 
presynaptic marker was examined in more detail.  
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Figure 4.2.4: Comparison of delta dystrophin with GAD 65 
Rat cortical neurons were fixed at 2 weeks in culture and immunostained for delta 
dystrophin and GAD 65 (a marker for the pre-synapse of inhibitory synapses). The 
box shows the area expanded in B. Delta dystrophin exhibited diffuse staining along 
the soma and various processes of the neuron (A1, 2). In contrast to a diffuse and 
internal staining exhibited by delta dystrophin, GAD 65 labelled the periphery (A1, 3) 
of the soma and processes labelled with delta dystrophin (A1-3). This suggests GAD 
65 is at the presynapse of GABAergic terminals that innervate the soma and processes 
labelled with delta dystrophin, thus sending inhibitory signals to delta dystrophin-
containing processes. Despite some digital overlap, the two proteins do not co-localize 
(arrow, B1-3), hence, delta dystrophin is not a presynaptic protein of inhibitory 
synapses. What is more, delta dystrophin is found in all dendrites innervated by GAD 
65-labelled GABAergic nerve terminals (A1-3), whereas GAD 65-labelled 
GABAergic nerve terminals did not label the surface of all processes containing delta 
dystrophin (arrow, A1-3), suggesting delta dystrophin is present in a range of neuronal 
subtypes when compared to neurons receiving GAD 65-labelled innervation. Delta 
dystrophin (green), GAD 65 (red). Scale bar 10µm. 
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               4.2.5 Comparison of delta dystrophin with synaptophysin 
in cortical neurons          
 
               To determine whether delta dystrophin is absent from excitatory and 
inhibitory presynaptic terminals, fixed neurons were co-labelled for delta dystrophin 
and synaptophysin (figure 4.2.5), a synaptic vesicle protein and a marker of all 
presynaptic terminals found in the brain (Leimer et al, 1996; Evans et al, 2005). In 
figure 4.2.5, synaptophysin exhibited a punctate staining located along the periphery of 
the neuron, suggesting a presynaptic localization at presumptive excitatory and 
inhibitory terminals (A1, 3). In contrast to this staining pattern, delta dystrophin 
exhibited a diffuse staining pattern throughout the soma and neuronal processes (A1, 2) 
which did not co-localize with the presynaptic staining pattern exhibited by 
synaptophysin (arrow, B1-3; arrow, C1-3), suggesting delta dystrophin is absent from 
the presynapse of excitatory and inhibitory terminals, in agreement with figures 4.2.3 
and 4.2.4. What is more, excitatory and inhibitory axon terminals containing 
synaptophysin always innervated dendrites containing delta dystrophin (A1-3), whereas 
not all processes containing delta dystrophin were innervated by nerve terminals 
labelled with synaptophysin (arrow, A1-3). Thus, delta dystrophin is localized in 
dendrites innervated by excitatory and inhibitory terminals. What is more, excitatory 
and inhibitory innervation does not occur along the axon, therefore, the distribution of 
delta dystrophin along processes that do not receive innervation by nerve terminals 
labelled with synaptophysin suggests delta dystrophin may localize in axons. This was 
further examined in subsequent experiments. Altogether, figures 4.2.1-4.2.5 show that 
delta dystrophin is widely distributed within a neuron, but is absent from pre and 
postsynapses of inhibitory and excitatory neurons, suggesting delta dystrophin is not 
part of the synaptic structure. What is more, the western blot data in chapter 3, in 
agreement with this immunocytochemical data, also highlighted delta full-length 
dystrophin as exhibiting a different subcellular distribution when compared to the 
highly PSD enriched classical full-length dystrophin protein. Given that DPC 
complexes in neurons localize at inhibitory postsynaptic terminals only (Brunig et al, 
2002), and given that the data up to this point in this thesis suggests delta dystrophin is 
not a synaptic protein, I next determined whether or not DPC complexes existed in 
these cultures, and I determined the exact localization of delta dystrophin within these 
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cortical neuronal cultures and in relation to other well established DPC components, 
notably β-dystroglycan. 
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Figure 4.2.5: Comparison of delta dystrophin with synaptophysin.  
Rat cortical neurons were fixed at 2 weeks in culture and immunostained for delta 
dystrophin and synaptophysin (a vesicle protein and marker of either excitatory or  
inhibitory presynapses).  Boxes show the areas expanded in B and C. Delta dystrophin 
exhibited diffuse staining along the soma and various processes of the neuron (A1, 2). 
In contrast, synaptophysin exhibited punctate staining along the periphery of the 
neurons (A1, 3), suggesting a presynaptic localization at presumptive excitatory and 
inhibitory terminals. Although delta dystrophin labelled dendrites innervated by 
synaptophysin, the two proteins did not co-localize (arrow, B1-3; arrow, C1-3), 
suggesting delta dystrophin is absent from the presynapse of excitatory and inhibitory 
terminals. What is more, delta dystrophin labelled all dendrites innervated by 
synaptophysin-containing nerve terminals, but not all synaptophysin-containing nerve 
terminals synapsed onto processes labelled with delta dystrophin, suggesting delta 
dystrophin is more widely distributed within a neuron. Delta dystrophin (green), 
synaptophysin (red). Scale bar 10µm. 
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           4.2.6 Comparison of delta dystrophin with β-dystroglycan 
in cortical neurons 
 
            In order to confirm classical dystrophin-containing DPC complexes 
existed in these cultures, and demonstrate delta dystrophin may not be part of these 
DPC complexes, fixed neurons were co-labelled for delta dystrophin and β-
dystroglycan (figure 4.2.6), a crucial core component of the classical dystrophin-
containing DPC complex at PSDs in brain neurons (Brunig et al, 2002; Pilgram et al, 
2009; Waite et al, 2009). In figure 4.2.6, β-dystroglycan was found as brightly labelled 
puncta arranged in lines running over cell bodies and dendrites only (A1, 3), in 
agreement with the published data (Brunig et al, 2002). In contrast, delta dystrophin 
exhibited diffuse staining along the soma and proximal dendrites stained by β-
dystroglycan (A1, 2), but they never co-localized (white arrow, B1-3; white arrow, C1-
3). What is more, delta dystrophin was found in all dendrites labelled with β-
dystroglycan (A1-3), whereas β-dystroglycan did not label all processes containing 
delta dystrophin (grey arrow, B1-3; grey arrow, D1-3). Thus, in agreement with our 
previous studies (figures 4.2.1-4.2.5), delta dystrophin is widely distributed within a 
neuron, but also between different neuronal subtypes. Furthermore, it does not co-
localize with the postsynaptic DPC component β-dystroglycan, and this is supported by 
earlier results (figures 4.2.1-4.2.5) demonstrating delta dystrophin is an extra-synaptic 
protein. The lack of co-localization between delta dystrophin and β-dystroglycan, a 
classical dystrophin-containing DPC component, suggests that delta dystrophin is likely 
to form novel DPC complexes whose molecular composition, as well as subcellular 
distribution, differs to classical dystrophin-containing complexes. Therefore in the next 
study, I tested whether classical dystrophin was also differently distributed when 
compared to delta dystrophin (figure 4.2.7), similarly to what has been observed with 
delta dystrophin and the classical dystrophin-binding protein, namely β-dystroglycan 
(figure 4.2.6).  
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Figure 4.2.6: Comparison of delta dystrophin with β-dystroglycan  
Rat cortical neurons were fixed at 2 weeks in culture and immunostained for delta 
dystrophin and β-dystroglycan (a DPC component at the PSD of inhibitory synapses). 
Boxes show the areas expanded in B-D. β-dystroglycan was found as brightly labelled 
puncta arranged in lines running over cell bodies and dendrites (A3). In contrast, 
although delta dystrophin was also localized within the same soma and proximal 
dendrites labelled by β-dystroglycan (A1-3), the staining was diffuse and the two 
proteins did not co-localize (white arrow, B1-3; white arrow, C1-3). This suggests delta 
dystrophin may not associate with β-dystroglycan to form novel delta DPC-like 
complexes at inhibitory postsynaptic structures containing β-dystroglycan. What is 
more, delta dystrophin was found in all dendrites expressing β-dystroglycan (A1), 
whereas β-dystroglycan was not expressed in all processes containing delta dystrophin 
(grey arrow, B1-3; grey arrow, D1-3) suggesting delta dystrophin is widely distributed 
within a neuron, but also between different neuronal subtypes. Delta dystrophin 
(green),  β-dystroglycan (red). Scale bar 10µm. 
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             4.2.7 Comparison of delta dystrophin with classical 
dystrophin in cortical neurons 
 
           14 div neurons were fixed and co-labelled for delta dystrophin and 
classical dystrophin (figure 4.2.7), a component of the classical dystrophin-containing 
DPC complexes found exclusively at inhibitory postsynapses (Knuesel et al, 1999; 
Knuesel et al, 2001; Brunig et al, 2002). Similarly to β-dystroglycan (figure 4.2.6), 
classical dystrophin was found as brightly labelled puncta arranged in lines running 
over cell bodies and dendrites (A1, 3), which was expected as the two proteins are 
known to associate and participate in the formation of classical dystrophin-containing 
DPC complexes exclusively localized at PSD structures of GABAergic synapses in the 
brain (Brunig et al, 2002; Pilgram et al, 2009; Waite et al, 2009; Vithlani et al, 2009). 
The profile of immunostaining of classical dystrophin is identical to that reported by 
Brunig et al (2002). The punctate labelling of classical dystrophin (A3; white arrow, 
B3; white arrow, C3) was different from the diffuse staining exhibited by delta 
dystrophin throughout the soma and neural processes (A1, 2). Similarly with β-
dystroglycan, classical dystrophin did not co-localize with delta dystrophin (white 
arrow, B1-3; white arrow, C1-3). What is more, delta dystrophin was always found in 
dendrites labelled with classical dystrophin (A1-3), whereas classical dystrophin did not 
always label processes stained by delta dystrophin (grey arrow, C1-3). In conclusion, 
these results suggest delta dystrophin is widely distributed within neurons expressing 
classical dystrophin, but also between different neuronal subtypes that do not express 
classical dystrophin. Furthermore, these results also suggest that delta and classical 
dystrophin exhibit different subcellular distributions in neurons, in agreement with the 
western blots presented in the preceding chapter (Chapter 3, figure 3.2.3.3, 3.2.3.4, 
3.2.4.1, 3.2.4.2). Therefore, given that delta dystrophin does not co-localize with 
classical dystrophin (figure 4.2.7) and β-dystroglycan (figure 4.2.6) and the inhibitory 
PSD marker (figure 4.2.3), the results re-confirm delta dystrophin does not replace 
classical dystrophin to form novel DPC-like complexes at PSDs of inhibitory synapses. 
Instead, delta dystrophin is likely to form novel DPC-like complexes outside the PSD 
(figures 4.2.1-4.2.5) that have a different molecular composition (figure 4.2.6) and a 
different distribution (figure 4.2.6 and 4.2.7) to classical dystrophin-containing DPC 
complexes. 
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Figure 4.2.7: Comparison of delta dystrophin with classical dystrophin  
 Rat cortical neurons were fixed at 2 weeks in culture and immunostained for delta 
dystrophin and classical dystrophin (a marker for the DPC complex at the PSD of 
inhibitory synapses). Boxes show the areas expanded in B-C. Classical dystrophin was 
found as brightly labelled puncta arranged in lines running over the cell body and 
dendrites (A3; white arrow, B3; white arrow, C3). In contrast, although delta 
dystrophin was also localized within the same soma and dendrites labelled by classical 
dystrophin (A1-3), the staining of delta dystrophin was diffuse (white arrow, C1-2) 
and the two proteins did not co-localize (white arrow, B1-3; white arrow, C1-3). This 
suggests delta dystrophin is absent from the PSD of inhibitory synapses containing 
classical dystrophin and therefore may not replace classical dystrophin to form novel 
delta DPC-like complexes therein. What is more, classical dystrophin did not stain all 
processes containing delta dystrophin (grey arrow, C1-3), whereas delta dystrophin 
stained all dendrites labelled with classical dystrophin (A1-3). This suggests delta 
dystrophin is widely distributed within neurons expressing classical dystrophin, but 
also between different neuronal subtypes that do not express classical dystrophin. 
Delta dystrophin (green), classical dystrophin (red). Scale bar 10µm. 
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          4.2.8 Comparison of delta dystrophin with rhodamine-
phalloidin in cortical neurons 
 
               Our studies clearly indicate that delta dystrophin is involved in extra-
synaptic functions. In order to determine a more precise localization of delta dystrophin 
within the cells, neurons were fixed and co-labelled for delta dystrophin and rhodamine-
phalloidin (figure 4.2.8), a marker that labels filamentous actin (F-actin). F-actin 
underlies all of the neuron plasma membrane (Capani et al, 2001; Dickinson et al, 
2004; Farah et al, 2008). This study was carried out because delta dystrophin, like 
classical dystrophin, contains an actin-binding domain. Classical dystrophin has been 
shown to utilise the C-terminal actin-binding domain in order to directly interact with F-
actin (Hemmings I et al, 1992). I therefore determined whether delta dystrophin might 
also interact with F-actin via its C-terminal actin-binding domain, and therefore localize 
delta dystrophin to the submembrane domain. In figure 4.2.8, F-actin staining localized 
adjacent to the plasma membrane (A1, 3) and dendritic spines (arrows, B1, 3) of the 
entire neurone, as expected (Dickinson et al, 2004). Delta dystrophin exhibited a diffuse 
staining pattern throughout the neuronal processes stained by F-actin (A1-3), but never 
co-localized with F-actin (arrows, B1-3; arrow, C1-3). In fact, delta dystrophin staining 
was always distant from the filamentous marker underlying all of the neuron plasma 
membrane, and was restricted to the more central parts of these neuronal processes (A1; 
arrow, C1-3). What is more, delta dystrophin labelled all processes containing F-actin. 
Given that F-actin is localized adjacent to the peripheral membrane of the entire cell 
(Dickinson et al, 2004) and is present in all neurons, the results suggest that delta 
dystrophin is a widely distributed protein present in most, if not all, neuronal processes. 
This is in agreement with the wide distribution of delta dystrophin suggested by the 
previous results (figures 4.2.1-4.2.7). In conclusion, delta dystrophin does not co-
localize with F-actin, and given that the localization of delta dystrophin appears to be 
more internal when compared to F-actin, it suggested delta dystrophin might co-localize 
with the microtubule-based cytoskeleton. I therefore determined whether delta 
dystrophin may co-localize with the microtubule-based cytoskeleton and whether such 
co-localization is restricted to axons, or dendrites, or to both these types of processes. 
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Figure 4.2.8: comparison of delta dystrophin with rhodamine-phalloidin 
Rat cortical neurons were fixed at 2 weeks in culture and immunostained for delta 
dystrophin and rhodamine-phalloidin (a marker that labels F-actin found adjacent to the 
plasma membrane of neurons). Boxes show the areas expanded in B and C. F-actin 
stained dendritic spines (arrows, B1, 3) and stained beneath the plasma membrane 
(arrow, C1, 3) throughout the neurone (A3). Delta dystrophin also stained all the 
neuronal processes stained by F-actin (A1), but never co-localized with F-actin (arrows, 
B1-3; arrow, C1-3). This study suggests delta dystrophin is distant from the membrane 
of the neuron and is therefore localized at the more central part of neuronal processes. 
Delta dystrophin (green), rhodamine-phalloidin (red). Scale bar 10µm. 
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          4.2.9 Delta dystrophin and MAP2 exhibit substantial co-
localization in cortical neurons 
 
            In order to begin to establish a potential delta dystrophin-binding partner 
within the central part of neuronal processes, 14 div neurons were fixed and co-labelled 
for delta dystrophin and MAP2 (microtubule associated protein 2) (figure 4.2.9). This is 
because MAP2 is associated with the tubulin cytoskeleton and similarly to delta 
dystrophin, is found in the soma and in the central parts of dendrites. More precisely, 
MAP2 is a marker for neurons and is restricted to a sub population of dendrites and it is 
absent from the axon (Matus et al, 1981; Bloom et al, 1983; Rao et al, 1998; Farah et 
al, 2008). In figure 4.2.9, MAP2 was localized along the central part of a subpopulation 
of dendrites (white arrow, B1, 3) and was also found in the soma of the isolated neuron 
(A1, 3). Delta dystrophin exhibited diffuse staining within the soma (A1, 2) and along 
the central part of a subpopulation of dendrites (white arrow, B1, 2) where MAP2 was 
found. Strikingly the two proteins exhibited substantial co-localization (white arrow, 
B1-3). Given that MAP2 is a neuronal marker, the coexpression of delta dystrophin and 
MAP2 within the same cell confirms that delta dystrophin is a neuronally expressed 
protein. What is more, delta dystrophin also exhibited diffuse staining in processes 
where no MAP2 staining was found (grey arrow, B1-3), suggesting delta dystrophin is 
more widely distributed than MAP2. In the processes where no MAP2 staining was 
observed, delta dystrophin again exhibited diffuse staining along the central part of the 
processes (grey arrow, B1-3). Given that MAP2 is absent from axons and some 
dendrites, this result does not exclude the possibility that delta dystrophin might also be 
found in the central parts of the axons of neurons, in addition to the central parts of 
dendrites where no MAP2 staining is found. Immunocytochemical studies using axonal 
markers are required in order to verify this hypothesis. In conclusion, delta dystrophin is 
more widely distributed within a single neuron when compared to MAP2, in agreement 
with earlier results (figure 4.2.1-4.2.8). Furthermore, its substantial co-localization with 
MAP2 further suggested that delta dystrophin may co-localize with the microtubule-
based cytoskeleton.  
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Figure 4.2.9: delta dystrophin exhibits substantial co-localization with MAP2 
Rat cortical neurons were fixed at 2 weeks in culture and immunostained for delta 
dystrophin and MAP2 (a late dendritic marker, not found in axon). The box shows the 
area expanded in B. Delta dystrophin was found in the same subpopulation of dendrites 
labelled with MAP2 and there is evidence of substantial co-localization (white arrow, 
B1-3). What is more, although delta dystrophin stained and substantially co-localized 
with all dendritic structures containing MAP2 staining (white arrow, B1-3), not all 
processes stained with delta dystrophin were labelled with MAP2 (grey arrow, B1-3). 
Given that MAP2 is known to stain only a subpopulation of dendrites and it is absent 
from the axon, this result suggests delta dystrophin is more widely distributed, but 
always expressed, within the central parts of neuronal processes, when compared to 
MAP2. Given that MAP2 is a neuronal marker, this study also confirms delta 
dystrophin is expressed in neurons. Delta dystrophin (green), MAP2 (red). Scale bar 
10µm.  
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            4.2.10 Delta dystrophin co-localizes with β3-tubulin in 
cortical neurons 
 
            The distribution of delta dystrophin in processes where MAP2 was 
absent, in addition to the substantial co-localization exhibited between delta dystrophin 
and MAP2 in a sub population of dendrites, suggested delta dystrophin may co-localize 
with the microtubule (MT) cytoskeleton. This is because the MT cytoskeleton is the 
‘highway’ along which MAP2 proteins travel to various destinations of the cell (Drewes 
et al, 1998; Dehmelt et al, 2004; Fletcher et al, 2010), and unlike MAP2, the MT 
cytoskeleton is found along the central parts of process throughout the entire neurone, 
including the axon (Mandell et al, 1995; Jaglin et al, 2009). To determine whether delta 
dystrophin is associated with the MT network, 14 div neurons were fixed and co-
labelled for delta dystrophin and β3-tubulin (figure 4.2.10). β3-tubulin is a molecular 
subunit of the MT cytoskeleton found along the central part of the soma, axon and all 
the dendrites (Mandell et al, 1995; Jaglin et al, 2009). Figure 4.2.10 shows delta 
dystrophin and β3-tubulin fully co-localized (white arrow, B1-3), with both proteins 
exhibiting diffuse staining throughout the central parts of the entire neuron, including 
the cell body, dendrites, and presumably the axon (A1-3). This study suggests that delta 
dystrophin is distributed in axons, soma and dendrites, in agreement with figures 4.2.1-
4.2.9. The co-localization between delta dystrophin and β3-tubulin also suggests delta 
dystrophin is directly or indirectly associated with the microtubule cytoskeleton found 
in all neuronal processes, including axons. Given that β3-tubulin is a protein known to 
be nearly completely devoid from spines (Calabrese et al, 2006), the full co-localization 
between delta dystrophin and β3-tubulin clearly indicates that delta dystrophin is also 
absent from spines. This finding is in agreement with figure 4.2.1, whereby PSD-95, a 
protein found exclusively in spines of excitatory synapses (Hunt et al, 1996), does not 
co-localize with delta dystrophin. The full co-localization between delta dystrophin and 
β3-tubulin (figure 4.2.10) is also consistent with the lack of co-localization between 
delta dystrophin and postsynaptic markers (GABA A R and NMDA receptors) as well as 
with presynaptic markers (GAD65 and synaptophysin), because β3-tubulin is nearly 
devoid in the synapse (Calabrese et al, 2006). Taken together, the results (figures 4.2.1-
4.2.10) clearly demonstrate delta dystrophin is an extra-synaptic protein, expressed 
within the central parts of neurons, directly or indirectly associated with β3-tubulin, and 
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therefore may not replace classical dystrophin to form novel delta DPC-like complexes 
at the PSD of GABAergic synapses. Lastly, the co-localization between delta 
dystrophin and β3-tubulin throughout most, if not all, neurons, suggests delta 
dystrophin is present in a range of neuronal subtypes, in agreement with figures 4.2.1-
4.2.9.  
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Figure 4.2.10: delta dystrophin co-localizes with β3-tubulin 
Rat cortical neurons were fixed at 2 weeks in culture and immunostained for delta 
dystrophin and β3-tubulin (a neuronal marker and molecular subunit of the MT 
cytoskeleton found in dendrites, soma and axon of all neurons). The box shows the 
area expanded in B. Delta dystrophin exhibited diffuse staining within the central parts 
of all neuronal processes labelled with β3-tubulin and the diffuse staining exhibited by 
delta dystrophin was identical to the diffuse staining exhibited by β3-tubulin (A1-3). 
The two proteins fully co-localized (arrow, B1-3), delta dystrophin labelled all 
processes containing β3-tubulin, and β3-tubulin labelled all processes containing delta 
dystrophin. Given that β3-tubulin is found within the central parts of the cell body, 
dendrites and the axon of all neurons, the full co-localization with β3-tubulin suggests 
delta dystrophin also localizes within the central parts of the cell body, dendrites and 
axon (A1-3) present in a range of neuronal subtypes. This suggests that delta 
dystrophin is associated, directly or indirectly, with the microtubule cytoskeleton, and 
is absent from the synapse. Delta dystrophin (green), β3-tubulin (red). Scale bar 10µm. 
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          4.2.11 Recombinant Cexon78 EGFP and Dexon78 EGFP 
sequences are unable to traffick differently in the cell 
 
            Studies up to this point (chapter 3 and 4) clearly demonstrate that 
classical and delta full-length dystrophin proteins exhibit different subcellular 
distributions in neurons of the brain. Classical full-length dystrophins containing 
classical exon 78 (Cexon78) at their C-terminus are segregated to the PSD (Beesley et 
al, 1999; Brunig et al, 2002; Pilgram et al, 2009; Waite et al, 2009), whereas delta 
dystrophin proteins containing delta exon 78 (Dexon78) at their C-terminus are 
segregated to the MT network (figures 4.2.1-4.2.10). Given that Cexon78 and Dexon78 
are the only sequences that distinguish classical from delta dystrophin respectively, I 
therefore transfected (figure 4.2.11.2) cortical neuronal cultures with C-terminally 
EGFP-tagged Cexon78 (figure 4.2.11.1B) and Dexon78 (figure 4.2.11.1C), in order to 
determine whether Cexon78 and Dexon78 alone may encode a trafficking signal to the 
PSD and MT network, respectively. Our collaborators Derek Blake and Chris Esapa 
kindly provided these vectors already containing the classical or delta exon 78 fused to 
EGFP. As a control, expression of the EGFP tag only (figure 4.2.11.1A) was 
investigated in 14 div neuronal cultures (figure 4.2.11.2A). The EGFP tag was 
successfully transfected into the neurons, as highlighted by the green fluorescence 
observed within the neurons (figure 4.2.11.2A). Similarly to publications (Bryen et al, 
2004), the EGFP protein was diffusely distributed throughout the neuron (A; white 
arrow, A1), and was also localized in spine-like structures (A1, grey arrow). Expression 
of the EGFP tagged Cexon78 (figure 4.2.11.2B) exhibited diffuse staining throughout 
the central parts of the neurone (white arrow, B1), and punctate staining in what appears 
to be spine-like structures (grey arrow, B1) was also observed. This staining pattern did 
not resemble the exclusively punctate staining exhibited by classical dystrophin in 
neuronal cultures (figure 4.2.7) and in those published by Brunig et al (2002). Similarly 
to Cexon78, the EGFP tagged Dexon78 (figure 4.2.11.2C) exhibited diffuse staining 
throughout the central parts of the neuron (white arrow, C1), and punctate staining in 
what appears to be spine-like structures (grey arrow, C1). The staining patterns of 
Dexon78 also did not resemble the exclusively diffuse staining pattern exhibited by 
delta dystrophin (figures 4.2.1-4.2.10) in neuronal cultures presented in this thesis. In 
fact, both Cexon78 and Dexon78 staining patterns showed a closer resemblance to 
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EGFP staining, although the latter did not exhibit this relative enrichment in spines 
(grey arrow, A1). Thus, these studies suggest that classical and delta exon 78 sequences 
alone are unable to traffick differently in the cell. It is highly likely that Cexon78 and 
Dexon78 interact with other structural elements within the dystrophin sequence in order 
to direct trafficking of the classical and delta dystrophin proteins to different parts of the 
neuron.  
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Figure 4.2.11.1: pEGFP-N3 vectors containing cDNAs of classical or delta exon 78 
fused with enhanced green fluorescent protein (EGFP). 
In order to study the function of classical exon 78 (Cexon78) and delta exon 78 
(Dexon78) found in the C-terminus of dystrophin isoforms, recombinant vectors 
containing the exon78 sequence of either classical or delta dystrophin were prepared. 
A. As a control, pEGFP-N3 vector containing only the EGFP tag (green) was used. B. 
pEGFP-N3 vector containing an EGFP tag (green) fused to Cexon78 (blue). Brackets 
contain the sequence of Cexon78 (blue). C. pEGFP-N3 vector containing an EGFP tag 
(green) fused to Dexon78 (red). Brackets contain the sequence of Dexon78 (red).  
EGFP, enhanced green fluorescent protein. 
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Figure 4.2.11.2: Dexon78 and Cexon78 exhibit a similar subcellular distribution in 
neurons.  
In order to study the function of classical exon 78 (Cexon78) and delta exon 78 
(Dexon78) found in the C-terminus of dystrophin isoforms, recombinant vectors 
containing the exon78 sequence of either classical or delta dystrophin were transfected 
into 14 div neurons. Boxes show areas expanded in A1-C1. A: expression of the EGFP 
tag only. B: expression of the EGFP tagged Cexon78. C: expression of the EGFP 
tagged Dexon78. Both Cexon78 and Dexon78 exhibited diffuse staining (white arrow, 
B1; white arrow, C1) throughout neuronal processes, as well as punctate staining (grey 
arrow, B1; grey arrow, C1) in what appears to be spine-like structures. Thus, classical 
and delta exon 78 sequences alone, do not encode the entire trafficking signal for the 
dystrophin isoforms, but are likely to encode only part of the trafficking signal 
sequence. EGFP, enhanced green fluorescent protein. Scale bar 10µm. 
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                                         4.3 Discussion 
 
 
          4.3.1 Delta dystrophin does not replace classical 
dystrophin at GABAergic synapses to form novel delta dystrophin-
containing DPC complexes. 
 
 
  To date, DPC complexes containing classical dystrophin in neurons 
have been exclusively localized at the PSD of inhibitory synapses (Brunig et al, 
2002). More precisely, the DPC complex in neurons contains the classical full-length 
dystrophin isoform, whereas the shorter classical dystrophin isoforms are reported to 
form different DPC-like complexes that are only observed outside of neurons (see 
chapter 1). In this chapter, I have utilised an immunocytochemical approach to 
determine whether delta dystrophin may replace classical dystrophin to form novel 
delta DPC-like complexes at the PSD of inhibitory synapses of cortical neuronal 
cultures. According to this work, I show that delta dystrophin is expressed in cortical 
neurons (figures 4.2.9, 4.2.10) and that a subpopulation of these neurons also co-
express classical dystrophin (figure 4.2.7). However, the two proteins are distributed 
differently within the cell and therefore do not co-localize (figure 4.2.7). Furthermore, 
I show that contrary to classical dystrophin, delta dystrophin is not a synaptic protein 
(figure 4.2.1-4.2.10), as it did not co-localize with any of the synaptic markers tested 
(figure 4.2.1-4.2.5). In fact, our studies show that delta dystrophin fully co-localizes 
with the microtubule cytoskeleton throughout the soma, dendrites and possibly axons 
(figure 4.2.10). My studies therefore suggest that delta dystrophin is directly or 
indirectly associated with the microtubule cytoskeleton network and therefore may 
not replace classical dystrophin in the formation of novel delta DPC-like complexes 
at the PSD of inhibitory synapses. Given that classical full-length dystrophin-
containing DPC complexes in neurons have, to date, only been localized at PSD 
structures of inhibitory synapses, the data presented in this thesis also suggests that in 
neurons, delta dystrophin can never replace classical dystrophin in DPC formation. 
Instead, I suggest delta dystrophin is likely to form novel, yet unidentified, delta-
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DPC-like complexes within the central parts of the neuron rather than at PSD 
structures, where classical full-length dystrophin is absent.  
 
               After researching the literature and comparing it to our results, it is 
becoming increasingly clearer that in neurons, delta dystrophin forms DPC-like 
complexes that are likely to exhibit a different molecular composition to DPC 
complexes containing classical dystrophin. This point is emphasised by the fact that 
delta dystrophin and β-dystroglycan, a core component of classical dystrophin-
containing DPC complexes, are differently distributed within our cortical neuronal 
cultures (figure 4.2.6), therefore β-dystroglycan may not be a component of delta 
dystrophin-binding DPC complexes in neurons of the forebrain. Brunig et al (2002) 
reinforces this result because they demonstrate β-dystroglycan is exclusively 
localized at PSD structures of inhibitory synapses of the forebrain, whilst I 
demonstrate that delta dystrophin is an extrasynaptic protein (figures 4.2.1-4.2.5) that 
co-localizes with the microtubule cytoskeleton (figure 4.2.10). Hence the two proteins 
are differentially distributed in neurons and therefore β-dystroglycan may not be a 
component of delta dystrophin-binding DPC complexes therein. What is more, Blake 
et al (1999) shows that delta dystrophin may not associate with a second classical 
dystrophin-binding DPC component, namely β-dystrobrevin, as delta dystrophin is 
not immunoprecipitated by β-dystrobrevin in the brain. This is in agreement with my 
result in chapter 3 (figure 4.2.7), whereby I demonstrate that delta dystrophin and β-
dystrobrevin exhibit a different subcellular distribution in the forebrain. Therefore β-
dystrobrevin may not be a component of delta dystrophin-binding DPC complexes. 
Given that β-dystroglycan and β-dystrobrevin are both components of classical 
dystrophin-containing DPC complexes that may not associate with delta dystrophin, 
these results strongly suggest that in neurons, delta dystrophin is likely to form DPC 
complexes whose molecular composition, as well as localization, differs to classical 
dystrophin-containing DPC complexes localized at the PSD of inhibitory synapses. 
This is further supported by the striking difference in the level of expression of the 
two dystrophin isoforms between the two brain regions studied, namely forebrain and 
cerebellum (Chapter 3, figures 3.2.4.1 & 3.2.4.2), with delta full-length dystrophin 
being expressed at low levels in the cerebellum when compared to the forebrain, 
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whilst classical full-length dystrophin is more concentrated in cerebellar fractions 
when compared to forebrain. 
 
            Although the sequence homology between classical and delta 
dystrophin is very high (they only differ by a single exon), the different molecular 
associations and localization within the cell, together with the difference in the level 
of expression exhibited by the two dystrophin isoforms in the forebrain when 
compared to the cerebellum (chapter 3, figures 3.2.4.1 & 3.2.4.2) suggests different 
roles for the two proteins. A co-localization between delta dystrophin and β3-tubulin 
suggests that delta dystrophin is directly or indirectly associated with the microtubule 
cytoskeleton. Prins et al (2009) show that classical dystrophin, the isoform of delta 
dystrophin, contains an MT-binding domain within the last spectrin domain through 
to the first third of the WW domain, and demonstrate via an (cosedimentation) 
immunoprecipitation approach, that classical dystrophin and the MT network can 
directly associate to one another. Given that delta dystrophin also contains this MT-
binding site unaltered by Dexon78 (as Dexon78 is not found within the MT-binding 
domain), and if we take into consideration the full co-localization between delta 
dystrophin and β3-tubulin, it is possible to suggest that delta dystrophin may also 
directly associate with β3-tubulin by utilising the MT-binding domain at the C-
terminal end of delta dystrophin. It is likely that classical dystrophin and delta 
dystrophin both associate with MTs, but if so they must associate with MTs found in 
two distinct parts of the neuron, as classical and delta dystrophin are never seen to co-
localize (figure 4.2.7) and exhibit different subcellular distributions (chapter 3, 
figures 3.2.3.3 and 3.2.3.4). It is possible that classical dystrophin associates with the 
few MTs present only at PSDs structures, whereas delta dystrophin, due to its 
restricted localization at the central parts of neuronal processes, may only associate 
with MTs found at the central parts of neuronal processes. Thus, although the two 
dystrophin proteins are almost identical in the amino acid sequence, this is a good 
example of how alternative splicing can control the subcellular localization of a 
protein and hence alter its functions within a cell. A key question is what are the 
signals that direct classical and delta dystrophin to such widely differing subcellular 
locations. 
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            In addition to its MT-binding domains, classical dystrophin also 
contains a domain that enables its association with actin, and another domain that 
enables its association with intermediate filaments (Stone et al, 2005; Prins et al, 
2009). Given that spines are strikingly enriched in actin and nearly completely devoid 
of intermediate filaments and MTs (Calabrese et al, 2006), and given that MTs and 
intermediate filaments are highly concentrated in the dedritic shaft (Calabrese et al, 
2006) and extensively meshed together along the central parts of axons and dendrites, 
my studies and studies by Prins et al (2009) lead to the suggestion that most of the 
binding to the MT network may be carried out primarily by delta dystrophin, and not 
classical dystrophin. In contrast, classical dystrophin may be important for associating 
with actin underlying the PSD of inhibitory neurons, as actin is the major cytoskeletal 
protein found therein. Taken together, these studies show that classical dystrophin 
and delta dystrophin may, together, function to stabilise the cell as a whole, by 
associating with actin and microtubules found throughout the neuron. Any interaction 
with intermediate filaments has not yet been investigated. 
 
            Prins et al 2009 has already demonstrated that classical dystrophin is 
capable of stabilising MTs from cold-induced depolymerisation. I suggest that delta 
dystrophin, in analogy to classical dystrophin, may also function to stabilise the MT 
cytoskeleton by utilising the same binding domain used by classical dystrophin. No 
studies have yet investigated whether delta dystrophin may indeed stabilise the MT 
network, however, studies have shown that the MT cytoskeleton becomes deranged 
when the DMD gene is mutated (Prins et al, 2009; Percival et al, 2007), and given 
that both classical and delta dystrophin originate from the DMD gene, this suggests 
that both the classical and the delta dystrophin isoform are likely involved in 
maintaining the stability of the MT cytoskeleton. The possible involvement of delta 
dystrophin in maintaining the stability of the MT cytoskeleton is further supported by 
the full co-localization exhibited between delta dystrophin and the MT cytoskeleton 
throughout the neuron (figure 4.2.10). Furthermore, delta dystrophin, in contrast to 
classical dystrophin, localizes in regions of the neuron where most of the MT network 
is found. Therefore, given that delta dystrophin contains an MT-binding domain and 
fully co-localizes with most of the MT network found in the neuron, it strongly 
suggests delta dystrophin may have a potential role in stabilising the MT cytoskeleton 
in neurons. Maintaining the stability of the MT cytoskeleton is vital for the cell, 
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because the MT cytoskeleton is considered to be the motorway on which vesicles and 
proteins are transported and targeted to their appropriate destination (Drewes et al, 
1998; Dehmelt et al, 2004; Fletcher et al, 2010). When the stability of the MT 
cytoskeleton is lost as a consequence of DMD mutation, the trafficking of proteins 
and a wide range of cellular functions may also be affected, leading to the cognitive 
impairments established in DMD patients. Therefore, the potential function for delta 
dystrophin in providing stability for the MT network deserves great attention and 
needs further investigation, as it could unravel novel pathways underlying the 
aberrant cognitions in DMD brains.  
 
 To date there is no knowledge on the function and binding abilities for 
Cexon78 and Dexon78 (see chapter 3). However, we show that as a consequence of 
these exons, classical and delta dystrophin distribute differently (chapter 3, figures 
3.2.3.3-3.2.3.4, 3.2.4.1-3.2.4.2; Chapter 4, figures 4.2.1-4.2.10). I therefore used a 
lipofectamine transfection approach on cortical neuronal cells to determine whether 
Cexon78 and Dexon78 alone may encode a trafficking signal that targets the two 
proteins to different parts of the cell: PSD and MT cytoskeleton, respectively (figure 
4.2.11.2). According to our study (figure 4.2.11.2), both Cexon78 (figure 4.2.11.2B) 
and Dexon78 (figure 4.2.11.2C) exhibited a mixture of diffuse staining throughout the 
neuron and punctate staining in spine-like structures, that is very different to the 
exclusively punctate staining exhibited by the classical dystrophin protein (figure 
4.2.7) and the exclusively diffuse staining exhibited by the delta dystrophin protein 
(figures 4.2.1-4.2.10), respectively. My results therefore show that Cexon78 and 
Dexon78 alone, are unable to traffick to the PSD and MT cytoskeleton respectively. 
Given that they are the only sequences that distinguish classical from delta 
dystrophin, and the two dystrophin isoforms are known to distribute differently in 
neurons, I suggest Cexon78 and Dexon78 are likely to interact with one or more 
sequences along the dystrophin protein to differentially target the dystrophin isoforms 
within the neuron.  
 
            Sakamoto et al (2008) have carried out a lipofectamine experiment 
using classical minidystrophins containing the C-terminus, as well as classical 
minidystrophins that lack the C-terminus and suggest that classical dystrophin 
contains a region extending from the WW domain to the C-terminal domain of 
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dystrophin that is important for the trafficking and binding to the membrane of the 
PSD. Sakamoto et al (2008) have not examined whether the entire domain, or only a 
part of this domain is important for the trafficking and binding to the membrane of 
the PSD. Cexon78 is found within this domain, and our lipofectamine study (figure 
4.2.11.2) demonstrates that Cexon78 alone is unable to encode a trafficking signal to 
the PSD, therefore a wider proportion of the WW domain to the C-terminal domain of 
the protein, in collaboration with Cexon78, is required in order to traffick to and 
associate with the PSD. What is more, whilst classical minidystrophins containing the 
C-terminus localize to the PSD, classical minidystrophins that lack the C-terminus 
reside in the cytoplasm, neurites and axons (Sakamoto et al, et al 2008), similar to the 
subcellular distribution observed for delta dystrophin throughout our immunostudies 
(figures 4.2.1-4.2.10) presented in this chapter. Therefore, the study by Sakamoto et 
al, (2008), combined with our immunocytochemistry and lipofectamine study reveals 
a very important potential function for Cexon78 and Dexon78. It is likely that 
Cexon78, found in the C-terminal domain of classical dystrophin, in cooperative 
interaction with the region extending from the WW domain to the C-terminal domain 
acts to localize classical dystrophin to the PSD in neurons. Furthermore, it is highly 
plausible that Dexon78 may function to disrupt the PSD-binding domain extending 
from the WW domain to the C-terminus, leading to delta dystrophin being distributed 
throughout the neurites and axons of the neurons (figures 4.2.1-4.2.10), similar to 
classical minidystrophins lacking the C-terminus domain. This may explain why delta 
dystrophin is localized within the central parts of neurites and axons, where it 
associates with β3-tubulin via its MT-binding domain. 
  
 In conclusion, delta dystrophin is an extrasynaptic protein, therefore it 
does not replace classical dystrophin at GABAergic synapses to form novel delta 
dystrophin-containing DPC-like complexes therein. I suggest delta dystrophin is 
likely to form novel delta dystrophin-containing DPC-like complexes within the 
central parts of the neuron rather than at PSD structures. I also suggest that the 
molecular composition of DPC complexes containing delta dystrophin will differ to 
DPC complexes containing classical dystrophin. This point is emphasised by the fact 
that delta dystrophin and β-dystroglycan, a core component of classical dystrophin-
containing DPC complexes, do not co-localize (figure 4.2.6). In support of this, the 
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difference in distribution of the two dystrophin isoforms in the forebrain and 
cerebellum (chapter 3, figure 3.2.4.2) suggest the two isoforms may carry out 
different functions in the neuron. I have demonstrated that delta dystrophin fully co-
localizes with β3-tubulin, a component of the MT cytoskeleton. I suggest Cexon78 
and Dexon78 collaborate with the region extending from the WW domain to the C-
terminus to traffick the two dystrophin isoforms to different cellular compartments. I 
suggest that in analogy to classical dystrophin, delta dystrophin may also directly 
interact with the MT cytoskeleton via its MT-binding domain. I also suggest that in 
analogy to classical dystrophin, delta dystrophin may participate in maintaining 
stability of the MT cytoskeleton, and hence may contribute together with classical 
dystrophin to the cognitive pathology in DMD patients by generating a deranged MT 
cytoskeleton, as a consequence of a mutated DMD gene. Lastly, from the 
immunocytochemical studies of the cortical neurons described in this chapter, all 
neurons viewed under the light microscope expressed delta dystrophin. Given that 
80% of forebrain neurons are excitatory, whilst only 20% of forebrain neurons are 
inhibitory (Xu et al, 2010), I confidently suggest that delta dystrophin is expressed in 
excitatory neurons of cortical neuronal cultures.  
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Chapter 5: 
 
 
     5.1 ε-sarcoglycan is likely to form novel complexes in the brain 
that are not related to dystrophin protein complexes 
 
 
                                    5.2 Introduction  
                                
   Having established that delta dystrophin does not replace classical dystrophin 
to form novel delta dystrophin-containing DPC complexes in GABAergic synapses of the 
brain (Chapter 4), my next goal was to determine whether ε-sarcoglycan, recently 
discovered to be present in the brain, may be part of the classical or delta dystrophin-
containing DPC complexes in the brain. The second goal was to generate an antibody 
against ε-sarcoglycan, in order to be able to carry out immunopurification studies for the 
identification of ε-sarcoglycan binding partners in the brain. The presence of ε-
sarcoglycan in DPC complexes outside the brain has already been described (Ervasti et 
al, 1990; Yoshida et al, 1990; Ozawa et al, 1998; Liu et al, 1999; Durbeej et al, 1999; 
Straub et al, 1999; Imamura et al, 2000; Fort et al, 2005; Chen et al, 2006; Cai et al, 
2007). To date, studies have suggested ε-sarcoglycan is not directly associated with the 
DPC complex, in fact, there are other sarcoglycan components that associate with ε-
sarcoglycan as well as the DPC complex, therefore creating an indirect link between the 
ε-sarcoglycan protein and the DPC complex (Ervasti et al, 1990; Yoshida et al, 1990; 
Ozawa et al, 1998; Durbeej et al, 1999; Fort et al, 2005). In smooth muscle for example, 
ε-sarcoglycan associates with three other sarcoglycan proteins (β, γ, δ-sarcoglycans) that 
together make up the sarcoglycan complex (Ervasti et al, 1990), it is the β/δ-sarcoglycan 
core that links ε-sarcoglycan to the DPC complex (Chen et al, 2006). In the outermost 
membrane of Schwann cells, ε-sarcoglycan forms a different sarcoglycan complex 
composed of ε, β, δ and ζ sarcoglycans, that is associated with the DPC complex via the 
β/δ-sarcoglycan core (Imamura et al, 2000; Cai et al, 2007; Chen et al, 2006) (See 
chapter 1 introduction, part two).  
 
      To date, there is no knowledge as to whether ε-sarcoglycan is part of DPC 
complexes in the brain. What is more, the formation of a sarcoglycan complex in the 
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brain, which appears to be important for linking ε-sarcoglycan to the DPC complex, has 
yet to be established in brain. Preliminary studies by western blot analysis suggest γ and 
δ sarcoglycans are absent from brain at the protein level (Hack et al, 2000), although δ-
sarcoglycan, but not  γ-sarcoglycan, has been detected at the mRNA level (Lim et al, 
1995; Bönnemann et al, 1995; Nigro et al, 1996; Nishiyama et al, 2004). ζ-sarcoglycan 
has, to date, been detected only at the mRNA level in the brain (Wheeler et al, 2002; 
Shiga et al, 2006), whilst β-sarcoglycan and ε-sarcoglycan isoforms have both been 
identified at the protein level in the brain (Ettinger et al, 1997; McNally et al, 1998; 
Wheeler et al, 2002; Xiao et al, 2003; Nishiyama et al, 2004; Chan et al, 2005; Shiga et 
al, 2006). It is clear from the publication data mentioned above that if a sarcoglycan 
complex exists in neurons, its molecular composition would significantly differ from the 
sarcoglycan complex found in smooth muscle, and is more likely to resemble the 
sarcoglycan complex found in Schwann cells. Therefore, given that the brain 
expresses ε, β, δ and ζ sarcoglycans at the mRNA level, and given that all four 
sarcoglycans are known to complex together in the Schwann cells and link ε-sarcoglycan 
to the DPC complex therein, this chapter presents a number of studies to determine 
whether ε-sarcoglycan, in analogy to Schwann cells, may be a component of the DPC 
complex in neurons of the brain.  
 
   The chapter initially describes a biochemical study that determines the 
subcellular distribution of ε-sarcoglycan in the two different brain regions (forebrain and 
cerebellum). This data was then used to compare the subcellular distribution of ε-
sarcoglycan with the subcellular distribution of other well-established DPC components 
in forebrain and cerebellum, presented in Chapter 3 (figure 3.2.3.2, 3.2.3.3, 3.2.3.4, 
3.2.4.1, 3.2.4.2). The aim was to determine whether or not ε-sarcoglycan exhibits the 
same subcellular distribution as delta dystrophin and/or other components of the classical 
dystrophin-containing DPC complexes, which would suggest whether ε-sarcoglycan may 
or may not be a component of classical and/or delta dystrophin-containing DPC 
complexes in forebrain and cerebellum. Μature cortical neuronal cultures were then used 
for immunocytochemical co-labelling for ε-sarcoglycan and classical dystrophin, a core 
component of the classical dystrophin-containing DPC complexes exclusively localized 
at PSD structures of GABAergic synapses (Blake et al, 1999; Brunig et al, 2002), in 
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order to determine whether there exists a co-localization between ε-sarcoglycan and 
classical dystrophin. Co-localization would suggest ε-sarcoglycan is part of the classical 
dystrophin-containing DPC complexes at GABAergic synapses. Thirdly, 
immunoprecipitation experiments were carried out to determine the potential for 
association between ε-sarcoglycan, classical and delta dystrophin, by establishing the 
ability of ε-sarcoglycan to pull-down classical and delta dystrophin isoforms from whole 
forebrain extracts. Lastly, I generated an anti-ε-sarcoglycan antibody for 
immunopurification and identification studies for ε-sarcoglycan-binding partners. 
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                                                   5.3 Results: 
 
 
               5.3.1 Isolation of forebrain and cerebellum subcellular fractions 
 
      Different subcellular fractions were obtained from forebrain and cerebellum 
of adult rat brains, as described in M&M (chapter 2). The following subcellular fractions 
were obtained: brain homogenate (BH), P2 pellet, myelin (My), microsomes (Mc), light 
membrane (LM), synaptic membrane (SM) and mitochondria (Mt). The SM fraction was 
fractionated further to give the PSD fraction. These forebrain and cerebellum subcellular 
fractions, isolated and described in Chapter 3, were utilised in this chapter to study and 
compare the subcellular localization of ε-sarcoglycan in the brain, therefore cross-
contamination tests and Coomassie Blue testing of these fractions can be verified in 
Chapter 3, figures 3.2.2.1-3.2.3.1. The subcellular distribution of ε-sarcoglycan in 
forebrain and cerebellum was determined by immunoblotting the range of subcellular 
fractions described above, including SMs and PSDs prepared from rat forebrain and 
cerebellum. PSDs of forebrain and cerebellum were isolated by the n-octyl-
glucopyranoside method.  
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               5.3.2 ε-sarcoglycan is a membrane-associated protein of the 
forebrain, and only present in low levels in PSDs 
 
         An immunoblot containing forebrain subcellular fractions was incubated with 
anti-ε-sarcoglycan antibody (figure 5.3.2), in order to determine the subcellular 
distribution of ε-sarcoglycan within the forebrain. As expected, the brain homogenate 
fraction contained two ε-sarcoglycan isoforms close to the 50kDa molecular weight 
(figure 5.3.2), with similar intensities to one another, suggesting the two isoforms exhibit 
similar levels of expression within the forebrain. Since ε-sarcoglycans are glycosylated 
proteins (McNally et al, 1998), the precise molecular weight of the two isoforms cannot 
be calculated and therefore their molecular weights can only be estimated by SDS 
analysis. According to previous immunoblot analysis of mouse wholebrain homogenates 
by Nishiyama et al (2004), the two ε-sarcoglycan isoforms had a molecular weight of 
47kDa and 49kDa. The two isoforms identified in figure 5.3.2 shared very similar 
molecular weights to those published by Nishiyama et al (2004) and therefore to avoid 
confusion, these were also labeled as 47kDa and 49kDa isoforms. Both isoforms enriched 
in the membrane fractions (microsomes, LM and SM), when compared to the brain 
homogenate fraction. What is more, ε-sarcoglycan isoforms did not enrich in the PSD 
fraction, although a weak doublet band was visible within the PSD lane. In conclusion, 
these results suggest that in the forebrain, the two ε-sarcoglycan isoforms are membrane-
associated proteins present in fractions of non-synaptic (LM and microsomes) and 
primarily synaptic (SM) origin. 
  
      Within the LM fraction, the two isoforms of 47 and 49kDa were expressed at 
similar band intensities. What is more, in the SM and microsome fractions, the two 
isoforms were expressed at similar band intensities when compared to the LM fraction, 
suggesting both isoforms were equally expressed within each particular subcellular 
fraction. Both isoforms were absent from the cytosol, suggesting that the two isoforms 
are membrane bound rather than freely distributed in the cytosol. The mitochondrial 
fraction showed only weak expression of the two isoforms, suggesting neither isoform is 
enriched within the mitochondrial fraction. In contrast to all these fractions, the myelin 
lane expressed the 47kDa isoform as a thick band whilst the band of the 49kDa isoform 
was only weakly expressed. This result suggests that the two isoforms do not always 
 179 
exhibit the same subcellular distribution in forebrain subcellular fractions and thus their 
distribution may undergo differential control mechanisms within the forebrain. 
 
      All subcellular fractions, with the exception of the cytosolic and 
mitochondrial fractions, contained bands of higher molecular weight proteins (figure 
5.3.2). According to the literature, there are to date no ε-sarcoglycan isoforms of such 
molecular weights in the brain or in any other organ studied. Therefore they are likely to 
represent cross-reactive bands or non-ε-sarcoglycan proteins reacting with the antibody. 
However, asterisks (figure 5.3.2) may represent potential dimeric or trimeric formation of 
ε-sarcoglycan isoforms that may form during the separation of the proteins in the SDS 
gel. Such bands would appear as high molecular weight bands of approximately 100kDa 
(dimer) and 150kDa (trimer) bands, respectively. However these higher molecular weight 
bands may be due to other cross-reacting proteins. It is not uncommon to find formation 
of dimeric and trimeric mammalian sarcoglycans in the presence of SDS, as previously 
reported by Shi et al (2004) and Hashimoto et al (2006). Furthermore, according to the 
western blot, there is some discrepancy in the mobility of the two isoforms when the 
subcellular fractions are compared to one another. This is likely to be due to some post-
translational modification, such as glycosylation (McNally et al, 1998) and 
phosphorylation (Ettinger et al, 1997; Nishiyama et al, 2004) exerted on the mammalian 
ε-sarcoglycan isoforms, similar to what has already been reported for other sarcoglycan 
family members (Shi et al, 2004; Hashimoto et al, 2006) and which slightly alters the 
mobility of the isoforms in the gel.  Based on these findings, the band observed between 
the 84kDa and 116kDa markers in the myelin lane may represent the dimeric form of 
47kDa isoform that has been glycosylated, rather than the dimeric form of the 49kDa 
isoform, given that the latter was only weakly expressed whereas the 47kDa isoform was 
strongly expressed in the myelin fraction. 
 
      In conclusion, the studies show ε-sarcoglycan isoforms are membrane-
associated proteins (figure 5.3.2) that are only present in low levels in the PSD fraction. 
Given that classical full-length dystrophin-containing DPC complexes are highly 
enriched in PSD structures (Chapter 3, figure 3.2.3.2, 3.2.3.3, 3.2.4.1), and classical 
dystrophin and associated DPC components are exclusively localized at GABAergic 
synapses (Blake et al, 1999; Brunig et al, 2002; Culligan et al, 2002), these studies 
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suggest that in the forebrain, both ε-sarcoglycan isoforms are unlikely to be components 
of classical dystrophin-containing DPC complexes due to the different 
compartmentalization of ε-sarcoglycan and classical dystrophin-containing DPC 
complexes. Secondly, given that delta dystrophin co-localizes with the MT cytoskeleton 
(Chapter 4, figure 4.2.10), these studies also suggest that in forebrain, both ε-sarcoglycan 
isoforms are unlikely to be components of delta dystrophin-containing DPC complexes. 
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Figure 5.3.2: Western Blot of forebrain subcellular fractions immunodeveloped with 
anti-ε-sarcoglycan antibody. 
Τwo ε-sarcoglycan isoforms of 47kDa and 49kDa are expressed in the forebrain, and are 
found to enrich in the LM, SM and microsomal fractions, but not in the PSD fraction. 
These results suggest ε-sarcoglycan isoforms are membrane-associated proteins. Protein 
loading is 20µg/lane. Lane 1, Brain Homogenate (BH); lane 2, Cell soluble (Cs); lane 3, 
Myelin (My); lane 4, Mitochondria (Mt); lane 5, Microsomes (Mc); lane 6, Light 
Membrane (LM); lane 7, Synaptic Membrane (SM); lane 8, Post-Synaptic Density (PSD). 
Molecular weight standards are indicated. *, potential dimeric and trimeric formation of 
ε-sarcoglycan isoforms. 
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               5.3.3 ε-sarcoglycan is a membrane-associated protein of the 
cerebellum, and only present in low levels in PSDs 
 
         The subcellular distribution and/or level of expression of a protein in the 
forebrain does not always reflect that of the cerebellum, as in the case of PSD95 (Hunt et 
al, 1996, Kim et al, 1992) and delta full-length dystrophin (Chapter 3, figure 3.2.4.2), 
respectively. Therefore, the subcellular distribution of ε-sarcoglycan isoforms in the 
forebrain and cerebellum was determined, in order to compare the subcellular 
localizations and level of expression of the two isoforms in the two different brain 
regions. This study was also carried out in order to determine whether ε-sarcoglycan may 
enrich in cerebellar PSDs and therefore be a potential component of classical dystrophin-
containing DPC complexes in PSDs of the cerebellum. Secondly, I was able to determine 
whether ε-sarcoglycan may have a similar subcellular distribution to delta dystrophin in 
the cerebellum, and hence, whether it may be part of delta dystrophin-containing DPC 
complexes, which according to results presented in Chapter 4, are localized at 
microtubule structures within neurons. Thirdly, these results were also important to 
suggest whether ε-sarcoglycan may or may not be part of novel protein complexes at 
membrane structures within the cerebellum. 
  
      An immunoblot containing a range of rat forebrain and cerebellar subcellular 
fractions was incubated with anti-ε-sarcoglycan antibody (figure 5.3.3). In figure 5.3.3, ε-
sarcoglycan was found as a 47kDa and 49kDa duplet band in both the forebrain and 
cerebellar brain homogenates. Within the brain homogenate of the forebrain, the 47kDa 
and 49kDa ε-sarcoglycan isoforms were expressed with similar intensity to one another 
(figure 5.3.3), suggesting that the two isoforms are expressed in similar quantities within 
the forebrain, in agreement with figure 5.3.2. In contrast, within the brain homogenate 
fraction of rat cerebellum, there was less of the 49kDa isoform when compared to the 
47kDa band, as previously observed by Nishiyama et al (2004). What is more, the 
intensity of the 47kDa isoform in the total homogenate of the rat cerebellum was similar 
to the respective fraction in the forebrain, whereas the band intensity of the 49kDa 
isoform in the cerebellum was lower compared to the forebrain, as observed by 
Nishiyama et al 2004. In other words, these results suggest that the 47kDa isoform is 
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expressed in similar levels in both brain regions, whereas the level of expression of the 
49kDa isoform in the two brain regions appears to be regionally controlled.  
    
      In the forebrain, the 47kDa and the 49kDa isoforms (figure 5.3.3) both 
enriched in microsomes, LM and SM fractions, in agreement with figure 5.3.2. Within 
the microsome fraction of the forebrain (figure 5.3.3), the 47kDa isoform exhibited the 
same band intensity as the 49kDa isoform, and these levels of expression were also 
observed within the LM and SM fractions of forebrain. In other words, all three fractions 
contained very similar levels of enrichment of both isoforms, in agreement with figure 
5.3.2. The cerebellum also exhibited a synaptic membrane enrichment pattern of both ε-
sarcoglycan isoforms, and similarly to the forebrain, neither isoform enriched in the PSD 
fraction (figure 5.3.3). Given that to date, classical dystrophin-containing DPC complexes 
in neurons of the cerebellum have been localized exclusively in PSD structures (chapter 
3, figures 3.2.3.2, 3.2.3.3 and 3.2.4.1; Moukhles et al, 2001), figure 5.3.3 suggests that 
the two ε-sarcoglycan isoforms are unlikely components of the classical dystrophin-
containing DPC complex at the PSD of the cerebellum, as well as the forebrain, because 
neither isoform is enriched in the PSD of forebrain and cerebellum. It is important to note 
however, that the PSD fraction is not completely devoid of the isoforms, in fact there 
exists a low level of ε-sarcoglycan isoforms in the PSD of the forebrain, followed by a 
more intense doublet band of the isoforms in the PSD of the cerebellum, suggesting the 
two isoforms certainly are present in the PSD fraction. In view of the high enrichment of 
classical dystrophin in the PSD fraction (Chapter 3, figure 3.2.3.3), and the low level of 
ε-sarcoglycan isoforms in this fraction, it is unlikely that ε-sarcoglycan is a component of 
the classical dystrophin-containing DPC complex at forebrain and cerebellar PSDs. 
Furthermore, with regard to delta dystrophin, the biochemical studies (Chapter 3, figure 
3.2.4.2; this chapter, figure 5.3.3) show that although both ε-sarcoglycan isoforms and 
delta full-length dystrophin enrich in the microsomal fraction, ε-sarcoglycan isoforms 
also enrich in the LM and SM fractions, whereas delta dystrophin does not. This is true in 
both forebrain and cerebellar subcellular fractions. The immunocytochemical study 
(Chapter 4, figure 4.2.10) confirm these differences, in fact delta dystrophin in neurons 
fully co-localizes with the MT cytoskeleton, away from the membrane (Chapter 4, figure 
4.2.8), whereas ε-sarcoglycan isoforms are exclusively membrane-enriched (this chapter, 
figures 5.3.2, 5.3.3). These studies therefore suggest that ε-sarcoglycan isoforms are 
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unlikely to be components of delta dystrophin-containing DPC complexes of the 
forebrain and cerebellum, due to different compartmentalization restrictions.  
 
         Although both ε-sarcoglycan isoforms are clearly membrane-associated 
proteins in both the forebrain and cerebellum, ε-sarcoglycan isoforms within the 
membrane fractions of the cerebellum are differently distributed when compared to the 
respective membrane fractions in the forebrain. In fact, only the SM fraction of the 
cerebellum contained both ε-sarcoglycan isoforms enriched therein, similar to the SM 
fraction found in the forebrain. In contrast, the microsomes and LM fractions of the 
cerebellum contained low levels of 49kDa isoform and enriched levels of the 47kDa 
isoform, whilst the forebrain microsomes and LM fractions contained both isoforms 
enriched therein. What is more, both isoforms are expressed at lower levels in membrane 
fractions of the cerebellum, when compared to the respective fractions in the forebrain. 
Therefore, the results clearly indicate that the 47kDa isoform exhibits the same 
membrane distribution in both brain regions, although at slightly lower levels in 
cerebellum, whilst the level of expression of the 49kDa isoform in the membrane 
fractions of the forebrain is by far greater when compared to the membrane fractions of 
the cerebellum. In other words, the level of expression of the 47kDa and 49kDa isoforms 
in the membrane fractions are regionally controlled, but unlike the 47kDa isoform, the 
49kDa isoform is differentially expressed in the membrane fractions of the forebrain 
when compared to the membrane fractions of the cerebellum. Furthermore, the myelin 
fraction of both forebrain and cerebellum only contained the 47kDa isoform, whilst 
negligible to null levels of the 49kDa band was observed. Thus, based on the myelin 
result, the 47kDa and 49kDa isoforms also appear to exhibit differential localization 
within the forebrain, as well as within the cerebellum. Lastly, the higher intensity of the 
doublet band within the membrane fractions of the forebrain when compared to the 
membrane fractions of the cerebellum, and the lower intensity of the 47kDa isoform in 
the myelin fraction of the forebrain when compared to the corresponding fraction in the 
cerebellum altogether suggest that the level of expression and distribution of the two 
isoforms in the two brain regions is highly regulated. 
 
      In conclusion, both ε-sarcoglycan isoforms occur predominantly in membrane 
fractions, both of synaptic (SM) and non-synaptic origin (LM and microsomes). There 
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appears to be lower expression of the 49kDa isoform in cerebellum compared to 
forebrain. Significantly only the 47kDa isoform is present in myelin. Neither isoform is 
enriched in the PSD fractions, unlike classical full-length dystrophin and associated DPC 
proteins (Chapter 3, figure 3.2.3.2, 3.2.3.3, 3.2.4.1), therefore it is most unlikely that ε-
sarcoglycan is a component of classical DPC complexes present in the PSD of either 
brain compartment. Given that to date, classical dystrophin-containing DPC complexes 
are said to exclusively localize at GABAergic synapses (Brunig et al, 2002), these studies 
suggest that ε-sarcoglycan may not associate with these classical dystrophin-containing 
complexes at GABAergic synapses. Lastly, given that the immunocytochemical data 
demonstrates delta dystrophin co-localizes with the MT cytoskeleton (Chapter 4, figure 
4.2.10), away from the membrane (Chapter 4, figure 4.2.8), whereas ε-sarcoglycan 
isoforms exclusively localize at the membrane, these studies also suggest that due to 
compartmentalization restrictions, neither ε-sarcoglycan isoform may associate with the 
delta dystrophin-containing DPC complexes in the forebrain and cerebellum. Hence, it 
seems likely that ε-sarcoglycan isoforms are likely to form novel, as yet unidentified 
protein complexes in brain. 
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Figure 5.3.3: Western Blot of forebrain and cerebellar subcellular fractions 
immunodeveloped with anti ε-sarcoglycan antibody.  
Two ε-sarcoglycan isoforms (47kDa and 49kDa) are expressed in forebrain and 
cerebellar compartments. The brain homogenate of forebrain expresses similar levels of 
these isoforms, whereas the cerebellum brain homogenate expresses lower levels of the 
49kDa isoform when compared to the 47kDa isoform in the cerebellum brain 
homogenate and with respect to the two isoforms in the brain homogenate of the 
forebrain, in agreement with Nishiyama et al 2004. Both 47kDa and 49kDa isoforms 
enrich in the SM fraction of the forebrain and cerebellum. No enrichment is observed in 
the PSD fraction of either brain compartment. In the forebrain, both isoforms are equally 
expressed in microsomes, LM and SM fractions. Contrary to the forebrain, the 
microsomes and LM fractions of the cerebellum express lower levels of the 49kDa 
isoform when compared to the 47kDa isoforms, whereas the SM fraction of the 
cerebellum expresses similar levels of both isoforms. Furthermore, the myelin fractions 
of the forebrain and cerebellum only express the 47kDa isoform, with the cerebellum 
expressing more of this isoform than the forebrain. Therefore, the two ε-sarcoglycan 
isoforms are membrane-associated proteins that exhibit differential localization within 
and between the two brain compartments. The fractions are run in pairs with the left and 
right hand samples being forebrain and corresponding cerebellar fractions respectively. 
Protein loading is 20µg/lane. Lanes 1 & 2, Brain Homogenate (BH); lanes 3 & 4, Cell 
Soluble (Cs); lanes 5 & 6, Myelin (My); lanes 7 & 8, Mitochondria (Mt); lanes 9 & 10, 
Microsomes (Mc); lanes 11 & 12, Light Membrane (LM); lanes 13 & 14, Synaptic 
Membrane (SM); lanes 15 & 16, Post Synaptic Density (PSD). Molecular weight 
standards are indicated.  F, forebrain. C, cerebellum. 
Mc Mc LM LM SM SM PSD BH BH Cs Cs My My Mt 
49kDa ε-sg 
47kDa ε-sg 
58kDa 
PSD 
F C C F C F F C F C F F C C F C 
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               5.3.4 ε-sarcoglycan, classical and delta dystrophin are 
differently distributed in cortical neurons, suggesting ε-sarcoglycan is 
unlikely to be a component of classical and delta dystrophin-containing 
DPC complexes in cortical neurons. 
 
          The biochemical studies (figures 5.3.2-5.3.3) presented in this chapter 
highlight that ε-sarcoglycan isoforms are membrane-associated proteins that are unlikely 
to associate with classical and delta dystrophin-containing DPC complexes in brain. The 
next goal was to demonstrate, via an immunocytochemical approach, the differences in 
subcellular distribution exhibited by ε-sarcoglycan and classical dystrophin (the core 
component of classical dystrophin-containing DPC complexes in PSD structures of 
neurons) and delta dystrophin (the core component of delta dystrophin-containing DPC 
complexes at MT structures of neurons), which would exclude the possibility of an 
interaction between them.   
 
          In order to study the distribution of ε-sarcoglycan and classical dystrophin 
within neurons of the forebrain, cortical neuronal cultures were grown for two weeks 
prior to immunolabeling. The cultures were grown for this long because at this time-point 
neurons reach a state of maturity, with 92-95% of the neurons containing the highest 
density of spiny dendrites, a characteristic feature of in situ neurones (Papa et al, 1995; 
O’Brien et al, 1997, Rao et al, 1998). 14 div neurons were fixed and then co-labelled for 
ε-sarcoglycan and classical dystrophin. Anti-ε-sarcoglycan antibody was directed against 
the last 98 amino acids of mouse ε-sarcoglycan, thus capable of recognising both 47kDa 
and 49kDa ε-sarcoglycan isoforms. Anti-classical dystrophin antibody was directed 
against classical exon 78 of the C-terminus, thus capable of recognising all four classical 
dystrophin isoforms expressed in the brain. Cortical neurons labelled with anti-classical 
dystrophin antibody (figure 5.3.4) exhibited brightly labelled puncta (arrowhead, B1, 3) 
arranged in lines running over cell bodies (A3) and proximal dendrites (arrowhead, B1, 
3) similar to that reported by Brunig et al (2002) in hippocampal neurons. Neurons 
labelled with anti-ε-sarcoglycan antibody stained the same soma (A2) and proximal 
dendrites (arrowhead, B1, 2) containing classical dystrophin, similar to that reported by 
Esapa et al 2007, however they never co-localized (arrowhead, B1). What is more, within 
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the same dendrites containing classical dystrophin, ε-sarcoglycan also stained the more 
distal parts of the dendrites (arrow, B1-3), whereas classical dystrophin staining was not 
found there (arrow, B1-3), rather, classical dystrophin immunoreactivity was restricted to 
proximal dendrites only (arrowhead, B1-3). Given that classical full-length dystrophin is 
the only classical dystrophin isoform expressed in neurons (Blake et al, 1999), it is a core 
component of DPC complexes exclusively localized at GABAergic synapses (Brunig et 
al, 2002) and does not co-localize with ε-sarcoglycan (figure 5.3.4), figure 5.3.4 suggests 
ε-sarcoglycan is unlikely a component of classical full-length dystrophin-containing DPC 
complexes at GABAergic synapses of cortical neurons of the forebrain, in agreement 
with figures 5.3.2 and 5.3.3.  
 
                The next goal was to demonstrate, via an immunocytochemical approach, the 
differences in distribution exhibited by ε-sarcoglycan and delta dystrophin. 
Unfortunately, both antibodies are rabbit antibodies and therefore would be recognised by 
the same rabbit secondary antibody, hence, merging the two images would not allow a 
clear distinction of ε-sarcoglycan staining from delta dystrophin staining. Furthermore, 
given that the distributions of the two proteins are clearly very different, and the antibody 
stocks were very limited, I decided to avoid fixing 14 div cortical neurons to directly 
compare the distribution of ε-sarcoglycan with delta dystrophin. Instead, I decided to 
compare the immunolocalization of ε-sarcoglycan exhibited in this chapter (figure 5.3.4) 
with the immunolocalization of delta dystrophin exhibited in Chapter 4 (figures 4.2.1-
4.2.10). The results clearly show that ε-sarcoglycan isoforms are exclusively distributed 
along the membrane of neurons (this chapter, figures 5.3.2-5.3.4; Esapa et al, 2007), 
whereas delta dystrophin isoforms are exclusively localized at the MT-cytoskeleton 
(Chapter 4, figure 4.2.10), away from the membrane (Chapter 4, figure 4.2.8). Hence, the 
different compartmentalizations suggest that ε-sarcoglycan is unlikely to be a component 
of delta dystrophin-containing complexes in cortical neurons.          
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Figure 5.3.4: ε-sarcoglycan does not co-localize with classical dystrophin. 
Rat cortical neurons were fixed at 2 weeks in culture and immunostained for classical 
dystrophin (a marker for the classical dystrophin-containing DPC complex at the PSD of 
inhibitory synapses) and ε-sarcoglycan (a membrane-associated protein). The box shows 
the area expanded in B. Classical dystrophin was found as brightly labelled puncta 
arranged in lines running over cell bodies (A3) and dendrites (arrowhead, B1, 3), in 
agreement with Brunig et al 2002. ε-sarcoglycan was also distributed along the same 
soma (A1, 2) and proximal dendrites (arrowhead, B1-3), in agreement with Esapa et al 
2007. The abundance of classical dystrophin in the soma was similar to that reported by 
Brunig et al 2002, but its significance remains to be investigated, whereas the abundance 
of ε-sarcoglycan in the cell body was due to its localization in some intracellular 
structures including the Golgi apparatus and post-Golgi vesicles (Esapa et al, 2007). 
Despite their abundance in the cell body, this figure highlights ε-sarcoglycan and 
classical dystrophin never co-localized (arrowhead, B1). ε-sarcoglycan was also 
distributed in more distal parts of the dendrites, where classical dystrophin was absent 
(arrow, B1-3). This suggests that ε-sarcoglycan is unlikely to be a component of classical 
dystrophin-containing DPC complexes at GABAergic synapses of cortical neurons of the 
forebrain. ε-sarcoglycan (green), classical dystrophin (red). Scale bar 10µm.  
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               5.3.5 The low levels of classical dystrophin isoforms 
imunoprecipitated by ε-sarcoglycan suggest ε-sarcoglycan is unlikely to 
associate with classical dystrophin-containing DPC complexes in the 
forebrain 
  
      Biochemical analysis (figures 5.3.2 and 5.3.3) and cortical neuronal (figure 
5.3.4) immunocytochemical studies all suggest that ε-sarcoglycan is unlikely to be a 
component of DPC complexes in brain, due to different compartmentalization 
restrictions. The next goal was to carry out an immunoprecipitation (IP) study using an 
immunoaffinity column cross-linked to the anti-ε-sarcoglycan antibody, in order to re-
investigate whether there is any binding interaction between ε-sarcoglycan and delta 
dystrophin, as well as with the neuron-specific classical full-length dystrophin isoform 
(cDp427) (Blake et al, 1999) in the forebrain. In order to carry out such experiment, 
forebrain homogenates were treated with RIPA buffer (see M & M), such that ε-
sarcoglycan isoforms could be solubilised from the membrane as part of any multi-
protein complexes that exist within the membrane and made available to interact with the 
anti-ε-sarcoglycan antibody during the immunoprecipitation experiment. Protein 
complexes are said to be more soluble in RIPA buffer when compared to other lysis 
buffers (Lambert et al, 2008), hence the choice of this buffer for these experiments, 
however, limitations of the RIPA buffer include lower solubility of membrane proteins, 
as well as of cytoskeleton and extracellular region proteins (Lambert et al, 2008). 
Therefore, a control experiment was carried out to ensure that the membrane-associated 
ε-sarcoglycan proteins were successfully solubilized by RIPA buffer, by using an anti-ε-
sarcoglycan antibody cross-linked to a column in order to allow immunoprecipitation (IP) 
of proteins from a BH preparation prior to RIPA buffer treatment, followed by an IP from 
a solubilized RIPA buffer BH preparation. Results showed that the RIPA buffer treated 
homogenate immunoprecipitated far more ε-sarcoglycan than in the control IP lane (data 
not shown), suggesting the solubilization with RIPA buffer was successful.  
 
                  Beads cross-linked to anti-ε-sarcoglycan antibody, kindly provided by 
our collaborators (Derek J Blake and Christopher T Esapa, University of Oxford), were 
mixed with the solubilized brain homogenate material in order to allow binding of the 
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anti-ε-sarcoglycan antibody with ε-sarcoglycan and any ε-sarcoglycan-binding proteins. 
An immunoblot containing brain homogenate (solubilized with RIPA buffer), 
immunoprecipitated protein (IP) material, and a control, was incubated with anti-ε-
sarcoglycan antibody (figure 5.3.5.1). The control lane contained eluates from beads that 
were not cross-linked with anti-ε-sarcoglycan antibody (figure 5.3.5.1), in order to 
measure the level of non-specific binding that may occur between the uncross-linked 
beads and the solubilized brain homogenate material. In the brain homogenate lane, two 
ε-sarcoglycan isoforms of 47kDa and 49kDa were present, as expected. In the IP lane, ε-
sarcoglycan was successfully immunoprecipitated as one thick band of about 50 kDa. 
Our control lane demonstrated that beads that had not been cross-linked with the anti-ε-
sarcoglycan antibody did not immunoprecipitate any ε-sarcoglycan protein. Asterisks 
refer to bands in the brain homogenate that may represent cross-reactive bands of non-ε-
sarcoglycan proteins, otherwise the same bands would also have been observed in the IP 
lane. 
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Figure 5.3.5.1: Western Blot containing anti-ε-sarcoglycan immunoprecipitated 
proteins of the forebrain, immunodeveloped with anti-ε-sarcoglycan antibody. 
The brain homogenate fraction contains two ε-sarcoglycan isoforms, 47kDa and 49kDa 
respectively. ε-sarcoglycan isoforms were successfully immunoprecipitated by the beads 
cross-linked to the anti-ε-sarcoglycan antibody, resulting into a thick band of around 
50kDa in the IP lane. The control lane, containing beads that were not cross-linked to the 
anti-ε-sarcoglycan antibody, contains no ε-sarcoglycan protein, suggesting that the beads 
alone were unable to immunoprecipitate the ε-sarcoglycan protein. Protein loading is 
20µg/lane. Lane 1, Brain Homogenate (BH); lane 2, immunoprecipitated material (IP); 
lane 3, Control. Molecular weight standards are indicated. *, may represent cross-reactive 
bands of non-ε-sarcoglycan proteins. 
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       Given that the IP lane contained a single thick band as opposed to a doublet 
band, I have demonstrated that the 50kDa band in the immunoprecipitate (IP) lane indeed 
represented the two ε-sarcoglycan isoforms (47kDa, 49kDa isoforms) rather than the 
cross-linked anti-ε-sarcoglycan antibody 50kDa IgG heavy chain protein that may have 
detatched from the beads during elution of the IP complex. Therefore, the immunoblot 
used in figure 5.3.5.1 was stripped using Glycine pH 2.5, a mild stripping procedure that 
reduces the amount of protein loss from the membrane when compared to other harsher 
SDS stripping treatments (http://www.piercenet.com/files/TR0023-Strip-&-reprobe-
blots.pdf), and subsequently incubated with the secondary antibody alone. The aim was 
to detect the presence of any primary antibody that may have detached from the column 
during the elution procedure. The stripped immunoblot was incubated using double the 
amount of secondary antibody that would normally be used, and results show that the 
antibody did not pick up any 50kDa antibody heavy chain band in the IP lane (figure 
5.3.5.2), demonstrating that the anti-ε-sarcoglycan antibody cross-linked to the beads was 
not removed from the column during elution of the IP material, but remained successfully 
cross-linked to the beads in the column. To verify that the stripping procedure with 
Glycine pH 2.5 did not remove all the protein on the blot, this western blot was re-
incubated with anti-ε-sarcoglycan antibody followed by a secondary antibody incubation 
procedure. The result obtained (data not shown) was weaker but identical to figure 
5.3.5.1, suggesting that most of the protein was not removed during the stripping 
procedure. Therefore, the thick 50kDa band (figure 5.3.5.1) represents the two ε-
sarcoglycan isoforms merged together, rather than the 50kDa antibody heavy chain. For 
example, in figure 5.3.3, the SM lane of the forebrain contains saturated levels of the two 
isoforms that, similar to the IP lane in figure 5.3.5.1, also appear as one thick band.  
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Figure 5.3.5.2: Western Blot from figure 5.3.5.1 stripped with Glycine pH 2.5, and 
subsequently immunodeveloped with anti-rabbit secondary antibody. 
The 47kDa and 49kDa ε-sarcoglycan isoforms are absent from the brain homogenate 
lane, suggesting that the stripping procedure was successful. The IP lane also contains no 
bands, suggesting that the primary anti-ε-sarcoglycan antibody was not removed from the 
column during the elution step of the immunoprecipitated complex. Protein loading is 
20µg/lane. Lane 1, Brain Homogenate (BH); lane 2, immunoprecipitated material (IP); 
lane 3, Control. Molecular weight standards are indicated. 
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 In order to test whether classical full-length dystrophin was also 
immunoprecipitated by the ε-sarcoglycan antibody and protein bound to the column, a 
duplicate immunoblot containing brain homogenate (solubilised with RIPA buffer), 
immunoprecipitated protein (IP) material, and a control, was incubated with anti-classical 
dystrophin antibody (figure 5.3.5.3). In the solubilised brain homogenate lane, the anti-
classical dystrophin antibody picked up all 4 classical dystrophin isoforms. In the IP lane, 
none of the immunoprecipitated dystrophin proteins were enriched in this lane when 
compared to the brain homogenate fraction, with the most abundant isoform being 
cDp71, followed by 2 equally weaker cDp140 and cDp116 protein bands. Possibly 
negligible amounts of cDp427 were also present. In the control lane, only negligible 
amounts of unspecific binding were observed, representing the cDp140, cDp116 and 
cDp71 bands, therefore suggesting that classical dystrophin isoforms in the IP lane were 
specifically immunoprecipitated by the ε-sarcoglycan antibody cross-linked to the beads 
rather than by the beads themselves. In conclusion, the level of cDp427 in the IP lane is 
negligible, and given that cDp427 is the only dystrophin isoform expressed in neurons 
(Blake et al, 1999) where it forms classical dystrophin-containing DPC complexes 
exclusively at GABAergic PSD structures, this study, in agreement with figures 5.3.2-
5.3.4, suggests that ε-sarcoglycan isoforms are not part of classical full-length 
dystrophin-containing complexes in neurons of the forebrain. Furthermore, given the low 
but existing levels of shorter classical dystrophin isoforms (cDp140, cDp116 and cDp71) 
in the IP lane, this result also suggests that outside neurons, where the shorter classical 
dystrophin isoforms reside (Blake et al, 1999), low amounts of ε-sarcoglycan may be part 
of non-neuronal classical dystrophin-containing complexes in the forebrain. However, 
given that the level of the short classical dystrophin isoforms that were 
immunoprecipitated by ε-sarcoglycan is low compared to that in the starting material, and 
that there is no enrichment compared to the brain homogenate level, it seems unlikely 
that ε-sarcoglycan complexes with these shorter dystrophin isoforms in the brain. 
However, it does seem likely that there may be other as yet unidentified binding partners 
in the brain. 
  
         Unfortunately, the anti-delta dystrophin antibody required to test whether 
delta dystrophin isoforms were immunoprecipitated by the anti-ε-sarcoglycan antibody 
was depleted. In order to overcome this problem, I decided to carry out a mass 
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spectrometry analysis study on ε-sarcoglycan interacting proteins, to investigate whether 
delta dystrophin would be identified in the list of ε-sarcoglycan associated proteins, and 
concominantly identify potential novel binding partners of ε-sarcoglycan. To achieve 
this, a large amount of anti-ε-sarcoglycan antibody was required and therefore it was 
necessary to raise an anti-ε-sarcoglycan antibody. The next section describes all the 
procedures for anti-ε-sarcoglycan antibody production. 
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Figure 5.3.5.3: Western Blot containing immunoprecipitated classical dystrophin 
isoforms of the forebrain, immunodeveloped with anti-classical dystrophin 
antibody. 
All four classical dystrophin isoforms, cDp427, cDp140, cDp116 and cDp71 are 
identified in the brain homogenate fraction. Only low levels of classical dystrophin 
isoforms are immunoprecipitated (IP lane). The highest level of immunoprecipitated 
protein is the cDp71 isoform, followed by cDp140 and cDp116 isoforms. The cDp427 
isoform is possibly immunoprecipitated at negligible levels. The control lane depicts only 
negligible levels of unspecific binding between the non-cross-linked beads and the 
classical dystrophin isoforms (cDp140, cDp116 and cDp71), suggesting the proteins in 
lane 2 are pulled-down by the ε-sarcoglycan antibody rather than the beads. Given the 
low yield of immunoprecipiated material, it suggests that ε-sarcoglycan isoforms are 
likely to associate with other novel-binding partners. Protein loading is 20µg/lane. Lane 
1, Brain Homogenate (BH); lane 2, immunoprecipitated material (IP); lane 3, Control. 
Molecular weight standards are indicated.  
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               5.3.6 Anti-ε-sarcoglycan antibody production for the 
characterization of ε-sarcoglycan binding partners 
 
                There are no anti-ε-sarcoglycan antibodies currently available commercially 
that have been raised against the same epitope as the antibody used in this chapter, and 
our collaborators Derek DJ and Esapa CT had depleted their in-house ε-sarcoglycan 
antibody stock, which I had been supplied with. The next section therefore describes the 
various steps carried out in order to obtain an anti-ε-sarcoglycan antibody that recognized 
the same epitope as the anti-ε-sarcoglycan antibody used up to this point of the chapter. 
The aim was to use the antibody to further investigate the potential association between 
ε-sarcoglycan and classical and/or delta dystrophin-containing DPC components, as well 
as to investigate novel interacting partners of ε-sarcoglycan. 
  
 In order to begin the antibody production, collaborators Blake DJ and Esapa 
CT provided me with a pET32b vector containing a peptide (figure 5.3.6.1A) that they 
had previously utilised to raise their in-house anti-ε-sarcoglycan antibody. The pET32b 
vector was used to transform BL21 (DE3) competent cells, a type of E.coli cells that are 
compatible with the pET32b vector. The ε-sarcoglycan peptide inserted in the vector had 
been previously fused to a series of tags at its N-terminus, and a His tag at its C-terminus 
(figure 5.3.6.1B), such that it could be easily traced and isolated without the need of an 
anti-ε-sarcoglycan antibody. An SDS gel containing five samples of BL21 (DE3) cells 
that had each been transformed with the pET32b vector containing the ε-sarcoglycan 
peptide was stained with Coomassie Blue gel stain (figure 5.3.6.2). Each lane represents 
BL21 (DE3) cells grown in a different 1 L flask, and given the need to produce large 
(8mg) quantities of the ε-sarcoglycan epitope, a total of 5 L culture was grown. All BL21 
(DE3) cells, except in lane 1, were treated with isopropyl β-D-1-thiogalactopyranoside 
(IPTG). As highlighted in figure 5.3.6.2, the IPTG treatment successfully induced the 
pET32b vector to express a large amount of the 33kDa ε-sarcoglycan peptide (lanes 2-5), 
when compared to BL21 (DE3) cells that did not receive IPTG treatment (lane 1).  In 
order to reconfirm that the overexpressed protein was represented by the ε-sarcoglycan 
peptide, a duplicate SDS gel was western blotted (figure 5.3.6.3) and incubated with an 
anti-His antibody, recognizing the His-tag of the ε-sarcoglycan peptide fused at the N- 
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and C-terminal end of the peptide (figure 5.3.6.1). Figure 5.3.6.3 confirmed that the 
overexpressed 33kDa protein was indeed the ε-sarcoglycan peptide in all flasks treated 
with IPTG (lanes 2-5), whereas only low levels of expression of the ε-sarcoglycan 
peptide were present where no IPTG was added (lane 1). This suggested that cells were 
successfully transformed and IPTG clearly induced the transformed BL21 (DE3) cells to 
produce large quantities of the desired peptide.   
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(CCRREGVEKRDMQTPDIQLVHHSSIQKSTKELRDMSKNREIAWPLSTLPVFHPVTG
EVIPPTHTDNYDSTNMPLMQAQQNPLHQTQIPQPQTTGKWYD) 
 
 
Figure 5.3.6.1: A pET32b vector designed for cloning and high-level expression of 
peptide sequences. ε-sarcoglycan peptide has been inserted in the Multiple Cloning 
Site (MCS).  
A. The pET32b vector contains a T7lac promoter, T7 transcription terminator, lac1 gene 
(lac repressor), pBR322 origins of replication, f1 for single-stranded plasmid production, 
and bla gene for ampicillin resistance. B. The ε-sarcoglycan peptide (accession number 
AAH12665) represents the last 98 amino acids (residues 316-413) of a 413 amino acid 
full-length ε-sarcoglycan protein. In the construct, the peptide contains a series of tags at 
its N-terminal end, and a His tag at its C-terminal end. The tags at the N-terminus of the 
peptide include thioredoxin (Trx), His tag, S-tag and an enterokinase (EK) tag. In 
brackets is the amino acid sequence of ε-sarcoglycan peptide (blue). 
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Figure 5.3.6.2: SDS PAGE separation of BL21 (DE3) cells transformed with the 
pET32b ε-sarcoglycan peptide and treated with IPTG.  
Aliquots of BL21 (DE3) cells were separated on a 12% gel. Proteins were visualized with 
Coomassie blue. As a control, BL21 (DE3) cells were not treated with IPTG, to 
demonstrate BL21 (DE3) cells alone are not able to overexpress the peptide (lane 1). 
Lanes 2-5 represent BL21 (DE3) cells treated with IPTG, resulting in overexpression of 
the 33kDa ε-sarcoglycan band. Sample loading is 10µl/lane, from a total fraction of 1L. 
Lanes 1-5, BL21 (DE3) cells transformed with the pET32b vector containing the desired 
peptide. Molecular weight standards are indicated. IPTG, isopropyl β-D-1-
thiogalactopyranoside. 
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Figure 5.3.6.3: Western Blot of IPTG induced BL21 (DE3) cells immunodeveloped 
with anti-His antibody. 
This study confirms that the overexpressed 33kDa band observed in figure 5.3.6.2 (lanes 
2-5) corresponds to the ε-sarcoglycan peptide, given that the anti-His antibody was able 
to pick up the His tag found exclusively in the N and C-terminus of the overexpressed 
33kDa ε-sarcoglycan peptide (lanes 2-5). The 33kDa ε-sarcoglycan peptide was the only 
immunoreactive band on the blot. Sample loading is 10µl/lane. Lanes 1-5, BL21 (DE3) 
cells transformed with the pET32b vector containing the desired peptide. Molecular 
weight standards are indicated. IPTG, isopropyl β-D-1-thiogalactopyranoside. 
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           BL21 (DE3) competent cells containing the overexpressed ε-sarcoglycan 
peptide were lysed and their protein content was run through a Nickel column in order to 
isolate the ε-sarcoglycan peptide from the protein mixture found in BL21 (DE3) 
competent cells. Given that the Nickel column binds specifically to the His tag, which 
was only present in the ε-sarcoglycan peptide, the latter was able to specifically bind to 
the Nickel column, therefore allowing specific isolation of the peptide from the protein 
mixture found in BL21 (DE3) cells. An SDS gel containing the various steps of ε-
sarcoglycan peptide purification was stained with Coomassie Blue gel stain (figure 
5.3.6.4). Lanes 1 and 2 depict the ε-sarcoglycan peptide obtained from lysed BL21 (DE3) 
competent cells before and after binding to the Nickel column, respectively. Lanes 3 and 
4 represent successful binding of the ε-sarcoglycan peptide to the Nickel column during 
the two washes through the Nickel column, as only negligible amounts of the ε-
sarcoglycan peptide were eluted off from the column (lanes 3 and 4). Lanes 5-7 and 8-10 
contained the ε-sarcoglycan peptide (33kDa) successfully eluted off the Nickel column 
with Elution Buffer (100mM NaH2PO4, 10mM Tris-HCl, 8M Urea) pH4.5 and pH5.9, 
respectively. High molecular weight doublet bands (asterisks) were visible in the eluted 
fractions, which may represent dimeric and trimeric forms of the ε-sarcoglycan peptide. 
However, these dimers and trimers were observed in the form of doublets. Given there is 
no glycosylation in BL21 (DE3) cells, the doublets may not represent different 
glycosylated dimeric and trimeric forms of the single 33kDa ε-sarcoglycan peptide eluted 
from the column. When a duplicate SDS gel was western blotted and incubated with anti-
His antibody (figure 5.3.6.5), it demonstrated that the 33kDa eluted protein from the 
Nickel column was indeed the ε-sarcoglycan peptide (lanes 2-6), that the peptide was 
completely eluted from the column (lane 7), and that only a single band from the dimer 
(asterisk) and from the trimer (asterisk) was identified by the His antibody, indicating that 
only these are indeed ε-sarcoglycan dimeric and trimeric aggregations, respectively. 
Therefore, the remaining bands next to the ε-sarcoglycan dimer and trimer (figure 
5.3.6.4, lanes 6-10) could represent endogenous proteins that lack Histidine residues but 
associated non-specifically with the ε-sarcoglycan tagged protein, and consequently 
eluted with the ε-sarcoglycan peptide (figure 5.3.6.4, lanes 6-10). 
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Figure 5.3.6.4: SDS PAGE separation of ε-sarcoglycan peptides isolated using a 
Nickel Column.  
Cleared lysates of IPTG-induced BL21 (DE3) cells containing the overexpressed ε-
sarcoglycan peptides were separated on a 12% SDS gel. Proteins were visualized with 
Coomassie blue. Lanes 1 and 2 originate from the same batch of total volume of lysed IPTG-
induced BL21 (DE3) cells, before (lane 1) and after (lane 2) the addition to the Nickel 
column, respectively. Only half of the peptide introduced (lane 1) exited the column (lane 2), 
suggesting enough peptide had successfully bound to the column until the column became 
saturated thus allowing the surplus peptide to exit the column. Lanes 3 and 4 confirmed that 
almost none of the bound ε-sarcoglycan peptide detatched from the Nickel column during the 
washing procedure. Lanes 5-7 and 8-10 depict the peptide was successfully eluted from the 
column with Elution Buffer pH4.5 and pH5.9, respectively, eliminating contaminating 
proteins normally found in BL21 (DE3) cells. Sample loading is 10µl/lane. Due to variations 
in the total eluted fraction volumes from which lanes 1-10 were obtained, appropriate 
dilutions on the sample for loading were carried out, such that each sample loaded was as if it 
originated from the same total eluted volume. Lane 1, ε-sarcoglycan before its addition to the 
nickel column; lane 2, surplus ε-sarcoglycan that did not bind to the Nickel column; lane 3-4, 
washes of the nickel column bound to ε-sarcoglycan peptides; lane 5-10, elution of the ε-
sarcoglycan peptide. Molecular weight standards are indicated. *, potential dimeric and 
trimeric forms of the ε-sarcoglycan peptide. IPTG, isopropyl β-D-1-thiogalactopyranoside. 
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Figure 5.3.6.5: Western Blot of purified 33kDa ε-sarcoglycan peptides 
immunodeveloped with anti-His antibody.  
In lanes 2-6, the anti-His antibody was able to recognize the His tag of a 33kDa protein, 
confirming it is the ε-sarcoglycan peptide. Lane 7 confirms that all the peptides bound to 
the column were successfully eluted within lanes 2-6, as no ulterior peptide is eluted in 
lane 7. Lane 1 demonstrates that most of the ε-sarcoglycan peptide remains bound to the 
column during the wash procedure, as only negligible levels elute during the wash 
procedure (lane 1). Sample loading is 10µl/lane. Due to variations in the total eluted 
fraction volumes from which lanes 1-7 were obtained, appropriate dilutions on the 
sample for loading were carried out, such that each sample loaded was as if it originated 
from the same total eluted volume. Lane 1, wash; lanes 2-7, elution of the ε-sarcoglycan 
peptide. Molecular weight standards are indicated. *, confirmed dimeric and trimeric 
formation of ε-sarcoglycan peptide. 
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           As shown in figure 5.3.6.1, the N-terminus of the ε-sarcoglycan peptide 
contained a variety of tags that may induce an unwanted immunogenic response, which 
could generate an antibody against the tag or part of the tag, rather than the peptide of 
interest. Therefore all four tags found at the N-terminus of the ε-sarcoglycan peptide were 
removed by recombinant enterokinase (rEK) treatment, an enzyme that cuts the 
enterokinase (EK) tag found adjacent to ε-sarcoglycan (figure 5.3.6.1), leading to the 
immediate removal of all tags found at the N-terminus of the ε-sarcoglycan peptide. An 
SDS gel containing the overexpressed ε-sarcoglycan peptide before and after rEK 
treatment was stained with Coomassie Blue gel stain (figure 5.3.6.6). Lane 1 contained 
the ε-sarcoglycan peptide (33kDa) prior to enzyme cutting and detachment of the N-
terminal tag sequence from the ε-sarcoglycan peptide. Lanes 2-7 show the tag (18kDa) 
was successfully removed from the 33kDa peptide at different enzyme incubation time-
points. The 14kDa band represents the ε-sarcoglycan peptide without the tags. S-tag 
Agarose beads already cross-linked to an anti-S-tag-antibody were utilised to promote the 
association between the S-tag found in the 18kDa peptide and the anti-S-tag antibody 
cross-linked to the beads, such that the 14kDa ε-sarcoglycan peptide remaining in 
solution contained almost no contamination by the 18kDa tag. An SDS gel (figure 
5.3.6.7) demonstrating the successful isolation of a purified ε-sarcoglycan peptide (lane 
1, 2) from the tag (lane 3, 4) was stained with Coomassie Blue gel stain. Lanes 1 and 2 
only contained the ε-sarcoglycan peptide, therefore the peptide does not appear 
contaminated by the 18kDa tag. Lanes 3 and 4 only contained the 18kDa tag, suggesting 
no visible contamination with the ε-sarcoglycan peptide. Figure 5.3.6.7 demonstrates that 
the two enzyme digest products were successfully separated from one another. A Folin-
Lowry protein assay was carried out in order to measure a total of 3mg of the 14kDa ε-
sarcoglycan peptide, which was subsequently lyophilized before being sent to Sigma-
Genosys, where the immunization for rabbit polyclonal antibody production took place in 
two rabbits. 
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Figure 5.3.6.6: SDS PAGE separation of 18kDa tag and a 14kDa ε-sarcoglycan 
peptide obtained by recombinant Enterokinase (rEK) digestion of the 33kDa ε-
sarcoglycan peptide. 
The experiment was carried out according to Materials and Methods (section 5.22). 
Aliquots of the 33kDa ε-sarcoglycan peptide mixed with the 97kDa rEK enzyme were 
separated on a 10% gel. Proteins were visualized with Coomassie blue. Lane 1 contains 
the 33kDa ε-sarcoglycan peptide prior to digestion with rEK. Lanes 2-7 show the 33kDa 
peptide is successfully digested into a 14kDa ε-sarcoglycan peptide and 18kDa tag at 
different incubation time-points. The optimal incubation time is 16hours (lane 7), where 
the digestion gives the highest level of digested peptide. Sample loading is 10µl/lane 
from a total volume of 50µl. Lane 1, undigested ε-sarcoglycan peptide; lane 2, 1:50 
(enzyme: protein concentration) two hours rEK incubation; lane 3, 1:100 two hours rEK 
incubation; lane 4, 1:50 four hours rEK incubation; lane 5, 1:100 four hours rEK 
incubation; lane 6, 1:50 sixteen hours rEK incubation; lane 7, 1:100 sixteen hours rEK 
incubation. Molecular weight standards are indicated. 
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Figure 5.3.6.7: SDS PAGE separation of the purified 14kDa ε-sarcoglycan peptide.  
The experiment was carried out according to Materials and Methods (section 5.23). 
Separate aliquots of the purified 18kDa tag and 14kDa ε-sarcoglycan peptide were 
separated on a 12% gel. Proteins were visualized with Coomassie blue. After a 16 hour 
digestion of the 8mg ε-sarcoglycan peptide by the rEK enzyme, equal amounts of the 
18kDa tag and 14kDa ε-sarcoglycan peptide were generated. S-Agarose beads, capable of 
binding to the S-tag found in the 18kDa tag, were added to the digest and allowed to bind 
to the S-tag. Subsequently, the solution was centrifuged, generating a pellet containing 
the 18kDa tag bound to the S-Agarose beads, and a supernatant with an uncontaminated 
14kDa ε-sarcoglycan peptide preparation. Lanes 1-2 demonstrate the 14kDa ε-
sarcoglycan peptide found in the supernatant is not contaminated by the presence of the 
18kDa tag. Lanes 3-4 demonstrate that the 18kDa tag eluted from the S-Agarose beads 
does not contain residual amounts of 14kDa ε-sarcoglycan peptides. Protein loading is 
10µl/lane. Lanes 1-2, 14kDa ε-sarcoglycan peptide; lanes 3-4, 18kDa tag. Molecular 
weight standards are indicated. 
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          Prior to the arrival of the antibody, dynabeads were cross-linked with the 
33kDa ε-sarcoglycan peptide. Upon the arrival of the immunized serum, the latter was 
run through a column containing dynabeads cross-linked to the 33kDa ε-sarcoglycan 
peptide, to affinity purify the antiserum such that only the antibody raised against the ε-
sarcoglycan peptide was present in the eluate. The bound antibody was then eluted from 
the column. Table 5.3.6 represents the spectrophotometer readings denoting which 
elution contained the anti-ε-sarcoglycan antibody eluted from the column. In order to test 
the ability of the antibody to recognize the native ε-sarcoglycan protein, as well as the ε-
sarcoglycan peptide, western blots containing forebrain homogenates and the purified 
33kDa ε-sarcoglycan peptide were incubated with the newly purified anti-ε-sarcoglycan 
antibody (figure 5.3.6.8). The newly purified anti-ε-sarcoglycan antibody was only able 
to recognize the 33kDa ε-sarcoglycan peptide whereas it was unable to pick-up the native 
ε-sarcoglycan protein. A duplicate western blot was prepared (figure 5.3.6.9) and 
incubated with the last aliquot of anti-ε-sarcoglycan antibody provided by our Oxford 
collaborators, in order to determine whether the inability to detect the native ε-
sarcoglycan protein was due to our in-house antibody or whether it was due to the brain 
homogenate preparation. According to this study (figure 5.3.6.9), the antibody clearly 
detected both the 33kDa ε-sarcoglycan peptide and the native 47kDa and 49kDa ε-
sarcoglycan isoforms, confirming that the newly purified anti-ε-sarcoglycan antibody is 
not able to recognize ε-sarcoglycan isoforms in the brain homogenate, and cannot be used 
further to purify ε-sarcoglycan binding proteins for identification by Mass Spectrometry. 
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       Column elutions* 
            *0.1M Glycine pH 2.5 
            Spectrophotometer Reading for 
                     protein determination 
                            (280nm) 
                Fraction 1, 1ml                                      0.00 
                Fraction 2, 1 ml                                      0.02 
                Fraction 3, 1ml 
                                     0.41 
                Fraction 4, 1ml 
                                     0.90 
                Fraction 5, 1ml 
                                     0.60 
                Fraction 6, 1ml                                      0.13 
                Fraction 7, 1ml                                      0.06 
                Fraction 8, 1ml                                      0.03 
 
 
 
Table 5.3.6: Spectrophotometer reading used to identify the elution containing the 
new anti-ε-sarcoglycan antibody. 
A column cross-linked to the 33kDa ε-sarcoglycan peptide as described in materials and 
methods (section 6.12) was used to affinity purify the new anti-ε-sarcoglycan antibody 
present in the rabbit antiserum. The antibody eluted in the third, fourth and fifth eluted 
fractions, where the spectrophotometer reading is the highest (red). The reading of the 
remaining eppendorf tubes is negligible suggesting that the new anti-ε-sarcoglycan is 
concentrated in eppendorfs 3, 4, 5 only. 
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Figure 5.3.6.8: Western Blot containing a forebrain homogenate preparation, and 
an aliquot of pure 33kDa ε-sarcoglycan peptide, immunodeveloped with the new 
anti-ε-sarcoglycan antibody. 
In the lane containing a preparation of pure 33kDa ε-sarcoglycan peptide, the new anti-ε-
sarcoglycan antibody is capable of recognizing the 33kDa peptide. However it is unable 
to recognize the native 47kDa and 49kDa ε-sarcoglycan isoforms that are known to be 
expressed in the brain homogenate (BH lane). These results demonstrate that although the 
antibody production was successful it was not able to recognize native ε-sarcoglycan in 
brain homogenate. Protein loading is 20µg/lane. Lane 1, pure aliquot of 33kDa ε-
sarcoglycan peptide. Lane 2, Brain Homogenate (BH). Molecular weight standards are 
indicated. 
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Figure 5.3.6.9: Western Blot containing a forebrain homogenate preparation, and 
an aliquot of pure 33kDa ε-sarcoglycan peptide, immunodeveloped with the last 
aliquot of anti-ε-sarcoglycan antibody provided by our Oxford collaborators. 
In contrast with the new anti-ε-sarcoglycan antibody, the original anti-ε-sarcoglycan 
antibody provided by the Oxford collaborators is able to recognize the 33kDa peptide in 
the lane containing a preparation of pure 33kDa ε-sarcoglycan peptide, and it is also able 
to recognize the native 47kDa and 49kDa isoforms in the brain homogenate fraction. 
Protein loading is 20µg/lane. Lane 1, pure aliquot of 33kDa ε-sarcoglycan peptide. Lane 
2, Brain Homogenate (BH). Molecular weight standards are indicated. 
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                                                     5.4 Discussion: 
 
 
               5.4.1 ε-sarcoglycan is likely to form novel complexes in the 
brain that are not related to dystrophin protein complexes 
 
 
      The data in this chapter highlights clear differences in the patterns of 
subcellular distribution of ε-sarcoglycan isoforms (figure 5.3.3) when compared to 
classical full-length dystrophin (Chapter 3, figure 3.2.4.1) in forebrain and cerebellar 
subcellular fractions. In fact, classical full-length dystrophin and associated DPC 
components enrich in PSDs of both forebrain and cerebellum (Chapter 3; figure 3.2.3.2, 
3.2.3.3 and 3.2.4.1), more precisely, in neurons of the brain they have been shown to 
localize exclusively at PSD structures of GABAergic synapses (Blake et al, 1999; Brunig 
et al, 2002; Culligan et al, 2002). Contrary to classical full-length dystrophin and 
associated DPC components, neither 47kDa nor 49kDa ε-sarcoglycan isoforms enrich in 
the PSD fraction of the forebrain or cerebellum (figure 5.3.2 and 5.3.3). Instead, both 
isoforms predominantly occur in membrane fractions of non-synaptic (LM and 
microsomes) and primarily synaptic origin (SM) of the forebrain and cerebellum (figure 
5.3.2, 5.3.3). What is more, the immunocolocalization study presented in this chapter is in 
agreement with the biochemical data, as it highlights that ε-sarcoglycan isoforms are not 
part of PSD structures of GABAergic synapses containing classical dystrophin, as ε-
sarcoglycan isoforms do not co-localize with classical dystrophin (figure 5.3.4) therein. 
Lastly, the staining pattern of ε-sarcoglycan isoforms presumably along the membrane of 
the neurone (figure 5.3.4) does not resemble the typical punctate staining pattern of 
classical dystrophin and associated DPC components found at the soma and along 
proximal dendrites (Chapter 4, figure 4.2.6, 4.2.7). In conclusion, the results presented in 
this chapter strongly suggest that although ε-sarcoglycan and delta dystrophin are 
expressed in the same neurons, ε-sarcoglycan isoforms may not be part of classical full-
length dystrophin-containing DPC complexes at GABAergic synapses in neurons, rather, 
they are likely to form novel and yet unidentified protein complexes at the membrane of 
neurons. 
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      The data in this chapter also highlights clear differences in the patterns of 
subcellular distribution of ε-sarcoglycan isoforms (figure 5.3.3) when compared to delta 
full-length dystrophin (Chapter 4, figure 4.2.11.1) in forebrain and cerebellar subcellular 
fractions. In fact, delta full-length dystrophin is highly enriched in the microsomal 
fraction, to a lesser extent in other membrane fractions, and only moderately enriched in 
the PSD fraction of the forebrain and cerebellum (Chapter 3, figure 3.2.4.2). In contrast, 
the 47kDa and 49kDa ε-sarcoglycan isoforms predominantly occur in membrane 
fractions of non-synaptic (LM and microsomes) and primarily synaptic origin (SM) of the 
forebrain and cerebellum (figure 5.3.2, 5.3.3). The immunocolocalization study presented 
in Chapter 4 (figure 4.2.10) confirms the differences in subcellular distribution between 
delta dystrophin and ε-sarcoglycan isoforms, as it clearly demonstrates that delta 
dystrophin exclusively co-localizes with the microtubule (MT) cytoskeleton found 
throughout the central parts of the entire neuron, away from the membrane (Chapter 4, 
figure 4.2.8). This is a very different subcellular distribution when compared to the 
exclusive neuronal membrane enrichment and localization of both ε-sarcoglycan 
isoforms (figure 5.3.2, 5.3.3; Esapa et al, 2007). Therefore, these results suggest that due 
to the different compartmentalization restrictions, ε-sarcoglycan isoforms are unlikely to 
associate with delta dystrophin-containing DPC complexes at MT structures within 
forebrain and cerebellar neurons. Instead, ε-sarcoglycan isoforms are likely to form 
novel, yet unidentified proteins complexes at the membrane of neurons. Furthermore, ε-
sarcoglycan staining was only identified in a subpopulation of neurons viewed under the 
microscope, whereas delta dystrophin was found in most if not all neurons, including 
neurons expressing ε-sarcoglycan. This result further reinforces the conclusion that ε-
sarcoglycan isoforms and delta dystrophins are not part of the same protein complex in 
neurons.  
 
      According to the results presented in figure 5.3.3, in membrane fractions of 
the forebrain and cerebellum, the level of expression and distribution exhibited by the 
two ε-sarcoglycan isoforms is not identical. In fact, figure 5.3.3 highlights that in the 
forebrain, both 47kDa and 49kDa ε-sarcoglycan isoforms are expressed at higher levels 
when compared to the respective membrane fractions of the cerebellum, suggesting that 
the level of expression of the isoforms in the membrane fractions are regionally 
controlled. What is more, unlike the 47kDa isoform, the 49kDa isoform is differentially 
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expressed within the membrane fractions of the forebrain when compared to the 
membrane fractions in the cerebellum. Lastly, significantly only the 47kDa isoform is 
present in the myelin fraction of the forebrain and cerebellum, suggesting that the 47kDa 
and 49kDa isoforms not only exhibit differential localization within the cerebellum, but 
also within the forebrain. Altogether these results suggest that the level of expression and 
distribution of the two isoforms in the two brain regions is highly regulated. On the other 
hand, the different subcellular distributions of ε-sarcoglycan isoforms in the two brain 
regions may reflect the differences in glycosylation of the isoforms, as opposed to true 
differences in their expression patterns. It is important to add that the patterns of level of 
expression of these sarcoglycan isoforms in the two regions is also very different from 
that of classical and delta dystrophin isoforms, further reinforcing the hypothesis that ε-
sarcoglycan isoforms form novel protein complexes independent of classical and delta 
dystrophin. 
 
         The immunoprecipitation study used to re-investigate the association 
potentials between ε-sarcoglycan and classical dystrophin isoforms within the forebrain 
highlights a very faint, almost undetectable, cDp427 band being immunoprecipitated by 
ε-sarcoglycan antiserum (figure 5.3.5.3). Classical full-length dystrophin (cDp427) is a 
neuron-specific isoform that exclusively localizes at PSDs of GABAergic synapses 
(Brunig et al, 2002). Given that the biochemical studies presented in this chapter (figure 
5.3.2, 5.3.3) highlight a weak doublet ε-sarcoglycan band in the PSD fraction of forebrain 
and cerebellum (figure 5.3.2, 5.3.3), the results cannot exclude the possibility that such a 
very small amount of ε-sarcoglycan may indeed reside in PSDs and interact with the 
cDp427 isoform localized therein. However, most if not all of cDp427 remained unbound 
in the starting brain homogenate material (figure 5.3.5.3, lane 1) used for the 
immunoprecipitation study, therefore suggesting that most if not all of the cDp427 is 
unlikely to associate with the ε-sarcoglycan isoforms, in agreement with the 
immunocytochemical study (figure 5.3.4), therefore suggesting ε-sarcoglycan isoforms 
are likely to associate with other novel, yet unidentified binding partners. Kinugawa et al 
(2009) describes that in MDS patients containing mutated ε-sarcoglycan proteins, the 
GABAergic inhibitory system is functionally intact. This statement further reinforces the 
conclusions from our studies that in neurons, ε-sarcoglycan isoforms are unlikely 
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components of DPC complexes in GABAergic synapses, otherwise the functions of the 
GABAergic system in MDS patients would have been altered.  
  
      The immunoprecipitation study highlights that higher levels of cDp140 and 
cDp71 isoforms were also immunoprecipitated by ε-sarcoglycan isoforms (figure 5.3.5.3, 
lane 3). cDp140 and cDp71 isoforms are reported to locate exclusively in astrocytic cells 
(Blake et al, 1999; Culligan et al, 2002), and given that only the 47kDa (not the 49kDa 
isoform) ε-sarcoglycan isoform is known to be expressed in astrocytes (Nishiyama et al, 
2004), the results suggest that in vivo, the 47kDa ε-sarcoglycan isoform may interact 
with the cDp140 and cDp71 isoforms in astrocytes and therefore be a component of 
classical dystrophin-containing DPC complexes therein. However, given that the band 
intensity of each of the immunoprecipitated short classical dystrophin isoforms (figure 
5.3.5.3, lane 3) was much less concentrated when compared to the classical dystrophin 
isoforms band intensity found in the starting material (figure 5.3.5.3, lane 1), it is likely 
that in forebrain, at least most of the classical dystrophin isoforms are not associated with 
ε-sarcoglycan. This again raises the possibility that ε-sarcoglycan isoforms associate with 
other as yet unidentified partners to form novel complexes. It is often hypothesized in the 
literature that brain ε-sarcoglycan may possibly associate with other kinds of membrane 
proteins and/or cytoskeletal proteins rather than the DPC complex (Nishiyama et al, 
2004; Esapa et al, 2007), in agreement with the data presented in this chapter. To date, 
the proteins interacting with ε-sarcoglycan in the brain have yet to be identified. 
 
  The brain is not the only organ whose ε-sarcoglycan protein may function 
independently from the DPC complex. The kidney and retina also contain ε-sarcoglycan 
proteins that do not associate with DPC complexes (Fort et al, 2005; Durbeej et al, 1999). 
In the kidney, both ε-sarcoglycan and DPC components are expressed within the same 
cell, but similarly to that observed in our cortical cultures (figure 5.3.4), they are 
differentially distributed and therefore do not interact (Durbeej et al, 1999). Also in 
neurons of the retina, ε-sarcoglycan is not part of the DPC complex (Fort et al, 2005), 
whereas in photoreceptor terminals of the retina, ε-sarcoglycan does associate with DPC 
components (Fort et al, 2005). Therefore, there are specific cells in the retina where ε-
sarcoglycan does associate with DPC components and other cell-types where ε-
sarcoglycan is independent of DPC complexes (Fort et al, 2005). In the lung also, 
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depending on the cell-type, ε-sarcoglycan is either associated with the DPC complex or 
due to compartmentalization restrictions, may be found independently from the DPC 
complex (Durbeej et al, 1999). These studies therefore strongly indicate that the function 
of ε-sarcoglycan can also work independently of the DPC complex, and that the brain 
may well contain ε-sarcoglycan proteins that function independently of DPC complexes.  
 
  The anti-ε-sarcoglycan antibody used in this chapter was unable to 
distinguish the 47kDa isoform from the 49kDa isoform, as the antibody recognised an 
epitope found in both isoforms, therefore from the immunoprecipitation study in figure 
5.3.5.3, it was impossible to decipher which of the two ε-sarcoglycan isoforms was 
associated with which of the immunoprecipitated classical dystrophin isoforms. Similarly 
in our cortical neuronal study (figure 5.3.4), it was impossible to determine whether both 
ε-sarcoglycan isoforms were co-expressed in the same cells or same parts of the cells, or 
whether each isoform was expressed in a cell-type specific manner or in different 
membrane compartments of the same cell. It would therefore be interesting to generate an 
antibody against exon 8 or exon 11b, the two epitopes that distinguish the 47kDa ε-
sarcoglycan isoform from the 49kDa ε-sarcoglycan isoform (chapter 1; figure 1.1.2.1) 
respectively. These could be used in immunocytochemical studies to establish their 
cellular localizations throughout the entire brain. Secondly, each ε-sarcoglycan antibody 
could be cross-linked to a separate column, in order to search for proteins that may 
specifically interact with their unique cytoplasmic tails, for subsequent analysis by Mass 
Spectrometry and ultimately the functions of any such proteins identified. These 
antibodies, in concomitance with other antibodies against the DPC components, would 
also allow to determine by immunocytochemical techniques, whether in analogy to the 
retina (Durbeej et al, 1999; Fort et al, 2005), the brain 47kDa and 49kDa ε-sarcoglycan 
isoforms may or may not be part of DPC complexes in some cells and be independent of 
DPC complexes in other cell-types.  
 
      In this thesis I have also attempted to produce a new anti-ε-sarcoglycan 
antibody such that a number of immunopurification studies could be carried out, and 
Mass Spectrometry could be used to investigate the nature of the immunopurified 
components of the complexes interacting with the 47kDa and 49kDa ε-sarcoglycan 
isoforms. Unfortunately the new antibody was only able to recognize the ε-sarcoglycan 
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peptide but not the native ε-sarcoglycan protein on western blots. I confirmed that the ε-
sarcoglycan peptide used for the immunization of the rabbit was not defective, as a small 
aliquot of anti-ε-sarcoglycan antibody gift remaining from our previous experiments was 
able to recognize the peptide, as well as the native protein, suggesting that the peptide 
contained an unmutated epitope against which an antibody could be successfully raised. 
One possible explanation as to why the new in-house antibody did not pick up the native 
ε-sarcoglycan protein may be that the new in-house antibody may recognize part, if not 
all, of the His tag left at the C-terminus of the 14kDa ε-sarcoglycan peptide used for the 
immunization. As a consequence, the new antibody would be unable to pick-up the native 
protein lacking the His tag, whereas it consistently recognized the ε-sarcoglycan peptide 
containing the His-tag. Another possibility is that the antibody was of low affinity and 
hence only recognized high concentrations of the peptide, but was not sufficiently 
sensitive to detect the lower concentrations of ε-sarcoglycan present in tissue samples. A 
third possibility is that the epitope recognized on the peptide is blocked in the full-length 
proteins, for example, as a result of glycosylation. For the future, in addition to the 
generation of antibodies specific for either the 47kDa isoform, or the 49kDa isoform, it 
would be interesting to also generate a new anti-ε-sarcoglycan antibody recognizing both 
isoforms, cross-link this antibody to a column, isolate the proteins that interact with ε-
sarcoglycan isoforms, and subsequently identify these associated proteins by Mass 
Spectrometry. These antibody productions will provide an important step forward 
towards the understanding of the function of ε-sarcoglycan isoforms in the brain. 
 
     The function of ε-sarcoglycan remains largely unknown (Tai et al, 2009), 
although it is well accepted that mutation of ε-sarcoglycan causes Myoclonus Dystonia 
(MDS; Chapter 1, part two). MDS patients with ε-sarcoglycan mutations do not show any 
signs of muscle disease, SGCE mutations appear to induce only neurological disorders 
(Hjermind et al, 2008). Further elucidations of the cellular localization of ε-sarcoglycan 
in mammalian brain will be important in the identification of candidate neuronal groups 
and circuits through which ε-sarcoglycan mutations lead to the specific psychiatric 
symptom complex associated with MDS (Chan et al, 2005). The membrane localization 
of ε-sarcoglycan isoforms (figures 5.3.2  & 5.3.3) and their expression in the mouse brain 
monoaminergic neurons (Chan et al, 2005) suggests that the symptom complex of MDS 
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may be related to the effects of decreased ε-sarcoglycan activity on the development or 
function of these neurons (Chan et al, 2005). Other neuronal-types have been found to 
express ε-sarcoglycan although the nature of these neurons remains to be identified, 
suggesting that ε-sarcoglycan may also influence neurotransmission by these neurons 
(Chan et al, 2005). The expression of the 47kDa ε-sarcoglycan isoform in astrocytes of 
the brain (Nishiyama et al, 2004) suggests that decreased ε-sarcoglycan activity in glial 
functions may also be a contributing factor to MDS, although this remains to be verified. 
Esapa et al (2007) suggested one possible mechanism by which a mutation of the ε-
sarcoglycan protein may lead to MDS. According to their studies, ε-sarcoglycan proteins 
containing mutations in the extracellular region are retained intracellularly and degraded 
by the proteosome. In other words, the ε-sarcoglycan mutant is no longer allowed to 
reach the plasma membrane where its functions are carried out. Therefore Esapa et al 
(2007) suggest MDS is probably caused by a loss of ε-sarcoglycan function at the plasma 
membrane. Esapa et al (2007) also suggest that ε-sarcoglycan, a membrane-associated 
protein (figure 5.3.2 & 5.3.3), is expressed in neurons of the basal ganglia and cerebellum 
(Esapa et al, 2007) and may therefore co-operate with other membrane proteins to 
modulate the activity of these neurons (Esapa et al, 2007). Hjermind et al, 2008 
hypothesised that the major cause of MDS might be related to the existence of a brain-
specific isoform, which may have brain-specific intracellular interactions that play a role 
in neuronal differentiation and synaptic transmission, as suggested in mice (Hjermind et 
al, 2008). When mutated, such a brain specific isoform gives rise to neurological 
disorders without affecting the muscle. It is clear from these studies that a lot of further 
work needs to be carried out before the mechanisms underlying MDS are understood. 
 
      The 47kDa and 49kDa isoforms exhibit structural differences at their 
cytoplasmic tails (Nishiyama et al, 2004), but the significance of these differences 
remains unresolved. No studies have yet investigated whether these structural differences 
may influence the trafficking of the protein. The results in this chapter, in agreement with 
Nishyama et al (2004), suggest differential localization of the two isoforms in forebrain 
and cerebellum subcellular fractions, which I suggest it may be due to their different 
cytoplasmic domains, although this hypothesis remains to be verified. Nishiyama et al 
(2004) suggest that the structural differences at their C-terminus may cause ε-sarcoglycan 
isoforms to play different roles at synapses within neurons of the forebrain and 
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cerebellum. However this hypothesis also remains to be verified. The extracellular 
domain of either ε-sarcoglycan isoform contains putative cadherin-like domains and a 
calcium-binding pocket which is typically found in proteins involved in homotypic or 
heterotypic interactions with other glycoproteins (Dickens et al, 2002; Ozawa et al, 
2005), it is therefore possible that ε-sarcoglycan may also be implicated in similar 
interactions, although this hypothesis remains to be verified. Proteins containing a 
cadherin domain have also been shown to modulate a wide variety of processes, such as 
cell polarization (Tepass et al, 2000), migration (Tepass et al, 2000) as well as cell 
adhesion (Dickens et al, 2002). Developmental studies on ε-sarcoglycan have suggested 
its participation in the early development of brain, muscle, liver, kidney and heart tissue, 
due to its high levels of expression in fetal life of rats when compared to adult life 
(Hjermind et al, 2008). The cadherin-like domains in the ε-sarcoglycan protein may be 
involved in modulating polarization and/or migration and /or adhesion during 
development, although again this hypothesis remains to be verified. It is clear that a large 
number of studies need to be carried out before the function of ε-sarcoglycan in the brain 
is understood.  
 
      In conclusion, based on the results presented in this chapter, ε-sarcoglycan is 
unlikely to be a component of classical and delta dystrophin-containing DPC complexes, 
rather, it is a membrane protein that is part of novel, yet unidentified, complexes in the 
brain. 
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Chapter 6    
 
                   6.1 Conclusions 
 
The work carried out in this thesis has led to the following novel conclusions: 
 
6.1.1 Part 1 
 
• Biochemical studies presented in this thesis suggest classical and delta 
dystrophin exhibit different regional and subcellular distribution in forebrain and 
cerebellum. The level of expression of classical dystrophin is higher in the 
cerebellum when compared to the forebrain, whereas the level of expression of 
delta dystrophin is lower in the cerebellum when compared to the forebrain. 
 
• Biochemical studies confirm the published data showing that classical full-
length dystrophin is exclusively enriched in PSDs of the forebrain and 
cerebellum (chapter 3, figure 10). 
 
• Biochemical studies show that in the forebrain and cerebellum, contrary to 
classical dystrophin, delta dystrophin is most highly enriched in microsomes and 
only moderately enriched in the PSD fraction.  
 
• Immunocytochemical data shows delta dystrophin is in fact an extra-synaptic 
protein that fully co-localizes with β3-tubulin (chapter 4, figure 10), a 
component of the microtubule (MT) cytoskeleton. Therefore, delta dystrophin 
may not replace classical dystrophin at GABAergic synapses to form novel delta 
dystrophin-containing DPC-like complexes therein. Instead, I suggest delta 
dystrophin is likely to form novel delta dystrophin-containing DPC-like 
complexes within the central parts of the neuron. 
 
• I also suggest that the molecular composition of DPC complexes containing 
delta dystrophin differ from DPC complexes containing classical dystrophin. 
This point is emphasized by the fact that delta dystrophin and β-dystroglycan, a 
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core component of classical dystrophin-containing DPC complexes, do not 
colocalize (chapter 4, figure 6). Indeed the difference in distribution in the 
forebrain and cerebellum (chapter 3, figure 11) exhibited by the two isoforms 
also suggests the two isoforms may carry out different functions in the neuron. 
Obviously it would be expected that some components of classical and delta 
DPC complexes would be common to both. 
 
• The data showing the different localization of full-length classical and delta 
dystrophin suggest Cexon78 and Dexon78 may interact with the region 
extending from the WW domain to the C-terminus to traffick the two dystrophin 
isoforms to different cellular compartments, PSD and microtubule cytoskeleton 
respectively. 
 
• I suggest that delta dystrophin may utilize the MT-binding domain to directly 
associate with the MT network it is found to colocalize with. 
 
• I also suggest that delta dystrophin may also participate in maintaining stability 
of the MT cytoskeleton, and hence, as a consequence of a mutated DMD gene, 
both delta dystrophin and classical dystrophin may contribute to the cognitive 
pathology in DMD patients by altering the MT cytoskeleton. 
 
• I suggest delta dystrophin is likely to be expressed in different neuronal sub-
types of excitatory neurons of the forebrain, since all forebrain neurons viewed 
under the light microscope expressed delta dystrophin, and 80% of these neurons 
are said to be excitatory (Xu et al, 2010), whilst only 20% are inhibitory (Xu et 
al, 2010).  
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6.1.2 Part 2 
 
• Both 47kDa and 49kDa ε-sarcoglycan isoforms occur predominantly in 
membrane fractions, both of synaptic (SM) and non-syanptic origin (LM and 
microsomes).  
 
• There appears to be lower expression of the 49kDa isoform in cerebellum 
compared to forebrain.  
 
• Significantly only the 47kDa isoform is present in a myelin enriched fraction. 
The myelin fraction also contains fragments of axon membrane attached to the 
myelin. 
 
• Neither isoform is enriched in the PSD fractions, unlike classical full-length 
dystrophin and associated DPC proteins (Chapter 3, figure 7, 8, 10). Therefore it 
is most unlikely that ε-sarcoglycan is a component of classical DPC complexes 
present in the PSD. Given that to date, classical dystrophin-containing DPC 
complexes are said to exclusively localize at GABAergic synapses (Brunig et al, 
2002), these studies suggest that ε-sarcoglycan may not associate with these 
classical dystrophin-containing complexes at GABAergic synapses.  
 
• Delta dystrophin localizes with the MT cytoskeleton (Chapter 4, figure 10), 
away from the membrane (Chapter 4, figure 8), whereas ε-sarcoglycan isoforms 
exclusively localize at the membrane. Therefore due to compartmentalization 
restrictions, neither ε-sarcoglycan isoform may associate with the delta 
dystrophin-containing DPC complexes in the forebrain and cerebellum.  
 
• Therefore ε-sarcoglycan isoforms are likely to form novel, yet unidentified 
complexes in brain. 
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6.2 Future Work 
 
6.2.1 Part 1 
 
• For future work, I suggest to generate an anti-mouse classical dystrophin 
antibody and an anti-rabbit delta dystrophin antibody to immunoprecipitate and 
isolate the proteins that interact with these isoforms, and subsequently identify 
these interacting proteins via Mass Spectrometry Analysis. Concominant with 
these studies, I suggest to carry out co-localization studies in various cell-types 
of the brain, to directly compare the distribution of these isoforms in various 
brain regions and with respect to the distribution observed in cortical neurons 
described in this Thesis. 
 
• For the future, I suggest studying the molecular composition of classical and 
delta dystrophin-containing DPC complexes in glial and neuronal cells. This is 
because evidence implicating glial and neuronal DPC complexes in DMD is 
continuously growing. For example, the abnormal cytoarchitecture of the 
cerebral cortex is due to the loss of a DPC component in glial cells (Satz et al, 
2010). Furthermore, deletion of some DPC components in neurons blunts 
hippocampal LTP, indicating the DPC is involved in synaptic activity (Satz et al, 
2010). Hence, the structural and functional brain abnormalities in DMD may be 
a consequence of a combination of DPC-like complexes in astrocyte cells in 
addition to the DPC complex found at the PSD of neuronal synapses. To date, no 
studies have yet determined whether delta dystrophin is expressed in glial cells.  
 
• The co-localization between delta dystrophin and β3-tubulin presented in 
Chapter 4 suggests that delta dystrophin is directly or indirectly associated with 
the microtubule cytoskeleton. For future work, I suggest to investigate whether 
such association occurs in a direct or indirect manner. Prins et al (2009) have 
already demonstrated that classical dystrophin does contain an MT-binding 
domain, with which it directly associates with the MT network. I have 
established that the MT-binding domain in delta dystrophin exists and is 
unaltered by Dexon78. I suggest establishing, via a (cosedimentation) 
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immunoprecipitation approach, whether the delta dystrophin MT-binding 
domain is utilized to directly associate delta dystrophin with the MT network.  
 
• The literature reveals that classical dystrophin contains actin and intermediate 
filament binding domains (Stone et al, 2005; Prins et al, 2009), and I have 
established that these domains in delta dystrophin exist and are unaltered by 
Dexon78. For future work, I suggest to investigate whether delta dystrophin 
utilizes these domains to directly associate with actin and intermediate filaments. 
 
• It has already been demonstrated that classical dystrophin is capable of 
stabilising MTs from cold-induced depolymerization (Prins et al, 2009). For 
future work, I suggest to investigate whether delta dystrophin may also function 
to stabilize the MT cytoskeleton, as no studies have yet investigated this. The 
MT cytoskeleton becomes deranged when the DMD gene is mutated (Prins et al, 
2009; Percival et al, 2007), and given that both classical and delta dystrophin 
originate from the DMD gene, this suggests that both the classical and the delta 
dystrophin isoform are likely involved in maintaining the stability of the MT 
cytoskeleton, and require further investigation. It would also be interesting to 
compare the stability of the MT network in wild-type and dystrophin-deficient 
mice, by utilizing cortical cultures obtained from wild, mdx mice, and if 
possible, other mdx models. 
 
• For the future, it would be interesting to investigate in more detail the function 
and binding abilities of Cexon78 and Dexon78 (see chapter 3). The studies 
presented in this thesis show that as a consequence of these exons, classical and 
delta dystrophin distribute differently (chapter 3, figures 8-9, 10-11; Chapter 4, 
figures 1-10). A key question is what are the signals that direct classical and 
delta dystrophin to such widely differing subcellular locations. My results show 
that Cexon78 and Dexon78 alone, are unable to traffick to the PSD and MT 
cytoskeleton respectively. Separate studies carried out by Sakamoto et al (2008) 
found that the region extending from the WW domain to the C-terminal domain 
is necessary to localize classical dystrophin to the PSD in neurons; 
mislocalisation to neurites and axons of neurons occurs when this region is 
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removed. I suggest that Dexon78, localized within the WW domain and C-
terminus region, may function to disrupt the PSD-binding domain found within 
this crucial C-terminal region, leading to delta dystrophin being distributed 
throughout the neurites and axons of the neurons (figures 1-10), similar to 
classical minidystrophins lacking the C-terminus domain (Sakamoto et al, 2008). 
This may explain why delta dystrophin observed in chapter 4 is localized within 
the central parts of neurites and axons, where it co-localizes with β3-tubulin. For 
the future, it would therefore be interesting to determine the fragments between 
the WW domain and the C-terminus domain, involved in trafficking the classical 
dystrophin isoforms to the PSD. The disruption of this trafficking signal by 
Dexon78 is a good indicator of a crucial region within the C-terminus containing 
the trafficking signal that directs classical dystrophin to the PSD. 
 
• There is to date no knowledge as to whether delta dystrophin is expressed in the 
muscle, the tissue whereby the disease is most drastically manifested. Hence I 
suggest investigating and comparing the cellular and subcellular distribution of 
classical and delta dystrophin therein, via the use of biochemical, 
immunohistochemical and immunocytochemical analyses. The identification of 
delta dystrophin in muscle tissue would provide a novel potential therapeutic 
target to treat patients with DMD. Ofcourse, the expression of delta dystrophin 
in other organs is important as well and will also need to be investigated. To 
date, with the exception of the liver (Blake et al, 1999) and the brain (this 
Thesis; Blake et a, 1999), there is no knowledge of any other organ expressing 
delta dystrophin. These studies will also be necessary, as they will reveal novel 
and potentially alternative routes underlying DMD. 
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6.2.2 Part 2 
 
• For the future, it would be interesting to generate a new anti-ε-sarcoglycan 
antibody able to recognize both the 47kDa and 49kDa isoform, cross-link this 
antibody to a column, immunoprecipitate and isolate the proteins that interact 
with the isoforms, and subsequently identify the associated proteins by Mass 
Spectrometry. It is often hypothesized in the literature that brain ε-sarcoglycan 
may possibly associate with other kinds of membrane proteins and/or 
cytoskeletal proteins rather than the DPC complex (Nishiyama et al, 2004; Esapa 
et al, 2007), in agreement with the data presented in this thesis. To date, the 
proteins interacting with ε-sarcoglycan in the brain have yet to be identified. 
This antibody production will provide an important step forward towards the 
understanding of the function of ε-sarcoglycan isoforms in the brain and in MDS 
pathology. 
 
• It would also be interesting to generate an antibody against exon 8 or exon 11b, 
the two epitopes that distinguish the 47kDa ε-sarcoglycan isoform from the 
49kDa ε-sarcoglycan isoform (chapter 1; figure 1) respectively. These could be 
used in immunocytochemical studies to establish and distinguish their cellular 
localizations throughout the entire brain. Secondly, each ε-sarcoglycan antibody 
could be cross-linked to a separate column in order to immunoprecipitate and 
isolate proteins that may specifically interact with their unique cytoplasmic tails. 
Mass Spectrometry could then be used to analyze and identify the isolated 
proteins. These antibodies, in concomitance with other antibodies against the 
DPC components, would allow to determine by immunocytochemical and 
immunohistochemistry techniques whether, the brain 47kDa and 49kDa ε-
sarcoglycan isoforms, in analogy to the retina (Durbeej et al, 1999; Fort et al, 
2005), may or may not be part of DPC complexes in some cells and be 
independent of DPC complexes in other cell-types.  
 
• For future work, it would be interesting to establish the significance of the 
structural differences exhibited at the cytoplasmic tails of the 47kDa and 49kDa 
ε-sarcoglycan isoforms (Nishiyama et al, 2004). The results in Chapter 5, in 
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agreement with Nishyama et al (2004), show differential localization of the two 
isoforms in forebrain and cerebellum subcellular fractions, which I suggest it 
may be due to their different cytoplasmic domains, although this hypothesis 
remains to be verified. Nishiyama et al (2004) suggest that the structural 
differences at their C-terminus may cause ε-sarcoglycan isoforms to play 
different roles at synapses within neurons of the forebrain and cerebellum. For 
the future, it would be interesting to verify both of these hypotheses.  
 
• For future work, I suggest to identify the proteins interacting with the 
extracellular domain of the 47kDa and 49kDa ε-sarcoglycan isoform. This is 
because the extracellular domain of either ε-sarcoglycan isoform contains 
putative cadherin-like domains and a calcium-binding pocket, which is typically 
found in proteins involved in homotypic or heterotypic interactions with other 
glycoproteins (Dickens et al, 2002; Ozawa et al, 2005). These interactions would 
normally lead to the modulation of a variety of processes, such as cell 
polarization (Tepass et al, 2000), migration (Tepass et al, 2000) as well as cell 
adhesion (Dickens et al, 2002). For future work, I suggest to immunoprecipitate 
the proteins that associate with ε-sarcoglycan’s extracellular domain, in order to 
determine whether ε-sarcoglycan may be involved in any of these processes.  
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         Appendix I: General Molecular Biology Reagents 
 
Box 1- Chemicals (SIGMA) 
 
All molecular biology grade laboratory chemicals were purchased from Sigma-Aldrich and stored 
at room temperature unless stated otherwise. Where necessary, solutions were sterilized by 
autoclaving, or filtering through a 0.22µm filter. 
 
3 (N-morpholino) propanesulfonic acid (MOPS); Invitrogen. 
Acetic acid 
Acrylamide Solution (40% w/v); BioRad 
Agar, Noble 
Ampicillin. Stock solution 205mg/mL in  
autoclaved purite H2O, stored at –20oC 
β-mercaptoethanol (β-ME) 
β-(N-morpholino) propanesulfonic acid (MOPS); Invitrogen 
Boric Acid 
Brilliant Blue R250 (Coomassie) 
Bromophenol Blue 
Calcium Chloride 
Citric Acid 
Copper Sulphate 
Dextran T-500; Pharmacosmos 
Dibasic Sodium Phosphate Dehydrate  
Dimethoxypropane (DMP) 
Disodium hydrogen phosphate heptahydrate (Na2HPO4) 
Deoxycholate (DOC) 
Ethanol 
Folin reagent 
Glycerol 
Glycine  
HCl 
isopropanol 
L-Glutamine 
Glutamic Acid (glutamate) 
Magnesium Chloride 
Marvel dried milk powder 
Methanol 
NaOH 
n-octyl glucopyranoside. Store at 4oC. 
Polyethylene glycol 6000 (PEG 6000); Sciencelab  
p-iodonitrotetrazolium violet (INT). Store at 4oC. 
Polyethylene glycol 
Ponceau S 
Potassium Acetate 
Potassium Chloride 
Protogel; National Diagnostics 
Sodium Azide 
Sodium Bicarbonate 
Sodium Carbonate 
Sodium Chloride 
Sodium dihydrogen phosphate 
Sodium dodecyl sulphate (SDS) 
Sodium hydroxide 
Sodium succinate 
Sodium tartrate 
Sucrose 
Sulphosalicylic acid 
Thimerosal;  
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Trichloroethane (TCA) 
Triethanolamine; Fisher Scientific. 
Tretrametiletilendiammina (Temed); Pierce 
Thiethanolamine; Fisher Scientific 
Thimerosal 
Triton X-100 
Tryptone; Neogen Corporation. 
Tween-20 (Polyoxyethylenesorbitan monolaurate) 
Urea  
Yeast extract; Difco Labs  
 
 
 
 
 
 
 
 
 
 
 
Box 2: Biological Kits and Systems 
 
AminoLink Column; Pierce. 
Bradford Method for protein Detection; Biorad 
ECL detection kit; Pierce 
Endofree-Maxiprep kit; Qiagen tip-500.  
Protease Inhibitors; Boehringer Manheim. 
Supersignal WestDura ECL HRP substrate detection kit; Pierce. 
 
 
 
 
 
 
 
 
 
 
 
 
Box 3: Markers and enzymes 
 
Prestained SDS-PAGE broad range standards; Biorad. 
SeeBlue Plus2 Pre-stained Standard; Invitrogen. 
Recombinant Enterokinase; Novagen. 
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Box 4: Buffers 
 
0.2M Triethanolamine Buffer pH 8.2: 2.98g triethanolamine, make pH 8.2, adjust volume with 
ddH2O to 100mL. Sterilize using a filter. Store at RT. 
1M Tris Buffer pH 7.5: 12.4g Tris, make pH 7.5, adjust volume with ddH2O to 100mL. Sterilize 
using a filter. Store at RT. 
10mM Tris Buffer pH 7.0:  0.121g Tris, make pH 7.0, adjust volume with ddH2O to 100mL. 
Sterilize using a filter. Store at RT 
50mM Tris pH 5.5 with SDS:  0.5mL of 1M Tris Buffer pH 5.5 + 1mL SDS, adjust volume with 
ddH2O to 10mL. Sterilize using a filter. Store at RT. 
Blotting Buffer pH 8.3: 25mM Tris, 192mM glycine, 1% (w/v) SDS, 20% (v/v) methanol. Store 
at 4oC. 
Buffer B (lysis buffer) pH 8.0: 100mM NaH2PO4, 10mM Tris-HCl, 8M Urea. Adjusted to pH 8.0 
and sterilized by Filter. Store at RT. 
Buffer QBT (equilibration buffer): 750mM NaCl, 50mM MOPS pH 7.0, 15% isopropanol (v/v), 
0.15% Triton X-100 (v/v). Sterilize using a filter. Store at RT. 
Buffer QC (wash buffer): 1.0 M NaCl, 50mM MOPS pH 7.0, 15% isopropanol (v/v). Sterilize 
using a filter. Store at RT. 
Buffer QN (elution buffer): 1.6M NaCl, 50mM MOPS pH 7.0, 15% isopropanol (v/v). Sterilize 
using a filter. Store at RT. 
Citrate-phosphate Buffer pH 5.0 (washing buffer): 4.7g Citric Acid + 9.2g Dibasic Sodium 
Phosphate. Adjust the pH to 5.0 ad adjust the volume to 1L with ddH2O. Sterilize busing a Filter. 
Store at RT. 
Citrate-phosphate Buffer pH 5.0 with 0.1% Tween 20: 99.9mL Citrate-phosphate Buffer pH 5.0 
+ 0.1mL Tween 20. Store at RT. 
Cleavage Buffer pH 7.4: 20mM Tris-HCl, 50mM NaCl, 2mM CaCl2. Adjusted to pH 7.4 and 
sterilized using a Filter. Stored at 4oC. 
Cleavage/Capture Buffer A: 200mM Tris-HCl, 500mM NaCl, 20mM CaCl2. Adjusted to pH 7.4 
and sterilize using a Filter. Stored at 4oC. 
Coupling Buffer pH 7.2:  0.1M phosphate, 0.15M Sodium Chloride. Adjust the pH to 7.2 and 
adjust the volume to 500mL with ddH2O. Sterilize using a Filter. Store at 4oC. 
Dilution/Storage Buffer pH 7.4: 20mM Tris-HCl, 200mM NaCl, 2mM CaCl2, 50% glycerol. 
Adjusted to pH7.4 and sterilize using a Filter. Stored at -20oC. 
Elution buffer pH2.5: 0.1M Glycine adjusted to pH 2.5. Sterilize using a Filter. Store at 4oC. 
Elution buffer pH 4.5: 100mM NaH2PO4, 10mM Tris-HCl, 8M Urea. Adjusted to pH 4.5 and 
sterilize using a Filter. Store at RT. 
Elution buffer pH 5.9: 100mM NaH2PO4, 10mM Tris-HCl, 8M Urea. Adjusted to pH 5.9 and 
sterilize using a Filter. Store at RT. 
Endotoxin-free Buffer TE: 10mM Tris-HCl pH 8.0, 1mM EDTA. Sterilize by autoclave/Filter. 
Store at RT. 
Neutralization buffer: 1M Tris-HCl in ddH2O. Adjust to pH 9.0. Sterilize using a Filter. Store at 
RT. 
P1 Buffer (resuspension buffer): 59mM Tris-HCl pH8.0, 10mM EDTA, 100µg/mL RNaseA. 
Sterilize by autoclave/Filter. Store at 4oC. 
P2 Buffer (lysis buffer): 200mM NaOH, 1% SDS (w/v). Sterilize by autoclave/Filter. Store at 
RT. 
P3 Buffer (neutralization buffer): 3.0 M potassium acetate pH 5.5. Sterilize by autoclave/Filter. 
Store at 4oC. 
Phosphate Buffered Saline (PBS): 8g NaCl + 0.2g KCl, 1.44Na2HPO4 in 800mL of ddH2O. 
Adjust the pH to 7.4 with HCl and adjust the volume to 1L with ddH2O. Sterilize by 
autoclave/Filter. Store at RT. 
Quenching Buffer pH 7.4: 1M TrisHCl, 0.05% Sodium Azide.
  
Adjust the pH to 7.4 and sterilize 
using a Filter. Store at 4oC. 
RIPA Buffer pH 7.5: 0.5mL 1M Tris Buffer pH 7.5 + 0.1mL Triton X-100 + 0.05g DOC + 1mL 
of 1M NaCl. Adjust final volume to 10mL. Sterilize using a Filter. Store at 4oC. 
Storage Buffer pH 7.4: PBS pH7.4, 0.5M NaCl, 0.02% Thimerosal. Sterilize using a Filter. Store 
at 4oC. 
Storage Buffer B pH 7.4: PBS containing 0.05% sodium azide. Sterilize by Filter. Store at RT. 
TE buffer: 10mM Tris (pH 8.0), 1mM EDTA (pH 8.0). Filter sterilize. 
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Tris-buffered Saline (TBS): Make 0.1% v/v polyoxythylenesorbitan monolaurate (Tween 20) in 
PBS. Sterilize using a Filter. Store at RT. 
Tris-HCl buffer pH 8.0: dissolve 121.1g of Tris base in 800mL of ddH2O. Adjusted the pH to 8.0 
by adding concentrated HCl, make final volume to 1L and sterilize by autoclaving. 
Wash/Bind Buffer pH 7.5: 20mM Tris, 0.15M NaCl, 0.1% Triton X-100. Adjusted the pH to 7.5. 
Sterilize using a Filter. Store at RT. 
Wash Buffer pH 6.3: 100mM NaH2PO4, 10mM Tris-HCl, 8M Urea. Adjusted to pH 6.3 and 
sterilized by Filter. Store at RT. 
 
 
 
 
 
 
 
 
 
 
 
Box 5: Cells, Buffers, Solutions and reagents used for bacterial growth and IPTG induction 
 
Bacterial cell line: 
BL21 (DE3) competent cells; Stratagene. 
 
Reagents:  
Ampicillin; Stock solution 205mg/mL in autoclaved purite H2O. Stored at –20oC. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG); Sigma, store at 4oC. 
β-mercaptoethanol (β-ME); Sigma, store at 4oC. 
 
Solutions: 
Lysogeny Broth (LB) media: 1L = 10g NaCl + 10g Tryptone + 5g Yeast extract. Adjusted to pH 
7.0 and autoclaved. 
Lysogeny Broth (LB) agar media: LB media + 2% Agar. Autoclaved and then cooled to 55oC 
before addition of ampicillin to 100µg/mL and pouring plates. 
SOC medium: 2M filter-sterilised glucose solution. 
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Box 6: Equipment 
 
Glass/Teflon homogeniser with 1mm clearance. 
15 cm tissue culture plates; Sigma-Aldrich. 
24 well tissue culture plates; Sigma-Aldrich. 
50mL high-speed polypropylene centrifuge tubes; Thermo Scientific. 
37oC and 42oC water bath. 
Beckman (Beckman GS 6R, Beckman GS 15 R, Allegra 21R). 
Beckman Ti60 rotor (angle), Beckmane 42.1 rotor, in a Beckman ultracentrifuge L8/L8M. 
Cell strainer, 70µm; BD Biosciences. .Store at RT. 
Centricon YM-10; Millipore. 
Dialysis membrane, MWCO 1,000; Spectra. 
Electroporation cuvettes; Invitrogen.  
Electroporator II; Invitrogen ( E. coli pulse/charge electroporation; 1800V). 
Filters; 0.22µm acrodiscs, Gelman Sciences. 
Glass coverslips 24mm, Thermo Scientific. 
Haemocytometer; Weber. 
High-speed centrifuge and SS-34 rotor (Sorvall), H1318 rotor (Sorvall) 
Hyper-film ECL; Amersham 
Incubator/shaker Model G-25; New Brunswick Scientific Co. Inc., NJ, USA. 
Inverted microscope: Nikon Eclipse TE300 microscope. 
Microscope slides; BDH. 
Nitrocellulose membrane, pore size 0.45µm; Amersham. 
Qiafilter Maxi Cartridge; Qiagen 
 Beckman Rotors: 42.1, Sw28, Beckman 
Semi-micro cuvettes with 1cm path length; FisherBrand. 
Sonicator with a 3-mm-diameter probe. 
Spectrophotometer, Heλios γ, Unicam. 
Spin-filter columns; Novagen. 
Tissue culture plastic; Nunc from life Technologies 
Transmission electron microscope; Hitachi H600. 
Ultra-free Centrifugal filter device; Millipore 
Vacuum for lyophilization. 
Zeiss Axioplan light microscope. 
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           Appendix II: Media, solutions and reagents for cell culture 
 
Box 1. Tissue culture media and reagents 
 
Reagents 
B27 supplement; Gibco. Store at –20oC. 
Bovine serum albumin (BSA); Sigma. Stored at 4oC. 
DMEM; Dulbecco’s Modified Eagles Media, Sigma. Stored at 4oC. 
Foetal calf serum (FCS); Seralabs. Stored at –20oC.  
Hanks’ Balanced Salt Solution (HBSS) without Ca2+ and Mg2+; Sigma. Stored at 4oC. 
Horse Serum; Gibco. Heat inactivated at 60oC for 30 minutes. Stored at –20oC. 
L-Glutamine; Sigma. 200mM stock. Stored at –20oC. 
Lipofectamine 2000; Invitrogen. Stored at 4oC. 
Methanol; Sigma. Stored at RT. 
Neurobasal Medium; Invitrogen. Store at 4oC. 
OPTI-MEM I; Invitrogen. Stored at 4oC. 
Paraformaldehyde (PFA); Sigma. Stored at –20oC. 
Penicillin; Gibco. Stored at –20oC. 
Poly-D-lysine; Sigma. Stored at –20oC. 
Streptomycin; Gibco. Stored at –20oC. 
Triton X-100; Sigma. Stored at RT. 
Trypan Blue; Sigma. Stored at 4oC. 
Trypsin; 2.5% stock solution; Gibco. Stored at –20oC. 
Vectashield Mounting Medium; Vector Lab. Stored at 4oC. 
 
Media: 
Day 1 Media: DMEM containing 10% FCS, 2mM Glutamine, 100U/mL penicillin/100µg/mL 
streptomycin. Stored at 4oC.  
Day 2 Media: Neurobasal Medium containing 2mM L-Glutamine, 1mL B27 supplement, 
100U/mL penicillin/100µg/mL streptomycin. Stored at 4oC.   
Neurobasal Media A: Neurobasal medium containing 0.5mM L-Glutamine, B27 supplement 
and 25µm glutamate. Stored at 4oC. 
Neurobasal Media B: Neurobasal medium containing 0.5mM L-Glutamine, B27 supplement, no 
glutamate.  Store at 4oC. 
 
Solutions: 
4%PFA in PBS: 4mL PFA in a total volume of 100mL PBS. Store at – 20oC. 
25mM Glycine in PBS: 1.87g Glycine in a total volume of 1L PBS. Store at 4oC. 
Blocking Solution with Triton X-100: 10% Horse Serum, 5% sucrose, 3% BSA, 82% PBS, 
0.2% Triton X-100. Store at -20oC. 
Blocking Solution without Triton X-100: 10% Horse Serum,. 5% sucrose, 3% BSA, 82% PBS. 
Store at -20oC. 
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           Appendix III: Antibodies 
 
      Table 1: List of antibodies used for Immunocytochemistry (IHC) and/or Western blots (WB). 
 
Antibody Company Protein 
recognised 
MW Species 
Reactivity 
IHC and 
WB 
dilutions 
Anti-classical 
dystrophin 
antibody 
 
Gift from 
Oxford 
Dr.Blake lab 
Classical 
Dystrophin 
cDp427,cDp140, 
cDp116, cDp71 
427, 
140, 
116, 
71kDa 
Rabbit IHC 1:10 
WB 1:100 
Anti-delta 
dystrophin 
antibody 
Gift from 
Oxford 
Dr.Blake lab 
Delta Dystrophin 
dDp427,dDp140, 
dDp116, dDp71 
427, 
140, 
116, 
71kDa 
Rabbit IHC 1:20 
WB 1:200 
Anti-
dystrobrevin 
antibody 
Gift from 
Oxford 
Dr.Blake lab 
α1,α2, β-
dystrobrevin 
78,  
59, 
55kDa 
Rabbit WB 1:1000 
Anti-ε-
Sarcoglycan 
antibody 
Gift from 
Oxford 
Dr.Blake lab 
ε-sarcoglycan 45kDa Rabbit IHC 1:50 
WB 1:500 
Anti-PSD95 
antibody 
Affinity 
BioReagents 
PSD-95 95kDa Mouse IHC 1:1000 
WB 1:100 
Anti-Gp65 
(anti-
neuroplastin) 
antibody 
In-house 
antibody 
np55, np65 55, 
65kDa 
Mouse WB 1:50 
Anti-Gp50 
antibody 
In-house 
antibody 
Gp50 50kDa Mouse  WB 1:1 
Anti-MAP2 
antibody 
Sigma MAP2a, 
MAP2b,  
MAP2c 
280, 
270, 
75, 
70kDa 
Mouse IHC 1:750 
WB 1:1000 
Anti-
MANDAG 
antibody 
Gift from 
Oxford 
Dr.Blake lab 
β-dystroglycan 43kDa Mouse IHC 1:50 
Anti-
GABAAR 
antibody 
Chemicon GABAA 
Receptor 
55kDa Mouse IHC 1:50 
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Anti-NMDAR 
antibody 
Millipore NMDA Receptor 130kDa Mouse IHC 1:100 
 
Anti-
synaptophysin 
antibody 
 
Sigma 
 
synaptophysin 
 
38kDa 
 
Mouse 
 
IHC 1:750 
WB 1:2000 
Anti-GAD-65 
antibody 
Chemicon GAD65 65kDa Mouse IHC 1:500 
Anti-β3-
tubulin 
antibody 
Sigma β3-tubulin 46kDa Mouse IHC 1:400 
WB 1:1000 
Rat 
polyclonal 
antibody 
Invitrogen Secondary Rat 
Antibody 
- Anti-rat WB 1:2000 
Mouse 
monoclonal 
antibody 
Invitrogen Secondary 
mouse Antibody 
- Anti-mouse WB 1:2000 
Αlexa Fluor 
568 
Molecular 
Probes 
Secondary 
Mouse Antibody 
- Anti-Mouse IHC 1:1000 
Αlexa Fluor 
488 
Molecular 
Probes 
Secondary 
Rabbit 
Antibody 
- Anti-Rabbit IHC 1:1000 
 
 
 
 
